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Abstract 
 
Intra-tumour biological heterogeneity is a characteristic shared by all cancers and is thought to 
contribute to treatment failure. Within-lesion spatial heterogeneity can be qualitatively visualised in 
Positron Emission Tomography (PET) imaging. Quantifying the variability of the biological processes 
and the complexity of the signal being measured in PET oncology is essential. The aim of this thesis 
was to develop and validate intensity- and spatial-based metrics to quantitatively account for the 
complexity of radiotracer uptake and to annotate intra-tumour PET heterogeneity.  
 
Texture analysis was employed to characterise the in vivo tumour heterogeneity of cell proliferation in 
breast tumours using 
18
F-fluorothymidine (
18
F-FLT) PET. The repeatability of the feature 
measurements was assessed in patients who had two PET scans prior to therapy. Associations 
between features at baseline and clinical response measured after three cycles of chemotherapy were 
explored. Associations between feature changes at one week after the start of chemotherapy and 
clinical response were also explored. Furthermore, the influence of analysis parameters and imaging 
protocols were studied. A subset of textural features produced reliable measurements and were 
associated with treatment response. 
  
A technique based on multifractal analysis was also developed for characterising the space-filling 
properties of an object of interest in PET imaging. The derived spatial index was further combined 
with intensity metrics and the technique was shown to correct for partial volume effects. The method 
was illustrated on mathematical objects, validated on test-retest 
18
F-FLT PET clinical data and applied 
to realistic PET simulations.  
 
This work contributes to the demonstration that intensity- and spatial-based image analysis methods 
can supplement existing methods in PET quantification studies. These techniques provide some 
improvements on existing methods to derive classical quantitative PET indices and permit extraction 
of additional information to further characterise patient populations in the clinical setting and in 
relation to therapy. 
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Chapter 1.  Introduction 
 
 
1.1.  Motivation and statement of the problem  
Cancer is a heterogeneous class of genetic diseases. According to Cancer Research UK 
(2013a), more than one in three people will develop cancer during their lifetime. The most 
common type diagnosed in the UK is breast cancer which represents a third of the cancers in 
women. Half of the people diagnosed with breast cancer still do not survive their disease for 
more than five years.  
 
Positron Emission Tomography (PET) imaging has grown from a detection and visualisation 
modality to incorporate more complex image processing and analysis methodologies, in order 
to quantify biological and biochemical processes. The aim is to capture more relevant, 
objective and reliable information that will benefit patient stratification, help understand the 
underlying biology of cancer, lead to increased effectiveness and help clinicians in their 
therapeutic choice, as well as improve treatment monitoring and cost-effectiveness. In this 
sense, standardised uptake indices are being used in the clinic, while more sophisticated and 
powerful methods based on kinetic modelling, although not practical in the clinical context, 
have been used in the research context. 
 
In the context of personalised medicine, there is a growing need for methods that can capture 
relevant and exhaustive information about the biology and genetics of lesions. Intra-tumour 
heterogeneity is increasingly being recognized as a key characteristic of cancer and a possible 
cause for treatment failure. Accurate characterisation and quantification methodologies in 
PET imaging need to take into account this intra-tumour biological heterogeneity at the 
macroscopic level. Although the resolution of PET is limited, it is expected that cellular 
heterogeneity is, at least partially, detectable with PET (e.g. tumour with a necrotic centre). 
This has called for the development of methods and descriptors that can capture the 
complexity of radiotracer uptake in lesions, beyond the use of standardised uptake indices.  
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Following the introduction of texture analysis to the field by El Naqa et al (2009), an 
increasing number of studies has been published in the last three years evaluating and 
proposing descriptors to quantify intra-tumour heterogeneity in PET. The visualisation of 
biological heterogeneity in PET has also been proposed within the context of radiotherapy for 
dose painting (Nyflot et al, 2012; Le Maitre et al, 2010). Other applications include the 
spatial correlation between different biological functions measured using PET imaging, on 
resected lesions or using multimodality imaging. Critical components of these applications 
are the limitations associated with PET quantification.  
 
The motivation of this thesis is to contribute towards the development of quantification tools 
that can describe and capture spatial and statistical complexity. Such tools can be used to 
measure the extent of disease as well as capture heterogeneity in the PET signal.  
 
1.2.  Outline of thesis  
In Chapter 2, an introduction to cancer and intra-tumour biological heterogeneity is provided. 
The role of intra-tumour heterogeneity and the need for more comprehensive methods for the 
characterisation of biological properties at the scale of the whole tumour are discussed.  PET 
imaging is introduced, in terms of its physical principles, main applications in the context of 
clinical oncology, as well as quantification methods that are already well established.  
 
A review of the literature regarding the quantification of PET radiotracer uptake, beyond the 
use of current indices in the clinic, is presented in Chapter 3. Of particular interest are studies 
taking into account the variability in PET radiotracer uptake, as well as its spatial extent. The 
main challenges and limitations to quantification are also outlined. The aims and objectives 
of this Ph.D. follow. 
 
In Chapter 4, the statistical texture analysis methods used to quantify intra-tumour 
heterogeneity are introduced. The principles of a multifractal approach, developed to recover 
the space-filling properties of neoplastic lesions in PET imaging, are introduced and 
illustrated using simple examples. Details of the clinical 
18
F-FLT PET dataset used in this 
thesis are also given in Chapter 4. 
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The results of the texture analysis work are displayed in Chapter 5. Further developments to 
the multifractal method, as well as results obtained on a range of datasets (fractal objects, 
synthetic simulations, realistic PET simulations and test-retest 
18
F-FLT PET dataset), are 
presented in Chapter 6.  
 
Results are discussed and described in the wider context of PET quantification in Chapter 7, 
before the thesis is concluded in Chapter 8. 
 
1.3.  Thesis contributions, publications and software developed 
1.3.1.  Thesis contributions 
To my knowledge, the work presented on texture analysis is the first study in which image 
descriptors of intra-tumour heterogeneity in PET images were applied to a tracer different 
from 
18
F-FDG in relation to therapy assessment, as well as to intra-tumour biological 
heterogeneity characterisation. It is also the first work that looked into associations between 
textural features, lesion size, and injected dose in the field.  
 
The multifractal method developed to recover the space-filling properties of objects, such as 
neoplastic lesions in PET imaging, is an original method that takes into account partial 
volume effects (PVEs) during the quantification stage and which allows for deriving classical 
indices while not relying on a robust delineation of the lesions’ voxels as in traditional 
approaches.  
 
1.3.2.  Publications 
Willaime, J. M. Y., Aboagye, E. O., Tsoumpas, C., Polycarpou, I. & Turkheimer, F. E. 
(2013) Space-filling properties of a complex object: A fractal approach to correcting partial 
volume effects in oncological PET imaging [In preparation] 
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Willaime, J. M. Y., Turkheimer, F. E., Kenny,  L. M. & Aboagye, E. O. (2013) 
Quantification of intra-tumour cell proliferation heterogeneity using imaging 
descriptors of 18F fluorothymidine-positron emission tomography, Phys. Med. Biol., 
58(2),187-203. 
 
Willaime, J. M. Y., Turkheimer, F. E., Kenny, L. M. & Aboagye, E. O. (2012) Image 
descriptors of intra-tumor proliferative heterogeneity predict chemotherapy response in 
breast tumors. SNM Annual Meeting, 9 Jun 2012 - 13 Jun 2012, Journal of Nuclear 
Medicine, 53 (S1):387. 
 
1.3.3.  Software developed 
 TexLAB: a MATLAB toolbox and graphical user interface for texture analysis. The 
software handles a range of image pre-processing tasks, creation of database for batch 
computation and input of additional variables. The output was designed to facilitate 
statistical analyses.  
 
 Filling-Factor software: MATLAB toolbox and graphical user interface for recovering 
the space-filling properties of an object using a multifractal approach. 
  
 
  27 
 
Chapter 2.   Background 
 
 
 
In this chapter, the background to my research is described. Notions that will be referred to in 
subsequent chapters regarding the biological bases of cancer and heterogeneity, clinical 
oncology, as well as PET imaging are also introduced.  
 
2.1.  Biological basis of cancer and heterogeneity 
Cancer is a heterogeneous class of genetic diseases which are characterised by uncontrolled 
cell growth, deregulated communication pathways and the capacity of cancer cells to invade 
surrounding tissues and to spread to other locations in the body via the bloodstream or 
lymphatic vessels to form nodes and metastases. 
 
2.1.1.  Hallmarks of cancer  
Hanahan and Weinberg (2000) conceptualised the biological traits that characterise cancer by 
identifying six hallmarks of the disease: sustained cell proliferation, insensitivity to 
antigrowth signals, infinite replicative potential, resistance to cell death, angiogenesis, and 
invasion and metastases. Normal cells proliferate through a highly controlled sequential 
process divided into four phases (G1: growth phase which entails enzyme synthesis, S-phase: 
deoxyribonucleic acid (DNA) replication, G2: protein synthesis, Mitosis: nuclear division) 
(Alberts et al, 2008). By contrast, cancerous cells bypass these controls and sustain 
proliferation independently of their environment. The mechanisms involved in the acquisition 
of these key functional cellular changes as well as the time at which these events happen are 
specific to each type of cancer. Hanahan and Weinber (2011) suggested that genetic 
instability and inflammation play a role in the progression of the illness by providing 
favourable conditions for the emergence of these hallmarks. 
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2.1.2.  Multi-scale extent of biological heterogeneity in cancer 
Cancer is a complex, dynamic and multi-scale process (e.g. across spatial and temporal 
scales) (Gillies et al, 2010) which displays important heterogeneity at the population and 
patient levels, as well as within individual lesions (Jin et al, 2011; Marusyk & Polyak, 2010; 
Basu et al, 2011). At the population level, distinct molecular subtypes have been identified 
for certain cancer types. For instance, oestrogen receptor alpha (ERα), progesterone receptor 
(PgR) and human epidermal growth factor receptor 2 (HER2) expressions in breast cancer 
have been identified as key biomarkers for cancer subtype stratification at diagnosis (Patani 
et al, 2013). Further, low concordance between the expression of molecular biomarkers 
measured at primary and metastatic sites has been reported for a range of cancers (Marusyk 
& Polyak, 2010; Jin et al, 2011). Heterogeneity between distant lesions also manifests as 
different patterns in response to therapy (Kenny et al, 2007). 
 
2.1.3.  Intra-tumour biological heterogeneity 
Individual lesions in each patient are composed of a heterogeneous pool of cells (e.g. cancer 
cells, immune/inflammatory cells, vascular structures) (Diaz-Cano, 2012). Virtually all 
tumour types display intra-tumour heterogeneity. This manifests through phenotypic 
expressions such as the diversity of cell morphology, the unequal expression of receptors and 
the inhomogeneity of the tumour microenvironment (Marusyk and Polyak, 2010; Campbell 
and Polyak, 2007). Different regions of the same tumour display different degrees of 
vasculature, hypoxia, metabolism and proliferation (Hanahan and Weinberg, 2011). Gerlinger 
et al (2012) exemplified the spatial nature of this heterogeneity, finding that different regions 
of the same tumour contained distinct genetic properties and/or genetic expressions 
associated with good and poor prognosis.  
 
The causes of intra-tumour heterogeneity might be multiple and are still poorly understood. 
Theories of tumour growth such as the “clonal evolution” (Nowell, 1976) and the “stem-cell” 
theory concept (Visvader and Lindeman, 2008) suggest different interpretations of this 
heterogeneity in terms of heritable and non-heritable traits (Marusyk & Polyak, 2010; 
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Campbell & Polyak, 2007). On the one hand, the “clonal evolution” concept proposes that 
tumour progression follows localised Darwinian processes in which small fractions of all the 
mutations affecting the cancerous cell population in an area of the tumour are selected and 
passed onto the next generations. On the other hand, the “cancer stem-cell” theory suggests 
that only a small group of cells within the tumours have acquired the capacity to proliferate 
infinitely and are driving tumour progression. This theory implies that intra-tumour 
heterogeneity is a non-inherited characteristic due to differentiated daughter cells. More 
recently, theories involving tumour cell plasticity have been suggested (Hill, 2006). This 
phenotypic plasticity concept suggests that cancer cells have different “stem-cell like” 
potentials which are influenced by their local microenvironment (Marusyk & Polyak, 2010; 
Smalley et al, 2005; Park et al, 2000).  
 
2.2.  Clinical oncology: strategies, therapies and clinical endpoints 
2.2.1.  Cancer management strategies 
2.2.1.1.  Cancer therapies 
The main treatment options for cancer therapy include chemotherapy, radiotherapy, surgery, 
hormone therapy and biological therapy (Cancer Research UK, 2013b). Chemotherapy is the 
treatment of cancer using drugs. Also known as “cytotoxic” treatment, chemotherapy is 
primarily aimed at killing highly proliferating cancer cells. It can be given as a single drug or 
as a combination of several drugs. Radiotherapy is the use of radiation to damage cancer cell 
DNA, thereby indirectly “killing” the cancer cells, using either external radiation (e.g. X-rays 
or cobalt irradiation) or internal radiation (e.g. radioactive source inserted in or around the 
tumour). Surgery may be used to cure cancer that is entirely contained within an area and has 
not spread, or in conjunction with other therapies when the cancer has spread elsewhere in the 
body. Hormonal therapy can also be used to treat cancer when tumour growth is dependent 
on hormone levels (e.g. breast, prostate, ovarian, uterine or kidney cancer). Biological 
therapies are a more recent treatment for cancer resulting from a better understanding of the 
underlying biological mechanisms involved. In the era of molecular imaging and genome, 
proteome and epigenome sequencing, specific pathways involved in cancer can be identified 
with the promise of yielding better patient stratification and more specific and targeted 
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therapies (Stricker et al, 2011). Biological therapies target specific biological processes in 
cancer cells, for instance, to block cell division and growth, identify and kill cancer cells (e.g. 
through cancer drugs or radiation), or to cause the immune system to recognise and target 
cancer cells (e.g. immunotherapy, vaccination).  
 
The availability of cancer treatment options depends on the location and grade of the 
lesion(s), the stage of the disease as well as the general health of the patient. Many of these 
treatments can be used together or at different time points during therapy. For instance, 
concurrent radiochemotherapy; chemotherapy or radiotherapy performed before (neo-
adjuvant) or after (adjuvant) surgery are common. 
 
2.2.1.2.  Cancer staging 
Cancer staging consists of assessing the extent to which a cancer has developed and spread in 
the body (TNM Staging Help, 2013; National Cancer Institute, 2013a). Cancer staging aims 
to assist clinicians in the context of treatment planning, provide an indication of prognosis 
and a framework for interpreting treatment outcome, as well as facilitate multi-centre study 
comparisons and drive further research. Cancer staging is specific to each cancer type. 
Different assessment systems have been proposed. The Tumour Node Metastasis (TNM) 
system is the standard method accepted across the world (Union for International Cancer 
Control, 2013). Other similar guidelines, such as the American Joint Committee on Cancer 
(AJCC) staging system which is based on the TNM system, are also widely used. These two 
staging methodologies describe:  
 the primary tumour (T) e.g. T0: not visible, Tis: carcinoma in situ, T1-T4: size and/or 
extent of the primary tumour; 
 lymph node (N) involvement e.g. N0: no nodal involvement, N1-N3: nodal 
involvement (number and size); 
 metastasis (M) e.g. M0: no metastasis and M1: metastasis. 
 
The TNM stage is then given an overall score (from I to IV) which indicates the severity of 
the cancer, also known as overall stage grouping:  
 Stage 0: isolated tumour (carcinoma in situ); 
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 Stage I: cancer localised to a specific area; 
 Stage II and III:  locally advanced cancer with lymph node involvements (specific 
classification depends on cancer type); 
 Stage IV: cancer that has spread to another organ(s). 
 
The staging process is performed using physical examinations, imaging (X-rays, CT, MRI), 
laboratory tests (e.g. blood, urine, other fluids), pathology (e.g. biopsy) and surgical reports. 
The staging often occurs before surgery using clinical examinations, also known as clinical 
staging. After surgery, a pathological examination is sometimes possible. However these two 
classifications are kept separate as the investigations used are different, and sometimes not 
performed under the same conditions (e.g. when tissue from neo-adjuvant therapy is used 
before resection of the tumour and pathological staging).  
 
2.2.1.3.  Tumour grading 
Tumour grading is a classification of cancer cells based on their appearance under a 
microscope (pathological examination). It is an indication of how different cancer cells are 
from the cells they originate from. It is sometimes used for the pathological grading of 
tumours. Grading systems vary across cancer types. The guidelines issued by the AJCC to 
grade tumours are as follows (National Cancer Institute, 2013b):  
 GX: cannot be assessed  (undetermined grade); 
 G1: well differentiated (low grade) ; 
 G2: moderately differentiated (intermediate grade) ; 
 G3: poorly differentiated (high grade) ; 
 G4: undifferentiated (high grade); 
 
2.2.2.  Clinical and pathological endpoints 
Assessing response to therapy is essential for the clinical management of cancer and for the 
selection of new targeted drugs (Wahl et al, 2009). Measures of tumour size reduction is one 
of the main variables taken into consideration when assessing response to therapy. Successive 
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guidelines have been proposed including the World Health Organisation (WHO) criteria in 
1981 and the more recent Response Evaluation Criteria in Solid Tumours (RECIST) criteria 
(Therasse et al, 2000; Eisenhauer, 2009). Tumour response assessment using the RECIST 
criteria is based on percentage changes in the sum of diameters (of multiple) lesions 
following therapy and in comparison to baseline. The guidelines include recommendations 
for measurement methods (e.g. callipers, CT images) and the minimum size of the lesion to 
be included. They originally recommended including a maximum of 10 lesions per patient 
(and 5 per organ), so-called target lesions, in the measurement. These numbers were later 
revised down to a total of 5 lesions per patient and 2 per organ (Eisenhauer et al, 2009).  
Other visible lesions, so-called non-target lesions, are only assessed visually to indicate 
overall response.  
 
Based on target lesion measurements, patients are classified as follows according to the 
RECIST criteria: 
 Complete response (CR): disappearance of all lesions and pathological lymph nodes 
less than 10mm in short axis; 
 Partial response (PR): a reduction in the sum of diameters of the target lesions of 
more than 30% (compared to baseline); 
 Progressive disease (PD): an increase in the sum of diameters of the target lesions of 
more than 20% (compared to baseline) or the appearance of new lesions;  
 Stable disease (SD): no reduction or increase in the sum of diameters above 30% and 
20% respectively. 
 
The RECIST criteria are purely based on an anatomical measurement of tumour shrinkage. 
However, this reduction in the tumour volume does not always occur and is not a relevant 
indicator of positive treatment outcome in the case of new cytostatic drug therapies 
(Michaelis & Ratain, 2006). In addition, this method could impede the chances of survival for 
patients who do not respond to conventional treatment by delaying a change in therapeutic 
strategy while exposing them to unnecessary toxic effects (Kenny et al, 2007).  
 
Assessment of tumour metabolic response using 
18
F-FDG PET has been also suggested as a 
biomarker of treatment outcome (Wahl et al, 2009). Reduction of radiotracer uptake, using 
the semi quantitative Standardized Uptake Value (SUV) index after the first cycles of 
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therapy, has been shown to predict tumour response in various cancer types (Avril et al, 
2009; Wahl et al, 1993; Wahl et al, 2009). Because of the lack of standardisation in 
18
F-FDG 
PET procedures these methods have not been adopted in the clinical context for volumetric 
functional assessment and response to treatment assessment (Eisenhauer et al, 2009). No 
agreement has been reached regarding the time of post-treatment scanning and a threshold 
value of SUV reduction (Avril et al, 2009). Changes in 
18
F-FDG uptake during therapy have 
also been shown to depend on the therapeutic agent (Avril et al, 2009; Dehdashti et al, 1999; 
Mortimer et al, 2001) and the administration protocol used (Schneider-Kolsky et al, 2010). In 
addition, the use of 
18
F-FDG PET for early assessment of therapy response has been criticised 
for its non-specificity to tumour activity (Brindle, 2008). Other PET imaging probes that are 
not sensitive to inflammation and target cell proliferation (e.g. 
18
F-FLT) (Kenny et al, 2007) 
or hypoxia could be more appropriate biomarkers of response to treatment because these 
processes are probably more affected by cytostatic treatments than glucose metabolism  
(Gambhir, 2002; Kenny et al, 2007; Weber, 2006). 
 
2.3.  Consequences of biological heterogeneity in cancer treatment 
and monitoring 
2.3.1.  Towards more specific targeted therapies 
Personalised medicine strategies rely on tumour genetic profiling for prescribing a treatment 
tailored to the individual (Stricker et al, 2011). It has been envisaged that this would be 
feasible using a single biopsy of the corresponding tissue (Gerlinger et al, 2012). For 
instance, targeted therapy has been successful in treating tumours for which systemic 
chemotherapy has failed, including lung cancers, hepatoma, renal-cell cancer, neuroendocrine 
tumours, melanoma, and others (Longo, 2012). However, although more specific 
classification of patient disease into subtypes (e.g. oestrogen receptor positive or negative 
breast cancer) has been possible through genetic and phenotypic profiling, the efficacy of 
targeted therapy and personalised medicine remains limited (Jin et al, 2011; Patel et al, 2011; 
Basu et al, 2011). For instance, very limited efficacy has been shown using epidermal growth 
factor receptor (EGFR/HER1) inhibitors in non-small cell lung cancer (NSCLC), head and 
neck and colorectal cancer with a response rate of between 5 and 15% (Patel et al, 2011; 
Fukuoka et al, 2003). Similarly, erlotinib and getinib which are tyrosine kinase (TK1) 
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inhibitors have shown only a 10% response rate to treatment in non-selected NSCLC patients, 
and the overexpression of EGFR is not associated with therapeutic response (Patel et al, 
2011). Better results have been obtained in selected patient populations exhibiting EGFR 
mutations (Landi et al, 2011; Janku et al, 2010). For instance, NSCLC patients who have 
never smoked are more likely to respond to erlotinib and getinib than smokers (Linardou, 
2009). On the contrary K-RAS oncogene mutations, which are more frequent in elderly and 
heavy smokers, (Subramanian & Govindan, 2008) have identified patients unlikely to 
respond to treatment. Curtis et al (2012) recently revealed and validated new breast cancer 
subgroups based on extensive genomic analyses that differentiated between clinical 
outcomes. 
 
Two main challenging factors in developing and assessing targeted therapies have been 
identified as genetic instability and intra-tumour heterogeneity (Moyret-Lalle, 2008; Stricker 
et al, 2011). Current diagnostic techniques such as individual biopsies and microarray 
sampling might underestimate biological variability because of averaging, and because of the 
localised nature of the sampling which might not be representative of the whole tumour, 
especially in the case of heterogeneous lesions (Gillies et al, 2010; Patel et al 2011; Gerlinger 
et al, 2012). As a consequence, these techniques can introduce potential bias and errors 
during diagnosis, classification and prognosis (Patel et al, 2011; Stricker et al, 2011). Silva & 
Gatenby (2010) pointed out that, due to genetic instability, genetic and phenotypic intra-
tumour heterogeneity might be present even in the smallest detectable lesions (around 1cm
3
) 
in the clinic, containing typically around 10
9
 cells. In this study, tumour heterogeneity was 
modelled using two populations of cancer cells. The first cancer cell population was located 
within the inner core of the lesion and characterised by a more hypoxic, less proliferative 
profile and within an acidic environment (lower pH). These biological characteristics were 
expected to confer chemotherapy resistance on this population of cells. The second 
population, better vascularised, was located in the outer rim of the lesion and characterised by 
greater proliferation, thus having a more chemo-sensitive profile. Two types of therapies 
were used: chemotherapy to target cells of the outer rim and a glucose competitor to deprive 
cells of glucose in the lesion core. The authors found that using glucose restriction therapy 
followed by chemotherapy was the most optimal therapeutic strategy, compared to these two 
therapies alone, simultaneously or chemotherapy followed by glucose restriction therapy. 
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One of the limitations of this work was failure to take into account the effect of mutations and 
resistance acquired during therapy.  
 
2.3.2.  Biological heterogeneity: a dynamic and adaptive landscape 
Beyond the need for characterising biological intra-tumour variability, one of the challenges 
is to identify which events drive cancer growth and which events are only by-products of this 
heterogeneity (Yap et al, 2012). The task is immensely complicated by the dynamic, 
stochastic and non-linear nature of this landscape (Gatenby, 2003), and by the 
interdependence of these driver and passenger events whose roles might change over time 
depending on the environmental context (Yap et al, 2012). Accumulating evidence suggests 
that genetic instability and intra-tumour heterogeneity favour the emergence of a variety of 
drug resistance mechanisms and the natural selection of fitter clones in response to cytotoxic 
and/or targeted therapies (Gottesman et al 2002; Gerlinger & Swanton, 2010; Coffey, 1998; 
Gatenby, 2003).  Studies have shown that populations of cancer cells can adapt to targeted 
therapy through mutations as early as after the first round of therapy (Patel et al, 2011). The 
distribution of drug in lesions is limited by poor and chaotic vascularisation, and (cytotoxic) 
drug efficacy is diminished in less proliferating cells and hypoxic and acidic regions 
(Minchinton & Tannock, 2006). Models of tumour response to therapy have suggested a 
broad range of sensitivities among cancer cells to cytotoxic drugs due to intra-tumour 
heterogeneity (Gatenby, 2003). This inherent complexity increases the difficulty in assessing 
response to new therapeutic strategies and in understanding the mechanisms responsible for 
tumour progression and treatment failure (Yap et al, 2012). 
 
2.3.3.  Capturing biological heterogeneity  
Tools are needed to assess and quantify intra-tumour heterogeneity at the scale of the whole 
tumour. These tools can potentially contribute to a better understanding of cancer complexity 
and support clinical cancer management such as the assessment of treatment outcome. 
Current diagnostic techniques such as individual biopsies and microarray sampling may not 
be representative of the whole tumour especially in the case of heterogeneous lesions. A 
number of authors have acknowledged the potential of imaging and in particular functional 
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and molecular PET imaging for assessing intra-tumour biological heterogeneity in a non-
invasive fashion (Gillies et al, 2010; Patel et al, 2011; Basu et al, 2011), through the use of 
adapted quantification methods (Asselin et al, 2012; Tomasi et al, 2012). 
  
2.4.  Imaging cancer using Positron Emission Tomography 
Imaging modalities allow the detection, staging and monitoring of cancer disease non-
invasively. Anatomical and functional modalities used in clinical oncology and in the 
research setting include Computed Tomography (CT), Magnetic Resonance Imaging (MRI), 
Ultrasound (US), Positron Emission Tomography (PET) and Single Photon Emission 
Computed Tomography (SPECT). PET is the most sensitive functional imaging modality 
available to study in vivo biological processes and their alterations at the cellular and 
subcellular level. A radioactive compound of negligible amount (pico- to femtomoles/gram) 
is injected into the bloodstream of a living subject to study a specific biochemical process of 
interest without perturbing it (Phelps, 2000). PET imaging is a “scalable” technology which 
has been used in the preclinical and clinical context, as well as within the pharmaceutical and 
biotechnology industries for drug discovery (Cherry, 2006). In the clinic, 
18
F-FDG PET has 
primarily been used as a qualitative tool (visual assessment) to detect, diagnose and stage 
cancer, as well as for patient follow-up and assessing recurrence. For instance, whole-body 
18
F-FDG PET has been extensively used for detecting and staging (and re-staging) the extent 
of disease within the TNM framework (primary tumour, nodes and distant metastatic 
involvement). This classification helps stratify the patients into pathological-clinical stages 
and give indications regarding prognosis and treatment options.  
 
2.4.1.  Nuclear physics and Positron Emission Tomography 
2.4.1.1.  Positron emission and radioactive decay detection 
PET is based on the indirect detection of the radioactive decay of a positron-emitting 
radioactive compound (radiotracer) injected into the bloodstream of a living subject (Cherry, 
2006; Paans et al, 2002; Phelps, 2000). A positron is the antiparticle of an electron with same 
mass and opposite charge. Typically a positron is emitted during the radioactive decay of the 
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radiolabelled compound (rich in protons). It annihilates with an electron after travelling a few 
millimetres in tissue, producing two gamma photons. These two gamma photons are emitted 
at 511keV in opposite directions (approximately 180 degrees). PET scanners are equipped 
with several rings of detectors (e.g. sodium iodide doped with thallium [NaI(TI)], bismuth 
germanate [BGO], gadolinium orthosilicate [GSO] or lutetium oxyorthosilicate [LSO]) and 
an electronic circuit of coincidence. A decay event is recorded by the electronic circuit when 
two gamma photons are detected simultaneously (within a few nanoseconds) by a pair of 
scintillators, forming a line of response (LOR). The energy resolution and maximum count 
rate of the system depends on the characteristics of the detectors and electronics. The 
radioactive decay events detected in coincidence can be due to true positron emission on the 
LOR, “Compton” scattered events due to the deviation of the photons’ trajectory, or random 
coincidences. The gamma rays can also be subject to photoelectric effect yielding energy 
attenuation and the non-detection of the radioactive decay event. However this phenomenon 
is negligible for gamma rays emitted at 511keV.  
 
2.4.1.2.  Image reconstruction and corrections 
The acquisition of PET images is performed either in a static or dynamic mode. PET images 
are typically reconstructed using analytic (e.g. filtered back projection - FBP) or iterative 
(e.g. ordered-subsets expectation-maximisation - OSEM) methods (Alessio & Kinahan, 
2006). Although PET imaging is quantitative by nature, a range of corrections need to be 
applied prior to image analysis. This includes correcting for photon attenuations in the body 
using a density map from a CT scan or a transmission PET scan, correcting for scattered 
radiation and random coincidences (Paans et al, 2002). Additional corrections for partial 
volume effects (Section 2.4.1.3) and motion (Section 2.4.1.4) can also be applied.  
 
2.4.1.3.  Partial volume effects and corrections 
Partial volume effects (PVEs) designate a range of phenomena which affect PET image 
appearance and result in contaminations (or “spill-over”) of radiotracer activities between 
various regions (e.g. target, background, other organs) (Rousset et al, 2007; Soret et al, 2007; 
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Erlandsson et al, 2012). At the “target-level”, two concurrent effects take place:  a “spill-out” 
effect which consists of the loss of apparent activity in the target because of the spread of this 
activity to the surrounding background, and a “spill-in” effect which consists of the 
contamination of the lesions’ voxels by the background activity (Rousset et al, 2007). For 
instance, in the case of a hot lesion in a cold background, PVEs are mainly characterised by 
“spill-out” effects which results in an increased apparent lesion size and a lowered apparent 
radiotracer uptake (Rousset et al, 2007). Similarly, in lesions with a necrotic centre, PVEs 
might give the impression that there is more viable tissue than there actually is. 
 
The main contribution to PVEs comes from the finite spatial resolution of the PET imaging 
system due to PET physics, which results in a characteristic blur in the reconstructed PET 
images. The low spatial resolution in PET imaging is due to the uncertainty between the exact 
location of a radioactive decay event relative to the corresponding annihilation detected by 
the PET scanner (a few millimetres corresponding to the positron range), as well as to the 
detectors’ size, the coincidence electronics and the acquisition mode used (2D versus 3D) 
(Rousset et al, 2007). Typically, these effects are modelled by a point spread function (PSF) 
attributed to the scanner. Another cause of PVEs is the so-called “tissue-fraction effect” 
which is introduced in any digital image, independently of the resolution of the system, when 
discretising the intensities onto a voxels’ grid (Rousset et al, 2007). The discretisation process 
generates a mixture of intensities between adjacent structures (tissue types) within individual 
voxels. This effect is mainly ignored when correcting for PVE in PET; algorithms primarily 
focus on the PSF of the system (Erlandsson et al, 2012). For instance, Soret et al (2007) 
illustrated the impact of the “tissue-fraction effect” on quantification, showing that increasing 
the pixel width from 4 to 6 mm led to a decrease in standardised uptake index of 7%. 
Although an independent cause of PVEs, the “tissue-fraction effect” is indirectly affected by 
the finite spatial resolution of the PET scanner because the voxel size is set with the objective 
to reduce the noise in the PET signal.  
 
PVEs are complex to correct for because they also depend on other parameters that cannot be 
controlled for such as tumour size, shape, target to background ratio (TBR), and surrounding 
tissues (Soret et al, 2007). “Spill-in” and “spill-out” do not cancel out and it is difficult to 
predict the extent to which the pixels are affected. In addition, reconstruction methods and 
parameters (e.g. number of subsets and iterations) modify PVEs (Rousset et al, 2007). 
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Additional PVEs can be introduced during pre-processing of the images, for instance when 
smoothing the images with a Gaussian kernel (after reconstruction) so as to reduce the noise 
level.   
 
Many approaches have been proposed to correct for partial volume effects (partial volume 
correction - PVC), but none has been accepted as standard (Erlandsson et al, 2012). Strategies 
include pre- and post-reconstruction methods computed on a region or at the voxel level. The 
first approaches used multiplicative indices calculated experimentally, known as recovery 
coefficients (RC), as a function of lesion size, shape and location, to correct for distortion in 
radiotracer uptake at the region of interest (ROI) level (Hoffman et al, 1979). Subsequently, 
more sophisticated methods that took into account the effect of warm background were 
introduced, such as the Contrast Recovery Coefficients (CRC) (Kessler et al, 1984). Other 
methods taking into account the PVEs contributions of more than one tissue have also been 
employed such as the Geometric Transfer Matrix (GTM) methods. Many approaches have 
also been proposed for correcting images at the voxel-level. The most widely used 
approaches are deconvolution-based approaches for which one corrects for the point-spread 
function (PSF) of the PET imaging system. These methods have the advantage of not 
requiring any other information (e.g. anatomical). However estimating the PSF (space-
invariant or map) accurately becomes the critical point. When applied in the image domain 
(after reconstruction), using these methods also leads to noise amplification and/or the 
generation of artefacts that need to be corrected for. Strictly speaking the PSF of the system 
varies in space. However the PSF can be assumed to be invariant if the data are preliminarily 
corrected for variations in detectors performance (Erlandsson et al, 2012). Multi-resolution 
approaches (e.g. wavelet-based) have also led to interesting results whereby high resolution 
details (e.g. from a CT or MRI) are incorporated to a low resolution image (e.g. PET) 
(Boussion et al, 2006; Boussion et al, 2009). PVC methods incorporated into the 
reconstruction of PET images have also shown enhanced results, e.g. by modelling the 
positron range, noncollinearity, intercrystal scattering, and penetration effects (Rousset et al, 
2007).  
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2.4.1.4.  Motion correction 
Additional PVEs are introduced into the PET signal due to cardiac, respiratory and patient 
motion (Erlandsson et al, 2012).  Respiratory motion correction methods include tracking the 
breathing signal with an external device to derive a gated PET acquisition (Visvikis et al, 
2006; Nehmeh & Erdi, 2008). The main drawback of this method is that only a small 
percentage of the counts are used to reconstruct images, which reduces the signal-to-noise 
ratio (SNR). Post-reconstruction algorithms, known as reconstruction transform-average 
methods (RTA) (Tsoumpas et al, 2011), have been proposed to make use of all statistics 
(Visvikis et al, 2006). The events detected are binned into discrete gated frames (within 
which motion is negligible), realigned based on a registration method (e.g. “optical flow” 
technique), and finally averaged across transformed gated frames to recover a motion-
corrected image. Spatial-temporal motion-field information can be obtained using an external 
respiratory monitoring system. Anatomical imaging (e.g. CT or MRI) has also been 
suggested to incorporate information about internal organs motion. More sophisticated 
methods that incorporate motion correction at the reconstruction stage have been proposed, 
the so-called motion-compensated image reconstruction (MCIR) methods (Chun et al, 2012). 
For instance, MCIR methods have been evaluated on realistic PET simulations after 
incorporating a realistic spatial-temporal motion field derived from MR images (Tsoumpas et 
al, 2011).  
 
2.4.2.  Molecular imaging probes in PET  
PET imaging radiotracers are composed of a molecule of biological interest (e.g. protein, 
nucleic acid, antibody, or drug) radiolabelled with a radioisotope element (commonly 
15
O, 
18
F, 
11
C, 
13
N). PET images are maps of radiotracer concentration (kBq/mL) in tissues (Phelps, 
2000). In practice the design and production of imaging probes require intensive research and 
sophisticated procedures. 
 
18
F-FDG (
18
F-fluorodeoxyglucose), an analogue of glucose, is the most widely used 
biomarker in clinical oncology. It follows the same metabolic pathways as glucose but is 
trapped in the cells once phosphorylated into (
18
F)FDG-6-phosphate. The amount of 
radiotracer retained by the cells is proportional to the rate of glycolysis (Phelps, 2000). 
18
F-
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FDG PET is currently used in clinical oncology for detecting primary tumours, nodes and 
metastases, for the purposes of staging and response assessment (Papathanassiou et al, 2009). 
However, low sensitivity and specificity have been reported in the case of tumours with low 
glucose utilisation. High uptakes of 
18
F-FDG are also observed in certain organs (e.g. brain, 
bladder) and in inflamed and infected areas (Salskov et al, 2007). In addition, quantitative 
comparison between patients is not possible due to variations in 
18
F-FDG uptake and 
measurement settings (Brindle, 2008; Weber, 2006). 
 
More specific PET biomarkers have been developed for imaging biological functions 
involved in cancer progression such as cell proliferation, angiogenesis, hypoxia, and hormone 
receptor expression. For example
 11
C-carbon-choline and 
18
F-fluoro-choline (
18
F-FCH) have 
been used to investigate membrane lipid synthesis, 
18
F-fluoroestradiol (
18
F-FES) for imaging 
oestrogen receptor expression, 
18
F-fluoro-galacto-RGD and 
18
F-fluciclatide as markers of 
metastases and angiogenesis, 
18
F-fluoromisonidazole (
18
F-FMISO) and 
62
Cu-diacetylbis(N4-
methylthiosemicarbazone) (
62
Cu-ATSM) for monitoring hypoxia and 
18
F-fluorothymidine 
(
18
F-FLT) as a measure of cell proliferation (Papathanassiou et al, 2009; Kenny et al, 2007; 
Kenny et al, 2008; Weber, 2006; Contractor et al, 2009). 
18
F-FLT is a thymidine analogue. 
Thymidine is the only nucleic acid not present in ribonucleic acid (RNA).
 18
F-FLT is 
phosphorylated by thymidine kinase 1 (TK1) during the S-phase of DNA replication. 
18
F-
FLT uptake has been shown to be correlated with cell proliferation (measured using the Ki-67 
labelling index) in breast cancer (Kenny et al, 2005) and various other cancers (Salskov et al, 
2007). 
18
F-FLT PET is a promising method for assessing cell proliferation in vivo and 
overcoming the limitations of biopsy, the gold standard method: it is non-invasive, providing 
a measurement at the scale of the whole tumour and the possibility of assessing multiple 
lesions (Salskov et al, 2007; Li et al, 2004; Kenny et al, 2004).  
 
2.4.3.  Applications of PET in oncology and quantification methods  
2.4.3.1.  SUV measurements 
Quantification methods have been proposed to further characterise radiotracer uptake in 
neoplastic lesions in PET imaging with the aim of improving lesion detectability and 
discrimination between tissue types (e.g. malignant/benign), as well as deriving prognostic 
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indices, monitoring treatment response and measuring early response to therapy.  For 
instance, quantitative analysis has been shown to complement visual characterisation in 
distinguishing between malignant and benign pathologies, and is recommended for reducing 
inter-observer rating variability (Avril, 1997). The Standardised Uptake Value (SUV) is the 
most commonly used semi-quantitative index to quantify 
18
F-FDG PET radiotracer uptake in 
clinical practice (Figure 2.1). It is a normalised measurement of the concentration of 
radiotracer in tissue (kBq/mL) corrected for the injected dose of radiotracer (MBq) and body 
surface area (BSA), body weight (BW) or lean body mass (LBM) of the patient (Thie, 2004). 
SUV measurements have shown promise in monitoring early response to therapy prior to the 
manifestation of anatomical changes (Wahl et al, 2009; Kenny et al, 2007; Kwee, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Standardised Uptake Value (SUV) measurements. Example for patient 8 (validation 
scan) from the 
18
F-FLT PET FEC-chemotherapy dataset (see Section 4.3). Images were normalised 
for injected dose and body weight (OSEM, Gaussian post-filtering: FWHM = 5mm, images summed 
between 32 and 65 minutes). SUVmean was the mean SUV in tumour (region of interest in purple). 
SUVmax was the maximum (single-voxel) intensity value (in blue). SUVpeak was defined as the 
mean SUV in a circular region of interest (in white) of fixed diameter (1 cm) which was centered on 
the most active part of the tumour. All SUV measurements are illustrated in 2D and can be extended 
to 3D. 
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2.4.3.2.  Kinetic modelling 
More robust methods have been developed in the research context for studying the 
pharmacokinetics (PK) of radiotracers using dynamic PET images. The use of kinetic 
modelling in PET imaging was originally developed in order to quantify the rate of 
physiological and biochemical processes in brain studies. Compartmental modelling is the 
most widely used technique and allows accurate quantification based on specific knowledge 
of radiotracer distribution in tissues. However, this method assumes homogeneity within 
compartments which can result in over- or underestimation of parameters when applied to 
heterogeneous tissues. More robust techniques such as Patlak, Logan plot and Spectral 
analysis require less knowledge of radiotracer distribution and tissue characteristics but 
provide less specific information on tracer distribution (Schmidt & Turkheimer, 2002). The 
use of dynamic protocols for the acquisition of PET images as well as invasive arterial 
sampling are not practical in the clinic, limiting the use of PK modelling to research. 
 
2.4.3.3.  Limitations of current quantification methods 
In practice the use of SUV indices is limited by the absence of a widely accepted cut-off 
value in distinguishing between malignant and benign tissues, the sensitivity of SUVBW to 
patient weight (due to body fat) (Zasadny & Wahl, 1993; Sugawara et al, 1999), the influence 
of the time of scanning after injection on the SUV value, the plasma glucose level and the 
parameters used to reconstruct and pre-process the PET images (Keyes, 1995). SUV 
measurements derived from 
18
F-FDG PET scans are prone to a range of technical errors, and 
are sensitive to biological factors (e.g. glucose level in blood) and physical factors (e.g. 
reconstruction, time of measurements) (Boellaard, 2009). Although efforts have been made to 
standardise protocols in order to allow multi-centre comparisons, SUV measurements remain 
dependent on physical factors such as the limited spatial resolution of the scanner (PVEs) and 
noise. For instance, PVEs can bias the mean standardised uptake value in a tissue of interest 
due to activity contaminations of neighbouring structures. SUVmax has been suggested as a 
better index to overcome this limitation. However, being computed from the single most 
intense voxel in the lesion it is highly sensitive to noise. SUVpeak, defined as the average SUV 
within a small volume of interest drawn around a high-uptake portion of the lesion, has 
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recently been suggested as an alternative metric to overcome these limitations (Wahl et al, 
2009). However, different definitions have been used to compute SUVpeak and have been 
shown to affect the feature value and associations measured with response to treatment 
(Vanderhoek et al, 2012). Another limitation of SUV measurements (mean, max, and peak) is 
the mere description of the uptake, which does not capture the complexity of the PET signal. 
In particular, it does not capture intra-tumour heterogeneity and the spatial properties of the 
lesion, as measured with PET imaging. 
 
It has been suggested that medical images might contain more useful information than may 
be perceived with the naked eye, giving birth to the field of “radiomics” (Lambin et al, 2012; 
Kumar et al, 2012). Medical imaging could provide a multi-level description of intra-tumour 
heterogeneity, including anatomy, physiology, metabolism, proteins and genome (Lambin et 
al, 2012). In the era of personalised medicine, additional features extracted from medical 
imaging could include 1) more accurate response variables, and 2) information linked to 
genetic and molecular biochemical pathology (Chicklore et al, 2013). Segal et al (2007) 
demonstrated that 28 imaging features, including heterogeneity scores, predicted 78% of gene 
expression in primary liver cancer. The ability to capture through novel image descriptors a 
greater portion of tumour variability might be critical to predicting response to treatment and 
assisting clinical management in addition to clinical examination, histopathology and other 
imaging modalities. In addition, these tools could be useful for the development and 
assessment of new targeted drugs (Schneider-Kolsky et al, 2010). In the next chapter, the 
literature and the growing evidence that demonstrate the potential for using such approaches 
to characterise and quantify intra-tumour heterogeneity in PET imaging are reviewed. Those 
papers that acknowledge the limitations of quantification using PET are also discussed.   
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3.1.  Literature review: descriptors of intra-tumour PET 
radiotracer uptake  
A literature review was conducted to identify previous work focussing on the quantification 
and characterisation of radiotracer uptake in neoplastic lesions using PET. MEDLINE and ISI 
Web Of Science were searched using the search terms listed in Appendix A1 (date range: 
1950-2013 and 1970-2013 respectively). 
 
Studies were included if: 
 The focus was on quantification methodologies of the radiotracer uptake variability in 
PET oncology beyond the use of SUV metrics; 
 They addressed issues related to quantification in PET imaging.  
 
Studies were excluded if: 
 PET radiotracer uptake characterisation or quantification was only mentioned and was 
not a theme of the paper; 
 Only detectability issues in PET were studied; 
 Quantification procedures were exclusively carried out for evaluating and validating 
scanners’ performance or correction algorithms; 
 The variability in PET radiotracer uptake was not addressed; 
 The disease studied was not cancer. 
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Reviewing the literature revealed that the characterisation and quantification of PET intra-
tumour variability has been approached from different perspectives which are often 
application-driven. After selecting the relevant papers (Appendix A2), studies could be 
further categorised as follows: 
 
(i) Papers that evaluated and introduced image analysis methods to characterise and 
quantify intra-tumour heterogeneity (N = 47);  
 
(ii) Studies correlating PET spatial intra-tumour variability across radiotracers, imaging 
modalities, or techniques (e.g. after surgical resection) (N =24); 
 
(iii) Use of PET spatial intra-tumour heterogeneity to inform radiotherapy treatment 
planning (N = 3). 
 
Within the scope of this thesis, given the large number of publications in each of these 
categories, the focus is on the use of image descriptors to characterise and quantify the spatial 
and intensity variability in PET radiotracer uptake in oncology (i). The main findings and 
limitations of these studies as well as challenges to accurate PET quantification are discussed. 
Although of interest and essential to the field, other applications (ii and iii) are only 
mentioned in the Discussion (Chapter 7).  
 
A total of 45* papers relating to the quantification of intra-tumour variability and 
heterogeneity in the PET signal were retrieved. Different methods, which take into account 
heterogeneity in the intensity and spatial distribution, have been proposed and introduced 
within the last few years: model-based, statistical methods and/or approaches comparing the 
local spatial uptake of successive scans. These are reviewed in detail in the subsequent 
paragraphs.  
 
 
 
 
* The full text articles were all accessible except for two reviews: Singh & Miles (2012) and Dimitrakopoulou et 
al (2012) which were not available from Imperial College London Library nor from the British Library.  
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3.1.1.  Model-based techniques 
O’Sullivan et al (2003) proposed a model-based technique to derive a heterogeneity index for 
sarcoma lesions as the deviation between local intra-tumour spatial uptake of PET radiotracer 
and the uptake in an equivalent homogeneously filled object, whose shape was approximated 
by an ellipsoid (Table 3.1). This homogeneous object model was fitted to the real data and a 
gradient of intensities applied so as to take into account PVEs typical in PET imaging.  The 
authors evaluated the ability of their heterogeneity index to predict clinical outcome in a 
group of 238 patients with sarcoma who were scanned using 
18
F-FDG PET, prior to 
neoadjuvant chemotherapy or surgical resection (Eary et al, 2008). They found that their 
elliptical heterogeneity index (HE) was a strong independent predictor of patient survival. 
One major limitation of the study was the use of a set of ellipsoidal contours for the 
homogeneous lesion model. A second limitation was the spatially invariant nature of the 
model proposed. The authors also noted that HE was poorly associated with the presence of 
necrosis within the lesion, which is an indicator of high grade sarcoma cancer. The 
researchers addressed the shape limitation in subsequent work (O’Sullivan et al, 2005). In 
this new approach, an independent delineation step was employed to define a realistic 
boundary for the lesion. A set of contours that took into account this external boundary were 
then defined for filling in the lesion with a gradient of intensities as before. The authors 
derived a new descriptor: the surface heterogeneity index (HS), similar to HE (except for the 
definition of the set of contours). In addition they derived a third index for which the set of 
contours became more elliptical from the boundary to the centre of the tumour (HG). They 
then compared the results with the previous method in a group of 179 sarcoma patients. They 
found that HS was strongly correlated with HE. In addition, little information was added by 
HS in a multivariate model when controlling for HE. However, the authors found that the 
increase in risk of death associated with one standard deviation in these variables was 
substantially greater for HS than for HE (71.7% versus 36.2%).  Further statistical analyses 
suggested that HS was the strongest predictor of survival for this group of sarcoma patients. 
In a recent study, O’Sullivan et al (2011) proposed a more sophisticated approach in which 
not only global deviations from a model of PET radiotracer uptake are taken into account, but 
the within-lesion radiotracer uptake is further characterised by taking into account different 
characteristics such as an intense or necrotic core, which are thought to mimic different 
stages of tumour development.  
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Another model-based technique derived from fractal analysis has been proposed by 
Dimitrakopoulou-Strauss et al (2002) to characterise the complexity of time activity curves 
(TACs) of different tissues in dynamic PET imaging. The method is based on the 
computation of the so-called fractal dimension (FD) to characterise time activity curves 
(TACs). FD is a measure of complexity across scales of measurement. Within the context of 
this study it was an index of the space-filling property of the TACs in a 2D plane. The 
authors applied the technique to a range of datasets. For instance, they showed that the FD 
yielded promising results in classifying bone lesions (benign versus malignant) with a 
sensitivity of 71.88%, specificity of 81.58% and accuracy of 77.14%. Combining FD with 
other metrics (SUVs and kinetic parameters) further improved the results. The authors also 
showed that a combination of kinetic parameters (which included FD alongside kinetic 
parameters derived from compartmental analysis) differentiated between short- and long-term 
survival (cut off set to 1 year) in metastatic colorectal cancer patients (Dimitrakopoulou-
Strauss et al, 2004). FD discriminated between primary colorectal tumours and normal colon 
tissue with an accuracy of 88.78% (Strauss et al, 2007) as well as between sarcoma and 
benign tumours (Okazumi et al, 2009).  However FD neither discriminated between short- 
and long-term survival in patients with advanced NSCLC (Dimitrakopoulou-Strauss et al, 
2007), nor was it a predictor of response to chemotherapy in patients with metastatic soft 
tissue sarcomas (Dimitrakopoulou-Strauss et al, 2010). One of the drawbacks of this method 
is that FD was solely derived from a graph of mean radiotracer uptake at successive time 
points, therefore not accounting for the spatial heterogeneity in the radiotracer uptake. 
Another drawback was the likely sensitivity of the metric to the imaging protocol (e.g. image 
pre-processing, noise level, etc.) FD combined with other variables might also be unable to 
predict overall survival (OS) because of possible alternative therapies prescribed when 
patients relapse.  
 
Brooks & Grigsby (2013a) recently proposed a new index of intra-tumour heterogeneity 
derived from an average measure of voxel intensity deviation from the smoothest intensity 
transition between any two voxels in a VOI. The authors compared the ranking obtained by 
their metric to clinicians’ ranking and found some statistically significant associations (p-
value < 0.05, Spearman rank correlation). However, the strengths of the correlations were not 
reported. Additionally, extensive pre-processing of the images for visual assessment was 
performed (interpolation of the pixel values). This is equivalent to inferring what the 
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heterogeneity might look like at greater resolutions. Another major limitation of the study 
was that only the largest cross-sectional image was used for each lesion. Agreement between 
these results and whole-lesion heterogeneity needs to be investigated. Brooks & Grigsby 
(2013a) also proposed a modified metric to take into account lesions with a more complex 
shape. This modification consists of ignoring the distance between two voxels on a line that 
are separated by some background, and instead considering that these voxels are neighbours. 
Although this approach might potentially be justified for characterising rim-core-like pattern 
uptakes in PET, the example given by the authors should be interpreted with caution. Indeed, 
Brooks & Grigsby (2013a) illustrated the method on a spherical object with decreasing 
intensity values from the centre to the object’s border. They decimated the object by 
randomly positioning an increasing number of background spherical VOIs and computed the 
heterogeneity metric for all these cases. The authors found an increase in their heterogeneity 
metric with the number of decimations used and concluded that the metric was sensitive to 
the increasingly complex nature of the object’s shape. However, for each randomly 
positioned background VOI, one might also expect greater intensity differences between 
voxels on each side of the background VOI (considered to be neighbours in the computation 
of the “shape-aware” heterogeneity metric) in comparison to intensity differences between 
real neighbouring voxels. Increasing the number of decimations will also increase the number 
of such paired voxels entering the computation. Therefore the reported increase in the “shape-
aware” heterogeneity metric value (for this example) could also be due, at least partially, to 
implementation of the metric.  
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Table 3.1 – Descriptors derived from model-based techniques for quantifying intra-tumour 
heterogeneity in PET imaging 
 
Authors (Date) 
Cancer type 
(number of 
patients) and 
treatment 
PET 
imaging 
Image descriptors Clinical endpoint 
Dimitrakopoulou-
Strauss et al 
(2002) 
bone lesions 
(n = 83) 
N/A 
18
F-FDG 
baseline 
Fractal 
(box-counting) 
based on TAC analysis 
Benign/Malignant 
(histopathology) 
O’Sullivan et al 
(2003) 
Sarcoma  
(n = 74) 
n.s. 
18
F-FDG 
n.s.
 
Spatial ellipsoid model-based 
method 
Survival 
Dimitrakopoulou-
Strauss et al, 
(2004) 
colorectal  
(n = 25) 
chemotherapy 
18
F-FDG 
baseline  
+ during 
treatment 
Fractal 
(box-counting) 
based on TAC analysis 
Short- and long-
term survival 
groups 
O’Sullivan et al 
(2005) 
sarcoma  
(n = 179) 
n.s. 
18
F-FDG 
n.s. 
Spatial model-based method Survival 
Dimitrakopoulou-
Strauss et al 
(2007) 
NSCLC  
(n = 14) 
chemotherapy 
18
F-FDG 
baseline  
+ during 
treatment 
Fractal 
(box-counting) 
based on TAC analysis 
Short- and long-
term survival 
groups 
Strauss et al 
(2007) 
colorectal  
(n = 22) 
N/A 
18
F-FDG 
baseline 
Fractal 
(box-counting) 
based on TAC analysis 
Malignant/Normal 
tissue 
Eary et al (2008) 
sarcoma  
(n = 238) 
neoadjuvant 
chemotherapy 
and/or resection 
18
F-FDG 
baseline 
Spatial ellipsoid model-based 
method 
Survival 
Okazumi et al 
(2009) 
sarcoma  
or benign lesions  
(n = 117) 
N/A 
18
F-FDG 
baseline 
Fractal 
(box-counting) 
based on TAC analysis 
Benign/Malignant, 
histological grade 
and prognosis 
Dimitrakopoulou-
Strauss et al 
(2010) 
sarcoma  
(n = 17)  
chemotherapy 
18
F-FDG 
baseline 
Fractal 
(box-counting) 
based on TAC analysis 
Response based on 
survival cut-off 
O’Sullivan et al 
(2011) 
sarcoma  
(n = 185) 
n.s. 
18
F-FDG 
n.s. 
Spatial model-based method Survival 
Brooks & 
Grigsby (2013a) 
uterine cervix  
(n = 73) 
N/A 
18
F-FDG 
baseline
 
Gradient intensity model-
based heterogeneity index 
 
N/A 
N/A = not applicable 
n.s. = not specified 
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3.1.2.  Texture analysis methods 
El Naqa et al (2009) were the first to use texture analysis techniques to quantify intra-tumour 
PET heterogeneity. Since then, a number of studies have investigated the predictive and 
prognostic power of various statistical texture analysis methods computed on baseline 
18
F-
FDG PET images (Table 3.2). PET textural features have also been combined with 
descriptors of CT images (Yu et al, 2009a; Yu et al, 2009b; Vaidya et al, 2012). The textural 
descriptors employed (Table 3.2) included First Order Statistics (FOS) which are derived 
from the radiotracer concentration distribution in a tumour volume, Second Order Statistics 
computed from the Grey Level Co-Occurrence Matrix (GLCM) method which capture 
information about local spatial relationships between pairs of voxels within the lesion, and 
Higher Order Statistics which entail information about bigger clusters of voxels: Grey Level 
Run Length Matrix (GLRLM), Grey Level Size Zone Matrix (GLSZM) and Neighbourhood 
Grey-Tone Difference Matrix (NGTDM).   
 
El Naqa et al (2009) explored the usefulness of texture- and shape-based descriptors as well 
as indices derived from the cumulative SUV-volume histogram (CSH) curve in predicting 
treatment outcomes. They illustrated the method on two independent 
18
F-FDG PET pre-
treatment datasets: 14 patients with cervix cancer and 9 patients with head and neck cancer. 
The ability of individual features to predict the outcome was correlated with disease 
persistence (cervix dataset) and overall survival rate (head and neck dataset) and compared 
using Spearman correlation coefficients. In addition, receiver operating characteristic (ROC) 
analyses were used to assess the performance of a subset of selected features on multivariate 
analysis. For the cervix cancer dataset, textural features had the highest prediction power in 
terms of risk of therapy failure, followed by CSH features. Combining the best individual 
descriptors (one textural and one CSH feature) in a bivariate logistic regression model led to 
an area under the ROC curve of 0.76 with a predominant contribution from the textural 
descriptor. On univariate analysis, shape and CSH descriptors showed the strongest 
correlation with clinical outcome for the head and neck cancer dataset. On multivariate 
analysis, a CSH volume descriptor related to the most metabolically active voxels in the 
tumour volume (V90: corresponding to the volume of voxels with intensities at least 90% of 
SUVmax), was by far the strongest predictor variable in the head and neck cancer dataset. The 
authors concluded that the predominance of one class of features (volume-, shape- or texture-
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based) might be dependent on cancer type and clinical endpoint. It is important to note that 
the analyses were performed on small datasets, therefore the results obtained using 
multivariate analyses should be interpreted with caution and cannot be generalised. Shape 
descriptors might also suffer from being extra sensitive to the delineation technique employed 
and to other factors influencing lesion shape (motion and PVEs). 
 
Yu et al (2009a, 2009b) proposed using texture analysis methods for tissue classification in 
radiotherapy in a local manner, around each voxel, to derive parametric textural feature maps. 
The PET information was supplemented by CT to derive useful metrics for tissue 
classification at the VOI level (2009a) and then applied at the voxel level to delineate tumour 
targets (2009b). The performance of this classification technique was compared to manual 
and thresholding methods (2009b). Results suggested that the proposed method performed as 
well as manual delineation. Further validation using ground truth datasets is necessary.  
 
Galavis et al (2010) studied the influence of reconstruction parameters on feature values for a 
range of texture analysis techniques (FOS, GLCM, GLRLM, GLSZM and NGTDM) in a 
group of 20 patients with various cancer types. 
18
F-FDG PET imaging was performed on a 
PET/CT General Electrics (GE) Discovery VCT scanner (Waukesha, WI) 45 to 60 minutes 
after injection. Data were acquired both in 2D mode (OSEM reconstruction: 14 subsets, 2 and 
4 iterations), and in 3D mode (reconstructed using an Iterative-Vue Point Algorithm: 2 and 4 
iterations). Results were computed across various grid sizes (128x128 and 256x256 pixels) 
and post-reconstruction filtering (3, 4 and 5mm full width at half maximum [FWHM]). They 
classified features into three groups depending on the within-lesion percentage variations that 
were computed across reconstruction parameters.  
 
Tixier et al (2011) compared the performance of 38 statistical textural features, computed on 
baseline 
18
F-FDG PET images, in discriminating between three response groups to chemo-
radiotherapy. A total of 41 patients with oesophageal cancer entered the study and were 
classified as complete responders, partial responders or non-responders using the RECIST 
criteria one month after the completion of therapy. SUVmean and SUVmax measurements were 
only able to discriminate between complete responders versus non- and partial- responders, 
whereas the difference between the three groups was only just statistically significant using 
SUVpeak (p = 0.045, Kruskall-Wallis test). A subset of textural features were good predictors 
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of response to treatment at baseline, including GLCM Entropy (p = 0.0006), NGTDM 
Coarseness (p = 0.0002), as well as GLSZM Intensity variability (p = 0.0002). Textural 
features also led to higher sensitivity (76-92%) than SUV measurements. The authors 
subsequently studied the repeatability of First Order Statistics and features derived from the 
GLCM and GLSZM methods in 
18
F-FDG PET imaging in a group of oesophageal cancer 
patients (Tixier et al, 2012). The dataset included 16 patients scanned twice prior to therapy 
within 2 to 7 days of each other. The normal fluctuations in textural features varied from 
small variations of less than ±30% (e.g. GLCM Entropy, Homogeneity and Dissimilarity) to 
medium variations of around ±50%  (e.g. GLCM Contrast, FOS Skewness) and large 
variations of more than ±100%  (e.g. GLSZM Small Area Emphasis). 
 
Since then, other studies have investigated the usefulness of the 
18
F-FDG PET textural 
approach in oesophageal cancer patients. Dong et al (2012) explored the association between 
a subset of two GLCM features measured on baseline 
18
F-FDG PET scans and histological 
grade, as well as TNM (Tumour-Node-Metastasis) and AJCC (American Joint Committee on 
Cancer) stages in 40 patients with oesophageal squamous cell carcinoma . The authors found 
moderate associations between T (Tumour) stage and both GLCM Entropy (rs = 0.69, p < 
0.001, Spearman Correlation) and GLCM Energy (rs = – 0.47, p = 0.002), as well as a weak 
association between SUVmax and T stage (rs = 0.39, p = 0.013). Similarly statistical 
associations were found between N (Node) stage and GLCM Entropy (rs = 0.50, p = 0.001), 
N stage and GLCM Energy (– 0.41, p = 0.008), as well as with SUVmax (rs = 0.33, p = 0.04).  
 
Tan et al (2013) proposed using intensity-, shape-, textural- and geometric-based features on 
pre-treatment, post-treatment and difference (pre – post, CT registered) 18F-FDG PET 
images. A large number of features (192) were individually tested for their ability to 
discriminate between response groups to treatment using the area under a ROC curve and 
Mann-Whitney U-Test. Only the image descriptors which had the highest area under the 
ROC curve and were not too highly correlated with other image descriptors of the same class 
were selected. One major limitation of the study was the large number of features tested for 
their discriminative power of response to treatment for a limited group of patients (n = 20). In 
addition the robustness of the selected features could not be investigated (e.g. through a 
repeatability study). 
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Vaidya et al (2012) demonstrated the value of a multi-modality approach (combined 
18
F-FDG 
PET and CT feature-based metrics) for radiotherapy tumour assessment in lung cancer. They 
derived a total of 32 First Order Statistics, total lesion glycolysis (TLG), GLCM features and 
CSH features from 27 baseline 
18
F-FDG PET CT scans of patients with NSCLC. The authors 
used the statistical framework detailed in previous work (El Naqa et al, 2009) to analyse the 
performance of individual features selected on univariate analysis (Spearman’s correlation) in 
predicting radiotherapy outcome on multivariable logistic regression analysis. Clinical 
endpoints included the development of disease recurrence within the irradiated area and 
within the thorax as assessed for a period of at least 6 months using CT imaging and after the 
completion of therapy. The influence of motion correction applied to PET imaging was also 
studied. The authors found that CSH features were the best predictors of clinical endpoints in 
PET on univariate analysis. However the strengths of the Spearman’s correlations were weak 
(from 0.12 to 0.37). Results improved slightly using a bivariate logistic regression model that 
included two CSH volume indices: V80 measured on PET images and V70 measured on CT 
images. Vx, derived from the cumulative SUV-volume histogram curve, represented the sub-
tumour volume with voxels having intensity at least x% of the maximum intensity in the 
VOI. The bivariate model led to rs = 0.4854 (p = 0.0067) and rs = 0.5908 (p = 0.0013) for 
two respective clinical endpoints. The strength of the associations between GLCM textural 
features and clinical endpoints was weak (< 0.3) and was not statistically significant on 
univariate analysis. The authors stated that correlations slightly improved after motion 
correction for the textural features. However, according to the results reported (Vaidya et al, 
2012), this was only the case for two out of four features, and only for one out of two clinical 
outcomes measured (yielding a total of 8 correlations between textural features and clinical 
outcomes). For all other descriptors, the correlations with clinical outcome weakened or 
remained unchanged following motion correction of the PET images. Therefore no clear 
trend seemed to emerge in this study regarding the use of motion correction in relation to 
clinical outcome.  
 
George et al (2012a) proposed a subspace-based prediction framework for studying response 
to treatment using follow up scans and incorporating textural characterisation of primary and 
nodal lesions. They found that textural metrics enhanced the predictive power of the analysis 
when compared to classical quantification indices alone in a study including 15 metastatic 
colorectal cancer patients. 
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Cook et al (2013) recently applied the NGTDM method to primary tumours of a series of 53 
patients with NSCLC. Patients were imaged at baseline using 
18
F-FDG PET imaging and 
measured for response to radiochemotherapy at 12 weeks using the RECIST criteria. In 
addition, overall survival (OS), progression-free survival (PFS) and local progression-free 
survival (LPFS) were collected. The authors found a statistically significantly lower NGTDM 
Coarseness (p = 0.004), higher NGTDM Contrast (p = 0.044) and higher NGTDM Busyness 
(p = 0.002) in non-responder versus responder patients. The other feature, NGTDM 
Complexity, and SUV measurements did not predict response to treatment. In addition, 
Coarseness was found to be an independent predictor of OS on multivariate analysis, while 
Contrast and Busyness were associated with PFS and LPFS. 
 
Salamon et al (2013) proposed using the ratio SUVmax/SUVmean as a semi-quantitative index 
of intra-tumour heterogeneity. They compared the metric performance to SUVmax as well as 
to a qualitative intra-tumour heterogeneity score in a group of 50 patients with peripheral 
nerve sheath tumours using 
18
F-FDG PET. The authors found a statistically significant 
difference in intra-tumour heterogeneity between benign versus malignant tumours (p = 
0.0002) using this semi-quantitative index. However, greater separability was achieved using 
SUVmax alone (p = 0.0001). Malignant tumours were also significantly bigger than benign 
tumours (p < 0.0001). Therefore, the differences observed might not be due to heterogeneity 
itself, but to lesion size and differences in mean and maximum standardised uptake values 
between the two groups of patients. The reason behind this choice of heterogeneity metric 
was not clear. Further, a major limitation of this index is its expected sensitivity to noise 
(similar to SUVmax). 
 
Yang et al (2013) recently applied the GLSZM and GLRLM methods to a cervical cancer 
dataset of 20 patients who were treated with radiochemotherapy. Patients were scanned using 
18
F-FDG PET at baseline, two and four weeks after the onset of therapy and after completion 
of therapy. The authors found that regions of high uptake decreased significantly with time in 
complete metabolic responders (p < 0.001). By contrast, SUV indices decreased in both 
response groups from baseline up to four weeks after the onset of therapy. Results obtained 
with both GLSZM and GLRLM derived textural features were similar.  
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A range of statistical texture analysis methods has been proposed in the literature for 
assessing intra-tumour heterogeneity using 
18
F-FDG PET imaging. Authors have often 
reported results for a subset of these techniques and features. Except for the repeatability 
study published by Tixier et al (2012) using 
18
F-FDG PET in oesophageal cancer patients, no 
work has been carried out to select a subset of techniques and features on an objective basis 
prior to assessing associations with clinical outcome. Further, these techniques have been 
applied to many different imaging protocols (e.g. scanner and reconstruction algorithms) and 
cancer types in different institutions. Given the resolution-dependent nature of textural 
features, it is difficult to determine whether certain techniques perform better than others, 
based on current literature. More studies are needed to answer this question.   
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Table 3.2 – Studies using texture analysis methods: descriptors and methods 
Authors 
(Date) 
Cancer type 
(number of patients) and 
treatment 
PET imaging 
PET quantification and 
Statistical/Evaluation methods 
Clinical endpoint 
Other metrics or 
methods 
El Naqa 
(2009) 
- cervix (n = 14) 
- head and neck (n = 9) 
radiochemotherapy 
18
F-FDG 
baseline 
GLCM features, CSH indices, shape 
descriptors 
 
 
 
- Disease persistence 
(cervix) 
- Overall survival rate  
(head and neck) 
SUV measurements 
(mean, max, min, 
standard deviation) 
Yu et al 
(2009a) 
head and neck (n = 20)   
+ lung ("controls" for head 
and neck areas) (n = 20) 
N/A 
18
F-FDG 
baseline 
FOS, GLCM, NGTDM 
- Textural maps generation  
- Classifier training and testing 
- Classification performance assessed 
with leave-one-out method 
N/A N/A 
Yu et al 
(2009b) 
head and neck (n = 10) 
N/A 
18
F-FDG 
baseline 
FOS, GLCM, NGTDM 
 
N/A manual delineation, 
threshold-based 
segmentation methods  
Galavis et al 
(2010) 
various solid tumours  
(n = 20) 
N/A 
18
F-FDG 
baseline 
FOS, GLCM, GLRLM , GLSZM, 
NGTDM 
Variability study for different 
reconstruction parameters 
 
N/A SUVmean 
Tixier et al 
(2011) 
oesophageal (n = 41) 
radiochemotherapy 
18
F-FDG 
baseline 
FOS, GLCM, GLRLM , GLSZM, 
NGTDM 
  
Response to treatment 
(RECIST) 
SUVmean, SUVmax and 
SUVpeak 
Dong et al 
(2012) 
oesophageal ( n = 40) 
surgery 
18
F-FDG 
baseline 
GLCM features 
 
Histological grade, TNM 
stage, AJCC stage  
SUVmax 
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Authors 
(Date) 
Cancer type 
(number of patients) and 
treatment 
PET imaging 
PET quantification and 
Statistical/Evaluation methods 
Clinical endpoint 
Other metrics or 
methods 
George et al 
(2012a) 
metastatic colorectal  
(n = 15) 
biological therapy 
18
F-FDG 
baseline 
+ during therapy 
FOS, GLCM, GLRLM and GLSZM Survival SUVmean, SUVmax, 
SUVpeak, TLV, TLG 
Tixier et al 
(2012) 
oesophageal (n = 16) 
radiochemotherapy 
18
F-FDG 
baseline 
FOS, GLCM, GLSZM 
 
N/A (Repeatability study) SUVmean and SUVmax 
Vaidya et al 
(2012) 
NSCLC (n = 27) 
radiotherapy 
18
F-FDG 
baseline 
FOS, CSH features, TLG and GLCM 
features derived from PET and CT 
images 
 
Disease recurrence within 
irradiated area and thorax 
SUVmean, SUVmax and 
TLG  
Cook et al 
(2013) 
NSCLC (n = 53)  
radiochemotherapy 
18
F-FDG 
baseline 
NGTDM 
Response to treatment 
(RECIST) and survival 
SUVmean, SUVmax, 
SUVpeak, TV and TLG 
Salamon et 
al (2013) 
neurofibromatosis type 1 
(n = 50) 
N/A 
 
18
F-FDG 
N/A
 
Heterogeneity index (SUVmax/SUVmean) Histopathological evaluation SUVmean, SUVmax, visual 
heterogeneity scoring 
Tan et al 
(2013) 
oesophageal (n = 20)  
radiochemotherapy 
18
F-FDG 
baseline 
+ post-treatment 
FOS, GLCM, shape/geometry-based 
descriptors 
Pathological response to 
treatment 
SUVmean, SUVmax, 
SUVpeak, tumour volume 
(TV) and TLG 
Yang et al 
(2013) 
cervical (n = 20) 
radiochemotherapy 
18
F-FDG 
baseline 
+ during therapy 
+ post-treatment
 
GLRLM, GLSZM Response to treatment 
 
SUVmean and SUVmax 
N/A = not applicable 
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3.1.3.  Quantifying the spatial extent of PET radiotracer uptake: total 
lesion activity 
The total lesion activity (TLA) has been suggested as an additional index to quantify the 
extent of radiotracer uptake in PET imaging (Larson et al, 1999; Hatt et al, 2011a). This 
image descriptor can be derived as:                  (where TV is the tumour volume). 
The index is also known as the total lesion metabolic activity (George et al, 2012b), the total 
lesion glycolysis (TLG) in 
18
F-FDG PET and the total proliferative volume (TPV) in 
18
F-FLT 
PET (Hatt et al, 2010). This feature provides additional information to tumour volume (TV) 
and standardised mean uptake value (SUVmean) as it represents the overall metabolic/active 
mass of the tumour. For instance, a change in volume and uptake after treatment could 
correspond to an unchanged TLA. 
 
Larson et al (1999) first introduced and evaluated the index looking at percentage change 
following chemotherapy in a group of 41 patients with locally advanced lung, rectal, 
oesophageal or gastric cancer. Lesions were delineated using an adaptive thresholding 
technique. Response to treatment was assessed visually by a group of experts.  
 
Hatt et al (2010) studied the repeatability and reproducibility of a range of intensity-volume 
features (TV, TLG, TPV, SUVmean and SUVmax) on an 
18
F-FDG oesophageal dataset and the 
18
F-FLT PET dataset used in this thesis (Section 4.3). Lesions were delineated using a range 
of methods: fixed and adaptive thresholding, fuzzy C-means and fuzzy locally adaptive 
Bayesian (FLAB) (Hatt et al, 2009). Repeatability results (multiple delineation of the same 
lesion) yielded variability below 5% for automatic methods (adaptive thresholding, fuzzy C-
means and FLAB) and from 5 to 35% for manual delineation.  
 
Hatt et al (2011a) studied the performance of the TLG alongside other spatial descriptors: TV 
and longitudinal length (TL), for their ability to discriminate between three groups of patients 
with oesophageal cancer (13 non-responders, 25 partial responders and 12 complete 
responders). Patients underwent baseline 
18
F-FDG PET imaging and were assessed for 
response to treatment following therapy using CT imaging and the RECIST criteria. Two 
segmentation techniques were used for comparison purposes: the automatic FLAB algorithm 
as well as an adaptive threshold algorithm. The authors found that SUV measurements 
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(SUVmean, SUVmax and SUVpeak) did not discriminate between the three response groups. By 
contrast, the other PET descriptors (TL, TV and TLG) predicted response to treatment on 
baseline 
18
F-FDG PET scans as assessed using Kruskal-Wallis tests. Sensitivity and 
specificity were above 75% and 85%, respectively, yielding better results than SUV 
measurements. Segmentation did not have an influence on these results. The single other 
variable that discriminated between response groups was AJCC stage: statistical significance 
was reached for complete responders versus non-responders and partial responders versus 
non-responders – however unlike the PET measurements (TL, TV and TLG) AJCC stage did 
not discriminate between complete responders versus partial responders. Although SUVmean 
did not discriminate between response groups, the authors found that combining SUVmean and 
TL through TLG yielded a stronger discrimination between response groups than when using 
TL alone. Segmentation did not influence the ability of TL, TV and TLG to discriminate 
between response groups. However some discrepancy between the segmentation techniques 
was noted by the authors: FLAB performed better than an adaptive threshold method in terms 
of area under the ROC curve, yielding higher sensitivity and specificity and smaller 
confidence intervals. Further, the authors studied the prognostic value of the image 
descriptors with regard to survival in a group of esophageal cancer patient imaged at baseline 
using 
18
F-FDG PET (Hatt et al, 2011b). They found that SUV measurements (mean, max, and 
peak) were not prognostic factors for overall survival. TV, TL and TLG were prognostic 
factor for survival. However TLG was not an independent prognostic factors on multivariate 
analysis.  
 
In a subsequent study, Hatt et al (2012a) showed that percentage change in TLG, in a group 
of breast cancer patients imaged at baseline and after two cycles of neoadjuvant 
chemotherapy, was a stronger predictor of histopathologic response than percentage change 
in SUVmean. In yet another study, the authors (Hatt et al, 2012b) found that correcting for 
PVEs had a significant impact on the feature values in a group of oesophageal cancer patients 
imaged at baseline (
18
F-FDG PET), although it did not significantly affect the predictive 
values. Hatt et al (2013a) showed that TLG was a strong predictor of pathological response in 
locally advanced rectal cancer on 
18
F-FDG PET scans acquired after two weeks of therapy 
(AUC 0.79, sensitivity 63%, specificity 92%). Similarly, percentage change in TLG after two 
cycles of neoadjuvant chemotherapy was found to be associated with response to therapy in 
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breast cancer patients (Groheux et al, 2013). TLG measured at baseline was not associated 
with treatment outcome in any of these studies (Hatt et al, 2013b; Groheux et al, 2013).  
 
Mertens et al (2012) proposed to derive an index related to total lesion metabolism, named 
standardised added metabolic activity (SAM). The advantage of such image descriptor is that 
it can be derived more easily than TLG while allowing for partial volume corrections and not 
relying on thresholding methods for segmentation. The method consists of drawing two 
regions of interest around the target. The first region (VOI1) is drawn around the lesion so as 
to include all the voxels belonging to the lesion as well as all background voxels 
contaminated by spill-over. A second region of interest (VOI2) that includes some 
surrounding background activity is drawn around VOI1. The mean background intensity is 
then estimated by taking into account voxels belonging to VOI2 and outside VOI1. Finally, 
the mean background activity is subtracted from the voxels’ intensities in VOI1, which are 
then summed to obtain the SAM index. Validation was carried out using a 
18
F-FDG PET 
phantom composed of sphere volumes of different sizes (diameter varying from 9.5mm to 
38.5mm) and filled in with different target to background activity ratios (5.40, 3.64 and 2.00). 
The influence of scanning time on the SAM index (
18
F-FDG) was assessed in a group of 15 
patients with primary squamous cell carcinoma. Further, index change following 
chemotherapy was studied in a group of 19 patients with metastatic colorectal cancer imaged 
with 
18
F-FDG PET. The authors were able to recover the expected SAM index with very 
good accuracy in homogeneous spheres placed in a homogeneous background (≥ 85%), 
independently of the lesion size, as long as it was visible in the PET images and could be 
delineated in the first instance.  They also found that scan duration (from 1 to 10 minutes) did 
not impact significantly on the results in patients with squamous cell carcinoma. Finally they 
found that percentage change in SAM discriminated between 8 responders and 11 non-
responders to chemotherapy (p = 0.001). Percentage SAM change was very high (99%) in 
responder patients and would need to be confirmed using additional datasets. Mertens et al 
(2013) recently applied SAM to response assessment in a group of patients with metastatic 
colorectal liver metastases. They found that both percentage changes in SUVmax and SAM 
were prognostic factors for PFS and OS. It is important to note that SAM does not represent 
the actual TLA because the mean background activity is subtracted from all voxels’ 
intensities in the lesion. As stated by the authors, it rather corresponds to the excess of 
metabolic uptake due to the lesion in the normal tissue under investigation. The authors 
62                                                                      Chapter 3 – Literature Review, Aims and Objectives 
  
 
justified this methodology by assuming that the tumour tissue could be seen as developing on 
top of normal tissue. However in a physical sense one would expect that an organ affected by 
cancer would be occupied by cancerous cells in specific areas, a mixture of cancerous and 
healthy tissue or stroma in other parts, and possibly exclusively healthy tissue or stroma in 
other areas.  As a consequence there are two direct limitations of the study:  
 It is well known that PVEs will affect lesions’ voxels differently depending on their 
location, tumour size, shape and Target to Background Ratio (TBR) due to the limited 
spatial resolution of the scanner as well as the tissue fraction effect. A simple 
subtraction of the mean background activity from all voxels’ intensities is unlikely to 
provide an accurate correction for this effect. 
 When using SAM, one makes the assumption that the lesion metabolism depends on 
the background metabolism. One could for instance consider the scenario in which the 
same lesion, filled in with a given total metabolic activity, is embedded in two 
different background tissues characterised by distinct mean activities. Assuming that 
the images are not affected by PVEs for the sake of simplicity, it turns out that unlike 
the TLA index, which would be identical for the lesion in both background tissues, 
SAM indices would be a function of the mean background tissue activity. 
Although SAM could be regarded as an appealing method for PET quantification given its 
simplicity and the fact that it takes into account PVEs, it is clearly a different approach from 
most PET quantification tools in that the background activity has an impact on the absolute 
values obtained.   
 
George et al (2012b) recently proposed a fuzzy classification method for estimation of the 
TLA via a direct method which does not require a delineation step. They showed that such 
approach avoids underestimation of the TLA which typically occurs due to PVEs when a 
traditional contouring method is used for quantification. The method was illustrated using a 
realistic 
18
F-FDG PET simulation of a liver lesion. It needs to be validated on a clinical PET 
dataset, applied to heterogeneous radiotracer uptake and to different image reconstruction 
parameters.  
 
At present, there is no unique method defined as the gold standard to measure disease extent 
using PET imaging. Robust delineation tools that are capable of contouring heterogeneous 
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lesions might be preferred. However, these techniques could reach a limit when lesion 
boundaries become more diffused.  
3.1.4.  Cumulative SUV-volume Histogram (CSH) curve  
Kidd & Grigsby (2008) originally proposed a heterogeneity index to capture the intra-tumour 
heterogeneity of 
18
F-FDG PET uptake based on the computation of a cumulative SUV-
volume histogram (CSH) curve (or intensity-volume histogram, or volume-threshold curve) 
(Table 3.3). This graph typically depicts the lesion volume as a function of an intensity 
threshold of the maximum uptake in the lesion. This graph is adapted from the dose-volume 
histogram representation used in radiotherapy. In this study Kidd & Grigsby suggested using 
the derivative (dV/dT) of the volume-intensity threshold function as an index of 
heterogeneity (HET). They applied the technique to a group of 72 patients with cervical 
cancer and showed that HET was associated with response to radiotherapy (p = 0.02), as well 
as risk of tumour recurrence (p = 0.002). However they found a strong correlation between 
the HET and lesion size in the PET image derived from a thresholding segmentation approach 
(R
2
 = 0.88, Spearman). In addition, lesion size was a stronger predictor of disease recurrence 
(p = 0.0003) than the heterogeneity metric (p = 0.0035). In a subsequent study by the same 
group, Brooks & Grigsby (2011) criticised this work and demonstrated that: 1) the metric 
proposed was intrinsically non-spatial, 2) more importantly it was directly proportional to 
lesion size (as delineated on baseline PET scans). This was indirectly confirmed in another 
study (Huang et al, 2012) in which the authors applied the heterogeneity metric originally 
proposed by Kidd & Grigsby (2008) to an independent dataset (40 patients with 
nasopharyngeal carcinoma). Study findings included a very strong visual linear correlation 
between the heterogeneity index and lesion size (r = - 0.98, Spearman).  
 
El Naqa et al (2009) proposed to derive additional intensity and volume indices from the 
CSH based on volume and intensity thresholds, for instance: Ix, the minimum intensity of the 
x% (e.g. 10% or 90%) most metabolically active voxels in the tumour volume, or Vx, the 
sub-lesion size of intensity at least x% (e.g. 10% or 90%) of the maximum intensity in the 
VOI. For a cervix cancer dataset, CSH features had the second highest prediction power 
(after texture analysis features) in terms of risk of therapy failure (see Section 3.1.3.3 for 
study findings).  
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Van Velden et al (2011) introduced the Area-Under a Curve (AUC) as a global index to 
characterise the cumulative SUV-volume histogram (AUC-CSH). The authors evaluated the 
method on PET simulations of lung lesions (taking into account the effects of attenuation and 
resolution, but without scatter or random coincidences), simulating both spatially 
homogeneous and heterogeneous (core and tumour rim) intra-tumour response to treatment 
with varying SUVs and tumour size. In addition they illustrated the method on four clinical 
cases. The study showed that a lower AUC-CSH is associated with greater heterogeneity 
using simulations and clinical data.  For instance, the authors showed a decrease in AUC-
CSH index in the primary lesion of a lung cancer patient following therapy; the 
18
F-FDG PET 
uptake appeared more heterogeneous after one cycle of chemotherapy than at baseline. 
However the authors did not report independent measurements of clinical outcome. Further 
validation using test-retest data, as well as using realistic PET simulations, are needed. In 
addition the usefulness of this index within the clinical context needs to be demonstrated. The 
usefulness of combining AUC-CSH with other independent indices (SUVmax, lesion size) 
needs to be validated. It could lead to situations in which, as pointed by Brooks (2013b), the 
metric is not informative.  
 
Table 3.3 – Studies using the cumulative SUV-volume histogram (CSH) curve 
Authors (Date) 
Cancer type 
(number of patients) 
and treatment 
PET 
imaging 
Image descriptors 
Clinical 
endpoint 
Kidd & Grigsby 
(2008) 
cervix (n = 72) 
radiochemotherapy 
18
F-FDG 
baseline 
Derivative (dV/dT) 
Tumour 
recurrence 
El Naqa et al 
(2009) 
- cervix (n = 14) 
- head and neck  
(n = 9) 
radiochemotherapy 
18
F-FDG 
baseline 
Intensity and Volume-indices 
at various thresholds 
- Disease 
persistence 
- Overall 
survival 
Brooks & Grigsby 
(2011) 
cervix (n = 72) 
radiochemotherapy 
18
F-FDG 
baseline 
Derivative (dV/dT) N/A 
Van Velden et al 
(2011) 
Simulations: lung 
Clinical:  
- NSCLC (n = 3) 
- liver metastases  
(n = 1) 
chemotherapy 
18
F-FDG 
baseline 
+post-
treatment 
AUC-CSH 
Visual pattern 
of response 
 
Hang et al 
(2012) 
nasopharyngeal 
( n = 40) 
radiotherapy  
or radiochemotherapy 
18
F-FDG 
baseline 
Derivative (dV/dT) 
Disease-free 
survival 
Brooks (2013b) N/A N/A AUC-CSH (SUV normalised) N/A 
N/A = not applicable  
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3.1.5.  Assessing local tumour changes using PET imaging 
Other groups have proposed the direct comparison of intra-tumour uptake of successive PET 
scans at the voxel level for assessing local tumour response to therapy. This requires 
registering the successive PET scans using anatomical images (e.g. CT). Necib et al (2008) 
introduced a method based on the computation of a subtracted image derived from two 
successive PET scans registered using CT (PET/CT). A graph of subtracted voxels against 
voxels’ radiotracer uptake of the first scan is obtained. A Gaussian mixture model using the 
Expectation-Maximisation (EM) approach was used by the authors to classify voxels into 
four classes: noise, physiological change other than in tumour, tumour voxels responding to 
therapy, and tumour voxels corresponding to tumour progression. Finally, all voxels 
belonging to the noise or physiological change (outside the tumour) classes are set to zero 
and only the voxels corresponding to an increase or decrease in SUV within the tumour are 
displayed in the resulting parametric image. The researchers illustrated the feasibility of the 
technique in 8 lung tumours of two patients (Necib et al, 2008) and further assessed its 
performance in relation to response to therapy (Necib et al, 2011). The dataset (Necib et al, 
2011) consisted of 28 cancer patients with metastatic colorectal cancer having a total of 78 
lesions (including primary, liver and lung metastases, as well as lesions in the peritoneum and 
other locations). The RECIST criteria were used as the gold standard for response 
assessment. The authors derived global descriptors from the parametric images (percentage 
change in volume, SUVmean and SUVmax) and compared the method to another classification 
method for PET response assessment based on the guidelines of the European Organisation 
for Research and Treatment (EORTC) (Young et al, 1999). They found that the technique 
proposed had a sensitivity of 100% and specificity of 53% compared to 85% and 52% for the 
EORTC-based classification, respectively. One of the main advantages of such a method is 
the possibility of generating a map in which the heterogeneity of local intra-tumour treatment 
response can be visualised and further quantified. One limitation of such approach is the 
introduction of potential errors during registration due to motion and patient positioning 
which might bias the results. The parametric method yielded good results in detecting 
responder patients (Necib et al, 2011). However a few non-responders (RECIST criteria) 
were classified as responders with this method. It might be more critical to identify non-
responder patients when assessing early response to therapy in the clinic.  
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Schreibmann et al (2012) recently proposed a similar approach. PET/CT registration was 
adapted from a deformable registration method proposed by Rueckert et al (1999) to correct 
for eventual anatomical changes between baseline and follow-up scans. The authors used a 
level set framework for classifying lesions’ voxels associated with an enhancement or a 
reduction in radiotracer uptake across successive scans. The method was visually assessed 
using a 
18
F-FDG PET/CT dataset consisting of 81 patients with head and neck cancer who 
were treated by radiochemotherapy. The authors demonstrated the advantage of a level set 
approach (to filter out signal changes outside the tumour based on spatial and intensity 
information) in comparison to a simple thresholding approach. The validation of the method 
was purely qualitative. Quantitative validation is needed to characterise the performance of 
the method and compare its accuracy to visual clinical examination. 
 
David et al (2012) proposed a multi-observation approach, based on Bayesian theory and 
previously used in astronomy, to assess successive PET scans and classify local changes 
following therapy. The method provides a theoretical framework to classify voxel changes 
into a given number of classes through an Expectation-Maximisation algorithm while 
providing a model for noise. The authors evaluated the method on simulated PET data that 
were assumed to be perfectly registered and displayed regions of radiotherapy resistance, 
response and proliferation. The method was also illustrated on a clinical dataset using a rigid 
registration method to compare successive PET scans. The method might only be applicable 
to certain body regions and cancer types that can be aligned successfully using a rigid 
registration technique, and in situations in which motion does not affect the results. Further 
developments are needed to include tumour heterogeneity assessment.  
 
3.2.  Aims and Objectives (Scope of the thesis) 
A range of methods have been investigated for characterising the complexity of the PET 
radiotracer uptake in neoplastic lesions (Section 3.1). However, image descriptors used to 
capture intra-tumour PET heterogeneity have not been applied to biological functions other 
than glucose metabolism. A range of cancer types have been studied including cervix, head 
and neck, oesophageal, colorectal and sarcoma. Study findings suggest that these image-
based descriptors might provide additional information to traditional quantification indices 
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such as SUV measurements, and that capturing the variability in radiotracer uptake might be 
helpful for tissue characterisation, stratification in treatment response groups, and prognosis. 
Only one group assessed repeatability of these image descriptors in 
18
F-FDG PET (Tixier et 
al, 2012).  
 
Another important aspect of quantification is the impact of PET physics and other factors on 
quantification. One of the main factors has been identified as PVEs. For instance, tumours 
with a necrotic centre might appear 1) to have more viable tissue within the centre than there 
actually is, and 2) to have an active part which appears less aggressive than it actually is 
(Soret et al, 2007). This results in a change in lesion appearance with PET image resolution, 
which would logically affect the resolution-dependent image metrics used to characterise 
intra-tumour heterogeneity (see Chapter 4, for instance). The effect of resolution (through 
PVEs) has also been shown to affect metrics such as TLA which are used to measure the 
extent of disease/metabolic activity in neoplastic lesions as illustrated by Hatt et al (2012b). 
However, one could expect that taking into account the effect of PET resolution during the 
quantification process might help to capture the extent of radiotracer uptake while limiting 
the impact of imaging protocol on the results. In other words, even if a lesion with rim and 
core appears to have different local spatial-intensity distributions at different resolutions, the 
overall extent of lesion activity might be recoverable.   
 
The aim of this thesis was to characterise and quantify the spatial properties and variability of 
PET radiotracer uptake in neoplastic lesions. Robust quantification methods in PET oncology 
which characterise the process being imaged are critical to providing the biologist and the 
clinician with indices that describe the complexity of the uptake. 
 
The objectives of this thesis were: 
  
 To explore whether robust image descriptors can be derived to capture intra-tumour 
biological heterogeneity (at the scale of the whole tumour) using PET imaging and 
when monitoring biological/biochemical processes other than glucose metabolism. 
The image descriptors used are presented in Section 4.1. Within the scope of this 
thesis, the biological processes investigated are limited to cell proliferation as 
assessed using 
18
F-FLT PET in a group of breast cancer patients (Section 4.3). Results 
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are presented in Chapter 5. Features are selected for their robustness based on a 
repeatability study (test-retest 
18
F-FLT PET dataset). 
 
 To investigate whether: 1) these descriptors of intra-tumour PET heterogeneity are 
associated with treatment response when measured at baseline (prior to 
commencement of chemotherapy), and 2) changes in image descriptors, occurring 
early after initiating treatment, are associated with treatment response. Associations 
with response to treatment are only tested for a subset of features selected on 
repeatability study (Chapter 5). Performance of these descriptors is also compared 
with that of the classical SUV indices. 
 
 To study the influence of factors such as VOI size, injected dose and time of imaging 
after injection on the descriptors’ values. 
 
 To advance tumour uptake quantification by combining intensity and spatial 
descriptors, capturing and correcting for the space-filling properties of neoplastic 
lesions, across a range of PET image resolution settings. The theoretical framework 
for this research, based on a multifractal approach, is introduced in Chapter 4 (Section 
4.2). Results of the validation on a range of datasets (fractal objects, synthetic 
simulations, realistic PET simulations and test-retest 
18
F-FLT chemotherapy 
(fluorouracil-epirubicin-cyclophosphamide; FEC dataset) are presented in Chapter 6. 
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Chapter 4.  Materials and Research Methods 
 
 
 
In this chapter, a brief introduction to existing texture analysis methods is given. The 
statistical techniques that were selected to analyse and characterise intra-tumour 
heterogeneity of 
18
F-FLT PET imaging are further elaborated on. A background to the fractal 
analysis approach that was developed is also provided. Finally, the clinical 
18
F-FLT PET 
dataset used, and for which results are presented in the subsequent research chapters 
(Chapters 5 and 6), is described.   
 
 Texture analysis 4.1. 
 Introduction 4.1.1. 
Visual texture is an intuitive and qualitative concept which does not have a unique definition. 
Different definitions of texture have been adopted depending on the field of application 
(Tuceryan & Jain, 1998; Petrou & Sevilla, 2006; Haralick, 1979). The perceived texture of an 
image is similar to the texture of an object such as a wooden surface when one uses one’s 
touch to sense it. The irregularities of the surface, their magnitude and prominence give the 
object a characteristic identity when compared with textures of other objects. Equally the 
intensity variations of a visual object, the spatial organisation and rate of these variations 
contribute to its visual texture. Visual texture variations can be a nuisance in the process of 
delineating an object in a scene. But texture also entails valuable information that can be used 
to characterise and differentiate between natural objects. Here we consider that texture is the 
spatial variation of intensities at scales smaller than the object of interest (Petrou & Sevilla, 
2006). By nature, and with the exception of fractal texture descriptors, texture is scale 
dependent. Various texture analysis methods and texture descriptors have been developed for 
image analysis in order to classify and segment images or regions of interest, and synthesise 
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textures. Fields of application include remote sensing, document processing, automated 
inspection and medical image analysis. 
 
Different approaches which emphasise different aspects of texture have been developed, 
namely model-based, statistical and geometrical approaches, structural and signal processing 
methods (see reviews by Haralick (1979), Tuceryan & Jain (1998) and Castellano et al 
(2004)). 
 
 Model-based texture analysis approaches 4.1.2. 
Model-based methods assume a model for the description of the voxels’ intensities. The 
values of the model parameters are subsequently used to characterise or synthetise the texture 
of the object of interest. Techniques include autoregressive models, random field models 
(such as Markov random field) and fractals (Lopes & Betrouni, 2009). Markov random field 
models assume that the intensity of each voxel within the object of interest depends only on 
the intensities of its neighbours. As a consequence, the coefficients obtained for a coarse 
texture will be similar for all the voxels belonging to the object, whereas they will vary 
widely for fine textures. Fractals are a class of mathematical objects that are self-similar at all 
scales of measurements. Fractal dimension (FD) has been introduced to characterise the 
complexity of these objects as well as other complex and natural objects while overcoming 
the limitations of traditional Euclidian geometry (Mandelbrot, 1982). Practically, this 
assumption is limited by the resolution and size of the images. Several techniques have been 
developed for computing the FD of binary and grey level images (e.g. box-counting, 
fractional Brownian motion and area measurement methods, multifractal approaches) (Lopes 
& Betrouni, 2009). 
 
 Geometrical and structural texture analysis methods 4.1.3. 
Structural methods constitute another approach which assumes that a visual texture is 
composed of primitives having certain properties (e.g. specific shape) and which follows 
certain placement rules or grammar. The use of these techniques is suitable when the texture 
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contains regular patterns (Petrou & Sevilla, 2006; Tuceryan & Jain, 1998). Geometrical 
approaches aim to detect textural patterns prior to texture analysis using statistical or 
placement rule methods. 
 
 Signal processing methods 4.1.4. 
Signal processing and transforms constitute another range of techniques for analysing image 
textures. Textural content can be characterised in terms of number of edges. A high number 
of edges will be associated with a fine texture whereas a poor number of edges will denote a 
coarse texture. Edge detection is achieved using spatial filtering methods (e.g. Robert’s and 
Laplacian operators). Texture can also be described in terms of frequency content. Finer 
objects will contain higher spatial frequency intensity variation whereas coarser objects will 
be characterised by lower frequency variations. Methods include the Fourier transform and 
more powerful techniques which retain spatial information (e.g. Gabor filtering and Wavelet 
transforms).  
 
 Statistical texture analysis approaches 4.1.5. 
Texture images are composed of two intrinsically linked basic elements: a set of intensities 
(or “grey levels”) and their spatial organisation. Statistical texture analysis methods are based 
on the description of the spatial distribution of grey levels in the image using higher order 
moments. First order statistics (FOS) consider the properties of individual voxels whereas 
higher order statistics take into consideration the relationship between pairs (second order 
statistics) or larger group of voxels’ intensities (higher order statistics). FOS are summary 
statistics of the grey level distribution (e.g. Mean intensity, Median, Mode, Standard 
Deviation, Skewness, Kurtosis and Entropy). The arrangement of pairs of voxels’ intensities 
is typically characterised using the Grey Level Co-occurrence Matrix (GLCM) method that 
was originally developed by Haralick et al (1973) for the characterisation of 2D synthetic 
aperture radar images. Higher order methods such as Grey Level Run Length Matrix 
(GLRLM) (Galloway, 1975), Grey Level Size Zone Matrix (GLSZM) (Thibault et al, 2009) 
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and Neighbourhood Grey Tone Difference Matrix (NGTDM) (Amadasun & King, 1989) are 
used to characterise the relationship between intensities of larger sets of voxels. 
In the work presented in this thesis statistical texture analysis methods were used to 
characterise intra-tumour heterogeneity in PET imaging.  
 
 Grey Level Quantisation 4.1.5.1. 
Statistical texture analysis techniques require normalising the image intensities into a smaller 
number of grey levels. Uniform quantisation is the most commonly used method. It consists 
of binning the range of original intensity values (given by the minimum and maximum 
measured intensity) into a given number of discrete intervals (grey levels). The formula is as 
follows:  
          ⌊
    
          
              ⌋      (4.1) 
 
Where   is the raw intensity of a voxel in the image,    is the number of quantisation levels 
used for normalising the intensities in the Volume of Interest (VOI), Imin and Imax are the 
minimum and maximum intensities in the original VOI, and ⌊x⌋ is the greatest integer no 
larger than x (floor function). Adding 0.5 ensures that the intensity is rounded to the nearest 
integer. 
 
Other normalisation techniques such as histogram equalisation, Gaussian and log transforms 
have also been employed (Soh, 1999; Clausi, 2001). A critical aspect of texture analysis is the 
choice of the grey level scale which is a trade-off between 1) retrieving relevant textural 
information while reducing the noise in the image and 2) preserving the information content. 
Clausi (2002) showed that the grey level parameter maximising the separability between 
different classes of images are feature-dependent although a unique and arbitrary parameter is 
often used in studies.  
 First Order Statistics (FOS) 4.1.5.2. 
The first set of features (FOS) was derived from the intensity distribution of radiotracer 
uptake in lesion to measure the variability of intra-tumour radiotracer uptake (Table 4.1).  
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Table 4.1 – FOS image descriptors 
 
 
 Grey Level Co-Occurrence Matrix (GLCM) method 4.1.5.3. 
The Grey Level Co-occurrence Matrix (GLCM) is a two dimensional histogram of pairs of 
voxel intensity occurrence. Let’s consider a volume of interest   belonging to a 3D image   
and the set of reference voxels      belonging to   as defined by their Cartesian coordinates 
         and their intensity  . The intensity of the voxels are normalised into a number    of 
grey levels. The GLCM is a square and symmetric matrix of size   .  Each entry        of the 
GLCM represents the frequency of co-occurrence of intensities       in   (  being the 
intensity of the reference voxel and   being the intensity of one of its neighbouring voxels). 
The distance   and orientation   between reference and neighbouring voxels are given as 
parameters. 
  
           
          
∑∑          
                                                 (4.2) 
With                 {
                  
  [              ]  [                    ]        
                     (                    )    
} (4.3) 
 
Name Description Mathematical formula 
CV Coefficient of Variation √
 
 
∑                
 
   
 
 
∑     
 
   
⁄  
Skewness 
Third standardised moment (measure of 
symmetry of the intensity distribution)  
 
 
∑               
 
 
   
    ⁄  
Kurtosis Fourth standardised moment  
 
 
∑               
 
 
   
    ⁄  
EntropyFOS Measure of information content  ∑             
  
   
 
Where      is the intensity of voxel   belonging to the VOI   ,   is the number of voxels belonging to 
 ,       and     are the mean intensity and standard deviation in the VOI,    is the number of quantisation 
levels used for normalising the VOI intensities and      is the probability of occurrence of normalised grey 
level  . 
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Where            is the number of pairs of voxels with intensities       belonging to  ,    is 
the offset between reference and neighbouring voxels given by        ,   is the distance 
between voxels within a pair,  [        ] is the direction between voxels within a pair, 
and ∑∑           is the total number of pairs of voxels belonging to  . 
 
In 3 dimensions a voxel has 26 neighbours. The computation of the GLCM can be performed 
along 13 different directions given by    (see Appendix B1). In this thesis, the textures were 
assumed to be isotropic. Therefore, a GLCM matrix was calculated for each of the 13 
directions  . An example is given in Figure 4.1.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Example of GLCM matrix calculation (for a distance d = 1 and direction +x between 
voxels within a pair).  
 
 
A total of 17 features were derived from the GLCM method  (Haralick et al, 1973; Soh, 
1999). The features included in this study are shown in Table 4.2. The feature values derived 
from each GLCM were averaged over the different directions (Haralick et al, 1973). 
 
  
Volume of Interest (I
ref 
,I
neigh
) - Co-occurrence matrix calculation 
y 
x 
GLCM (parameters:  
d = 1, +x direction) 
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Table 4.2 – Textural features derived from the GLCM  
 
 Grey Level Size-Zone Matrix (GLSZM) method 4.1.5.4. 
The Grey Level Size-Zone Matrix (GLSZM) method (Thibault et al, 2009) is an extension of 
the Grey Level Run-Length Matrix method (GLRLM) developed by Galloway (1975). The 
GLRLM method consists of counting the number of consecutive voxels with the same 
intensity along a given direction. The rows of the GLRLM matrix represent the different grey 
levels and the columns represent the length of the runs. Similarly, the GLSZM counts the 
number of voxels with the same intensity in a neighbourhood along all 13 directions at a 
time. The columns of the GLSZM represent the number of voxels contained in these patches 
(an example is given in Appendix B2). Five initial features were derived from the GLRLM 
(Galloway, 1975). Additional features and the normalisation procedure have been described 
Name Description Mathematical formula 
Correlation 
Measure of linear dependency between 
intensities of pairs of voxels  
( : uncorrelated,    : linearly correlated) 
∑   ∑                  
  
   
  
   
    
 
InfCo2 
Measure of non-linear dependency between 
intensities of  pairs of voxels  
“informational coefficient of correlation”  
( : independent variables,  : dependent 
variables) 
                         
       ∑ ∑                 
  
   
  
   
 
       ∑ ∑                {          }
  
   
  
   
 
       where  
Angsmo 
Measure of texture uniformity  
(       : heterogeneous,  : homogeneous) 
∑ ∑ {       }
  
   
  
   
 
EntropyGLCM 
Measure of information content  
( :  predominant combination of  pairs of 
voxels’ intensities,         : equal 
contribution of all pairs) 
 ∑ ∑                 
  
   
  
   
 
ContrastGLCM  
 
Local intensity variations. ( : no contrast,  
       : maximum contrast) 
∑   
    
   
{ ∑ ∑       
  
   
  
          
} 
Dissimilarity 
Contrast weighted linearly with the difference 
of grey level values ( : similarity (diagonal 
GLCM),        dissimilarity) 
∑ ∑            
  
   
  
   
 
Homogeneity 
Opposite of contrast ( : dissimilar,  : similar 
(diagonal GLCM)) 
∑ ∑
 
         
      
  
   
  
   
 
 
Where        is the        entry of the GLCM which is the frequency of occurrence of pairs of voxels’ 
intensities       within the VOI   for a given distance δ and orientation Ө between paired voxels,       and 
       are the marginal probability matrices obtained by summing the rows and the columns of        
respectively;    is the number of quantisation levels used for normalising the VOI intensities;   ,   ,   ,    
are the means and standard deviations for the rows and the columns of the GLCM. 
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in other papers (Dasarathy & Holder, 1991; Chu et al, 1990; Thibault et al, 2009; Loh et al, 
1988) (Appendix B3).  
 
 
Table 4.3 – Textural features derived from the GLSZM 
Name Description Mathematical formula 
Smallzone Emphasises small zones ∑∑(
       
 
)
   
   
  
   
      ∑∑      
  
   
  
   
⁄  
Largezone Emphasises large zones ∑∑           
        
  
   
  
   
∑∑      
  
   
  
   
⁄  
Glnonunif Measure of grey level 
variability 
∑(∑      
  
   
)
   
   
∑∑      
  
   
  
   
⁄  
Sznonunif Measure of Size-Zone 
variability 
∑(∑      
  
   
)
 
  
   
∑∑      
  
   
  
   
⁄  
Szpcent 
Ratio between the number of 
zones and the total number of 
possible zones (number of 
voxels) 
∑∑      
  
   
  
   
 ⁄  
Zonelogl Emphasises zones of low grey 
level 
∑∑
      
  
  
   
  
   
∑∑      
  
   
  
   
⁄  
Zonehigl Emphasises zones of high grey 
level  
∑∑        
  
   
  
   
∑∑      
  
   
  
   
⁄  
Szonelogl Emphasises small zones of low 
grey level 
∑∑(
       
 
)
       
  
  
   
  
   
∑∑      
  
   
  
   
⁄  
Szonehigl Emphasises small zones of high 
grey level 
∑∑(
       
 
)
   
   
  
   
        ∑∑      
  
   
  
   
⁄  
Lzonelogl Emphasises large zones of low 
grey level 
∑∑
            
  
  
   
  
   
      ∑∑      
  
   
  
   
⁄  
Lzonehigl Emphasises large zones of high 
grey level 
∑∑                    
  
   
  
   
∑∑      
  
   
  
   
⁄  
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 Neighbourhood Grey Tone Difference Matrix (NGTDM) method 4.1.5.5. 
The Neighbourhood Grey Tone Difference Matrix (NGTDM) method (Amadasun & King, 
1989) is based on the computation of intuitive textural descriptors (Coarseness, Contrast, 
Busyness, Complexity and Strength of texture) derived from a vector matrix. The    entry of 
the vector matrix   is the sum of the differences between all the voxels of intensity    in the 
VOI    and the mean intensity of their 26 neighbouring voxels. 
 
     {
∑ |             |
  
                       
                                                
      (4.4) 
 
Where Ni is the number of voxels with intensity i in V,            is the mean intensity of 
the 26 direct neighbours of each voxel of intensity i. 
 
  
Glvariance Weighted variance of grey level 
 
 
     
∑ ∑                
   
   
  
    
     
with      
 
     
∑ ∑              
  
    
Szvariance Weighted variance of size-zone 
 
 
     
∑ ∑                          
   
   
  
    
     
with      
 
     
∑ ∑                         
  
    
 
Where        is the         entry of the GLSZM which records the number of clusters of voxels having 
intensity   and a number of voxels   within the VOI.    is the number of quantisation levels used for 
normalising the VOI intensities,    the number of zones in the image and   the number of voxels in the VOI, 
    and the     are the mean intensity and zone size respectively. 
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Table 4.4 – Features derived from the NGTDM 
 
 
 Fractal analysis, multifractal analysis and space-filling 4.2. 
properties 
 Introduction 4.2.1. 
The power of fractal analysis lies in its ability to characterise the irregularities of complex 
objects beyond the use of ideal shapes drawn from Euclidian geometry (Mandelbrot, 1982). 
Fractal analysis has already been applied to many fields including medicine and to some 
imaging modalities (see for instance a review by Lopes & Betrouni, 2009). Through the 
computation of a dimension, the Fractal Dimension (FD), fractal analysis provides a “scale-
free” description of the space-filling properties of a binary object (Cross, 1997). A unifying 
framework to compute the FDs of non-uniform objects (e.g. grey level images) has been 
proposed (Kinsner et al, 2005). The latter approach is used in this thesis to recover the 
Name Description Mathematical formula 
Coarseness Measure of texture uniformity [   ∑      
  
   
]
  
 
ContrastNGTDM 
Measure of contrast taking into 
account the global dynamic range of 
grey levels and local variations 
[
 
        
∑∑         
 
  
   
  
   
] [
 
  
∑    
  
   
] 
Complexity 
Complexity increases with high 
spatial intensity variations, Contrast 
and the presence of small clusters of 
voxels of different intensities 
∑∑{
     
     
} {             }
  
   
  
   
 
Strength 
Measure of ‘distinguishability’ 
between clusters of voxels. This 
depends on cluster sizes and grey 
level differences between patches  
[∑             
   
   
]
[   ∑     
  
   
]
          
 
Where      is the     entry of the NGTDM which is the sum of the intensity differences between each voxel of 
intensity   belonging to the VOI    and its 26 direct neighbours in 3 dimensions,   is a small number to prevent 
the denominators of Coarseness and Strength being zero,    is the number of quantisation levels used for 
normalising the VOI intensities,    is the number of different grey levels present in the image,    is the 
probability of occurrence of grey level i,    is the number of voxels of intensity   used in the calculation and   is 
the total number of voxels used in the calculation. 
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apparent volume-filling properties and intensity-volume features of lesions in PET imaging 
that are affected by PVEs. In this section, the fractal, multifractal and space-filling factor 
concepts that are used in Chapter 6 are described.  
 
 Fractal geometry and fractal dimension (FD) computation 4.2.2. 
Fractal geometry was introduced by Mandelbrot to describe mathematical and natural objects 
with highly irregular shapes (Mandelbrot, 1982). Instead of relying on ideal shapes and 
measurements derived from Euclidian geometry, fractal analysis introduces a fractional 
component to dimension in order to account for the irregularities of these objects. In classical 
Euclidian geometry, dimensions are described by an integer (0 for a point, 1 for a line, 2 for a 
plane and 3 for a solid). However, the Euclidian dimension does not take into account the 
spatial properties of these objects across scales. Many natural objects display the same 
amount of complexity at different scales (West et al, 1999; Brown et al, 2002; Cross, 1997). 
This makes classical measurements (length, surface area, etc.) scale dependent as new details 
are unravelled at higher resolutions. One of the most common examples is when measuring 
the coastline of Great Britain (Mandelbrot, 1967). It can be easily shown that the 
measurement obtained depends on the length of the yardstick (or ruler) being used. The same 
happens with area measurements (Baish & Jain, 2000). Take for instance the case of a unit 
cube (Figure 4.2 B, iteration 0). Both the unit cube and the Sierpinski carpet (Figure 4.2 B, 
iteration > 0) have the same Euclidian dimension (D = 2). However these objects are 
intrinsically different and any measurements on complex objects such as the Sierpinski carpet 
become scale dependent.  
 
One of the first applications of fractal analysis has been to study and comprehend objects 
generated by a set of rules that tends toward the same solution (known as an attractor), which 
is independent of the object itself, when a process is repeated many times. These self-similar 
objects are constructs that repeat themselves at smaller scales by contraction (the distance 
between any two points is reduced) and sometimes following additional affine 
transformations (i.e. shearing, reflexion, rotation or translation). In mathematical terms, this 
set of rules is known as an iterated function system (IFS). Examples of such constructs are 
the Cantor set in 1 dimension (Figure 4.2 A) and its 2 dimensional equivalent: the Sierpinski 
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carpet (Figure 4.2 B). The Cantor set consists of a segment line [0 1] at iteration 0 (Figure 4.2 
A) which is divided into two segments at iteration 1 by removing the middle third of the 
interval [1/3 2/3]. Subsequently, at each new iteration, the object is obtained by removing the 
middle third of each segment that remained at the previous iteration. Similarly, the Sierpinski 
carpet (Figure 4.2 B) is a unit square which is divided into 9 identical sub-squares at iteration 
1 and from which the central sub-square is extruded. The process is repeated at iteration 2 by 
subdividing each of the 9 sub-squares into 9 smaller identical squares (sub-sub-squares) from 
which the central sub-sub-square is extruded. This process is iterated ad infinitum. The actual 
area of such object (Sierpinski carpet) is iteration dependent. Instead it is better characterised 
by its FD which can be calculated analytically and equals 1.8928. Similarly, the FD of the 
Cantor set is 0.6309. Many fractal objects are known as self-similar in the sense that they 
consist of N copies of themselves at smaller scales, as in the case of the Sierpinski carpet. 
 
 
Figure 4.2 - Example of self-similar fractal objects generated using a deterministic iterated 
function system (IFS) at different iterations: Cantor set (A) and Sierpinski carpet (B). 
 
 Fractal dimension definition 4.2.2.1. 
The FD of an object is generally derived from measurements of a quantity N(s) which 
characterises the irregularities of an object for a range of scales s. The FD is defined as the 
power law behaviour which describes the relationship between the two quantities as s  0. 
Many definitions of the FD have been proposed, of which the Hausdorff, packing and box-
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counting dimensions are the most common. The Hausdorff dimension is central to the theory 
of fractals but is difficult to implement in practice. Other methods such as the box-counting 
method are preferred in practice (Peitgen et al, 2004; Falconer, 1997). 
 
 Computation of the fractal dimension (box-counting method) 4.2.2.2. 
One of the most practical methods to compute the FD of a fractal/natural object is known as 
the box-counting method. The technique consists of superimposing a grid of mesh size    
onto the object of interest and counting the number of boxes      of the grid the object falls 
into. This process is repeated for a number of covering k (at least 3) with different mesh size 
   so as to count the number of boxes     needed to cover the object across scales. The scale 
   is bounded by the object width (    ) and by the minimum possible scale in the image 
(given by the pixel or voxel width). In the box-counting method, all the boxes of the grid are 
identical (same size) at a given scale of measurement. The FD is obtained as the power law 
between     and the scale of measurement   . Plotting the quantity log(     against 
       ⁄   provides a description of this relationship. Practically, the FD is obtained as the 
slope of a regression line fitted to the data points (generally using a least-squares approach): 
           
        
       ⁄  
         (4.5) 
with    : the number of boxes occupied by the object and    : the associated scale at the k
th
 
covering. 
 
An example is given for the Sierpinski carpet (2 iterations) in Figure 4.3, with different 
meshing superimposed onto the object at different scales so as to measure the associated 
quantity     of boxes needed to cover the object (values reported in Table 4.5). The log-log 
graph of the two quantities after fitting a regression line to the data points is shown in Figure 
4.4. Applying the box-counting method to the Sierpinski carpet gives FD = 1.8928 (Figure 
4.4).  
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Figure 4.3 – Object meshing for computing FD (box-counting method). Example of a Sierpinski 
carpet after two iterations (9x9 pixels image) meshed with grid widths corresponding to a ratio (1/sk) 
of 1, 1/3 and 1/9 of  the  image length from left to right (k = 1 to 3).  
 
 
 
 
 
Table 4.5 – FD computation using the box-counting method: computation of the quantity     
(number of boxes occupied by the fractal object) with scale reduction of (1/sk) of the grid width 
at the k
th
 covering. Example of the Sierpinski carpet at 2 iterations (Figure 4.3). 
 
Covering index k Scale sk     log2(1/sk) log2(   ) 
1 1 1 0 0 
2 1/3 8 1.5850 3 
3 1/9 64 3.1699 6 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – Log-Log plot (quantity     versus 1/sk) and fit of the regression line to obtain FD. 
Example of the Sierpinski carpet at 2 iterations (Figure 4.3 and Table 4.5).   
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 Application of fractal geometry to life sciences and oncology 4.2.2.3. 
Fractal geometry has been used in many fields, including medicine, to assess vascular 
networks  and organ blood flow in relation to pathologies (e.g. Cross, 1997; Charalampidis et 
al, 2006; Kleen et al, 1998), and to characterise tumour boundaries (Carbonetto et al, 2010) 
and tumour cell morphology (Timbó et al, 2009). Histopathologists have observed that, 
similar to a fractal object or to the coastline of Great Britain, tumour boundaries maintain the 
same amount of complexity at different scales of magnification (from macroscopic scales 
down to individual cells) (Cross, 1997). Natural and biological objects often differ from 
mathematical fractals in that they are not, strictly speaking, self-similar across scales. The 
range of scales at which these natural entities can be investigated is also finite (e.g. bounded 
by the resolution of an imaging system and the size of the object of interest) (Atupelage et al, 
2012). Nevertheless, similar to using ideal shapes derived from Euclidian geometry to 
characterise an object, one can use fractal geometry to characterise the complexity and 
irregularities of biological entities (Baish & Jain, 2000). The FD might be more informative 
than smoothed measurements derived from Euclidian geometry when it comes to capturing 
the complexity and irregular shapes characteristic of neoplastic lesions (Baish & Jain, 2000).  
FD measurements have been successfully used to discriminate between tissue types on biopsy 
measurements (Landini & Rippin, 1993). Studies have shown that FD computed on 
histological slices can discriminate between tumour grades (Tambasco et al, 2008). Bizzari et 
al (2011) proposed a fractal approach to characterise cancer morphology within a system 
biology framework. Fractal analysis has also been integrated to models of cancer growth 
(Janecka, 2007; Norton, 2005; d’Onofrio, 2009; Brú et al, 2008).  
 
Fractal geometry has been applied to imaging modalities such as CT and MRI (see for 
instance a review by Lopes & Betrouni, 2009). Di Giovanni et al (2012) found an association 
between FD (computed using the box-counting method) and ER receptor status in 33 breast 
cancer patients imaged using dynamic contrast enhanced (DCE) MRI imaging (after 
adjusting for tumour size): FD was significantly lower in tumours not expressing ER 
receptors (p = 0.003, η2 = 0.26, general linear model). Goh et al (2009) explored fractal 
analysis to assess colorectal tumour perfusion as measured with perfusion CT, as well as its 
reproducibility (Sanghera et al, 2012). It is important to note that, in order to apply a 
morphological fractal analysis based on the box-counting method, grey level images (or 
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intensity maps) were converted into binary images (thresholded versions of the original 
images) and so any information related to the relative occupancy of the object in space was 
lost after this preprocessing step. Other authors (Al-Khadi et al, 2008; Kido et al, 2003) 
proposed using a modified version of the box-counting method, the so-called differential box-
counting method (DBC), which is an adaptation of the box-counting method to compute FD 
on grey level images. In DBC implementation (Sarkar & Chaudhuri, 1994) the quantity     at 
each scale s is derived from the computation of normalised intensity differences in each 
volume element (vel) of the mesh. This textural FD has proved useful, for instance, in 
differentiating between aggressive and non-aggressive lung tumours in CE-CT imaging (Al-
Khadi et al, 2008), as well as between bronchiolo-alveolar cell carcinomas (good prognosis) 
and other bronchogenic carcinomas (poor prognosis) on high-resolution CT images (p-value 
< 0.0001) (Kido et al, 2003). Lv et al (2009) derived FD from the DBC method (named by 
the author: texture fractal dimension, TFD) as well another modified FD metric (the 
histogram fractal dimension, HFD) in a group of 55 prostate cancer patients imaged with MR 
and compared the results to a control group. They found that both metrics were statistically 
significant in differentiating between the cancer versus control group with an AUC of 0.691 
and 0.966 for TFD and HFD respectively. However, it is important to note that these metrics 
captured different properties of the object at different scales (quantity Nsk in equation 4.5) to 
derive FD. As detailed in the literature review (Section 3.1), fractal analysis has also been 
used to characterise time activity curves (TACs) in PET imaging (Dimitrakopoulou-Strauss et 
al, 2002) using the box-counting method. However to date, no studies have investigated the 
potential of FD to recover the space-filling properties of objects in PET imaging.   
 
 From fractal dimension to space-filling properties of an object 4.2.2.4. 
The FD is an index, which captures the space-filling properties of an object (e.g. tumour) 
embedded in space of given topological dimension (Cross, 1997; Di Ieva et al, 2011). The 
closer the FD value to the topological dimension, the more the object fills the space it is 
embedded in. Di Ieva et al (2011) proposed using the FD index as an indicative descriptor of 
the space-filling properties  of tumour vasculature measured using ultra-high field MRI (Di 
Ieva et al, 2011). The quantification of an object’s space-filling property has been taken 
further in studies of solar flare area for instance, in which the actual area occupied by the 
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object is derived from the FD (Aschwanden et al, 2008). The FD provides an index of these 
space-filling properties which goes beyond Euclidian measurement (topological dimension). 
In physiology, for instance, metabolism has been shown to obey a power law with the scale 
of observation, both, within and across animal species, rather than with the volume or the 
mass of an organ (Peitgen et al, 2004; West et al, 1999). Oncologist Larry Norton (2005) 
suggested using a fractal approach to capture the space-filling properties of breast lesions, 
using histological slices, as an index of cell density (ratio of the FD to the 3D volume 
occupied by the tumour) for use in cancer therapy. He argued that the more dense a lesion 
(the closer its FD to the topological dimension), the more dense it remains when the tumour 
grows. By contrast, when this density is initially less, it drops dramatically with a subsequent 
increase in the lesion’s volume.  
 
By definition of the FD (equation 4.5, box-counting method), the number of boxes     
needed to cover the fractal object at scale s is given by:      (
 
  ⁄ )
   
. It follows that if 
one only considers the smallest scale used for the FD computation of such an object (pixel 
width given for the greatest k), then the area of the fractal is directly proportional to the width 
of the object (the inverse of the reduction factor    :       
 
  ⁄ ) raised to the power of the 
FD of the object:             
  . Let’s consider, for instance, the Sierpinski carpet at 
iterations 1, 2 and 3 (Figure 4.2 B) to be square images of dimensions 3x3 pixels, 9x9 pixels 
and 27x27 pixels (respectively) so that the smallest black or white area in the images 
represents one pixel. It follows that one can recover the area occupied by the fractal object 
(black pixels in Figure 4.2 B) at the pixel scale. For 1 iteration, AreaFD = 3
1.8928
 = 8 pixels; for 
2 iterations, AreaFD = 9
1.8928
 = 64 pixels and for 3 iterations, AreaFD = 27
1.8928 
= 512 pixels. 
Similarly the corresponding filling factor can be derived as filling factor = L
FD-2
. It follows 
for 1 iteration, filling factor = 3
1.8928-2
 = 8/3
2
; for 2 iterations, 9
1.8928-2
 = 64/9
2
 and for 3 
iterations, 27
1.8928-2 
= 512/27
2
. 
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Moreover, from the FD and AreaFD estimates, one can recover 
the intensity of the object (Iobj). Indeed the mean intensity 
(IBOXmean) in the square image (Figure 4.5) is given by a 
combination of the intensity of the fractal object (Iobj) and 
background intensity (IBG).  Knowing how much of the box is 
occupied by the fractal object (AreaFD and filling factor 
estimates), one can recover the intensity in the object as 
follows: 
 
 
                                                              
So 
     
 
  
            
      
  
               (4.6) 
 
 From fractal sets to multifractal measurements 4.2.3. 
The FD is a single value which captures the complexity features of highly irregular objects 
under the assumption that such features are spatially invariant (Mandelbrot, 1989) and 
therefore can be described as sets. By contrast, many objects and images are characterised by 
non-uniform distributions. The properties of such objects have been shown to be better 
characterised by a spectrum of FDs (Mandelbrot, 1989; Kinsner, 2005; Atupelage, 2012). The 
concept of multifractal measurements is an extension from fractal geometry. The single FD is 
extended to a spectrum of dimensions which captures properties of the object related to its 
relative density, mass or probability in different regions of space. Kinsner (2005) proposed a 
unifying framework for fractal and multifractal analysis; he showed that the various 
definitions of FD that can be derived for objects with a uniform distribution are a subset of 
the entropy-based FDs derived from a Rényi multifractal spectrum. 
 
Two different approaches to the multifractal formalism have been introduced (Falconer, 
1997), namely a fine and a coarse theory. The former is a local approach, based on measuring 
the fractal properties of the different sets the object is composed of. The latter is based on 
measuring the irregularities of the non-uniform distribution as a whole (global averaging) at 
Figure 4.5 – Sierpinski 
carpet at 2 iterations 
with background and 
object intensity 
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different scales using a lattice covering the object (as in the box-counting method) or using a 
point-centre method (Harte, 2012). The study of global behaviour is described by the work of 
Alfred Rényi on information theory. This is a global averaging or information theory 
approach which results in a spectrum of FDs that can be used as a bounded signature of an 
object. 
 
As with the fractal analysis, multifractal analysis has been applied to both mathematical 
multifractal objects that are characterised by different power-law scaling in their probability 
distribution, and to natural/complex objects characterised by a non-uniform distribution such 
as the histopathology of cancer cells. For instance, Atupelage et al (2012) used multifractal 
analysis to classify prostate cancer tissues (histology) based on H&E (Hematoxylin and 
eosin) stained slices. They achieved an accuracy of 94% in classifying cancerous/non-
cancerous tissues. They showed that classification performance (cancerous/not-cancerous) 
obtained with their technique out-performed other texture classification techniques such as 
Haralick features and Gabor filter bank. Lopes et al (2011) showed that combined fractal and 
multifractal features provided a robust classification of brain tissues imaged with both MRI 
and SPECT imaging. The large volumes (55,000 and 28,000 voxels for MRI and SPECT 
respectively) allowed the authors to use a local approach to compute the features (based on 
the fine multifractal formalism). Rose et al (2009) proposed a multifractal approach based on 
the Rényi spectrum to calculate a set of FDs for lesions measured on DCE-MRI and showed 
that the derived heterogeneity metrics can differentiate between low and high grade 
malignant tumours. 
 
In this thesis, the generalised Rényi multifractal spectrum based on the box-counting 
computation is proposed to characterise the global irregularities of heterogeneous PET 
radiotracer uptake distribution in neoplastic lesions. This is practically more adapted to PET 
imaging than a local approach given the relatively low resolution in PET and the limited size 
of neoplastic lesions, which limits the range of available scales at which the entropy-based 
measure can be computed. As in the case of binary objects, this approach is proposed to 
recover the space-filling properties of an object characterised by a non-uniform distribution, 
with the particular aim of characterising the most “active” parts of this object. The method is 
illustrated on modified fractal objects in the following paragraphs. In Chapter 6, the 
technique is extended to recover the space-filling properties of objects embedded in non-zero 
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background intensities and affected by PVEs due to low resolution, as observed in PET 
imaging. 
 
 Generalised Rényi fractal dimension spectrum 4.2.3.1. 
Similar to the box-counting method (introduced in Section 4.2.2.2) for estimating a single-
valued FD, computation of the generalised Rényi FD spectrum is based on the partitioning of 
a square-box image at different scales. At each covering k, a grid of mesh size    is 
superimposed onto the object of interest. The major difference is that unlike the box-counting 
method in which the quantity of interest is the number of boxes     of the grid the object falls 
into (binary outcome), in the generalised approach, the quantity takes into account how much 
of the object falls into each of the sub-squares (also known as vels, contraction of volume 
elements).   
 
Let’s for instance consider the kth covering of the object,    is the mesh size of the grid and 
∑      the sum of intensities of the object (or total object intensity – TOI). The density of the 
object in the i
th
 vel at the k
th 
covering can be defined as:  
      
    
∑     
⁄  ,          (4.7) 
where       ∑                , namely the intensity in the i
th
 vel at the k
th
 covering (or scale 
  ) is the sum of intensities of the voxels belonging to the vel. The measurement is 
normalised so that the sum of probabilities    equals unity at each k covering. The average 
information content of the fractal object at the k
th
 covering is then given by the Shannon-
Entropy as follows: 
 
       ∑                        (4.8) 
 
Then the information fractal dimension across k coverings can be defined as follows: 
 
          
   
    
 
 
                (4.9) 
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At each scale of measurement s, the quantity   s measured is an index of the averaged 
information content at this scale. Similar to the box-counting method, the measurements are 
repeated across scales. The Rényi dimensions are a generalisation of the information 
dimension obtained by weighing the probabilities    using a range of arbitrary moments Q. 
The moment Q emphasises different intensity contributions in the image, with Q = 0 
weighting all the radiotracer activity concentrations equally (e.g. a completely filled square 
box object without any zero activities will typically have FD = 2 in the 2-dimensional case), 
Q = 1 reducing to the Shannon-Entropy (averaged information content, rule of L’Hospital) 
(Weisstein, 2013), and as Q    the Rényi entropy is determined by the contributions of 
the densest regions (greatest activity concentrations). Typically the (Dq,Q) spectrum is an 
inversed S-shape. The fractal dimensions (Dq) for the range of moment Q, is given by: 
 
 q         
 
   
    ∑  
 
    
 
 
             𝑄         (4.10) 
 
 
By the rule of L’Hospital, the case Q = 1 corresponds to the information FD:  
 
 q         
 ∑        
    
 
 
         𝑄        (4.11) 
 
 Cantor set generated using a probabilistic iterated function 4.2.3.2. 
system (IFS) 
The transition from a measure on a set to a measure on an object with an inhomogeneous 
distribution can be illustrated, for instance, using a fractal object such as the Cantor set 
(Figure 4.6 A) (Mandelbrot, 1989; Harte, 2012) or the Sierpinski triangle (Falconer, 1997). 
Let’s associate a mass µ to the Cantor set at iteration 0 (Figure 4.6 B), which is the interval [0 
1]. One can, at each step of the Cantor set generation, not only divide the interval into thirds 
according to the cantor set deterministic IFS, but also distribute the associated mass µ across 
each sub-segment according to a specified probability rule that supplements the deterministic 
IFS. This set of rules effectively assigns arbitrary weights (or probabilities) to each sub-
interval at each iteration i. The example given in Figure 4.6 B uses the Cantor set as support 
of the measure. In the example given, the actual mass associated with any two sub-segments 
(at iteration i), “left and right sub-segments”, corresponds to 1/3rd and 2/3rd (respectively) of 
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the segment’s mass they were drawn from (at iteration i-1). Using the Rényi multifractal 
spectrum, one can then recover not only the FD of the support (D0 = 0.6309), but also a 
spectrum of FDs which characterise the associated probability distribution. This will be 
illustrated with a 2-dimensional example in the following paragraph.   
 
 
 
 
 
 
 
 
Figure 4.6 - Cantor sets generated using a deterministic (A) and a probabilistic (B) IFS  
 
 Generation of modified Sierpinski carpets in zero background 4.2.3.3. 
The example of the modified Cantor set can be extended to the Sierpinski carpet, its two-
dimensional equivalent (Figure 4.7). Here the mass attributed to each vel at different 
iterations is directly encoded as a grey level. Effectively, the IFS used is probabilistic rather 
than deterministic. Instead of assigning the same probability to each of the 8 contractions wi 
at each scale, an arbitrary probability p/4 is assigned to four of the vels and (1-p)/4 to the 
remaining four vels depending on their spatial location in the object. If we choose, for 
instance, probabilities of 1/3 and 2/3 for p and (p-1) respectively (Figure 4.6 B, case 2), the 
total object intensity (TOI) (∑Ibox = 9) will be distributed across four of the vels with a weight 
of 1/12
th
 and across the remaining four vels with a weight of 2/12
th
.  
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Figure 4.7 – Generation of heterogeneous Sierpinski carpets: Illustration of the process by which 
the modified Sierpinski is generated in comparison to the classical Sierpinski carpet (A) and 
generation of four cases with different associated weights (p, q) (B). Case 1 corresponds to p = 1/2 
(classical Cantor set), case 2 to p = 1/3, case 3 to p = 1/10 and case 4 to p = 1/50. 
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 Multifractal spectrum measurements on modified Sierpinski 4.2.3.4. 
carpets in zero background  
The method described in 4.2.3.1 was applied to the modified Sierpinski carpets (Figure 4.7). 
Results of the associated multifractal spectrums are shown in Figure 4.8. As expected the 
multifractal spectrum of a mono-fractal object such as the Sierpinski carpet (Figure 4.7 B, 
case 1) is flat, having a unique FD equal to 1.8928 (Figure 4.8). By contrast, when the 
measure on the fractal support is characterised by a non-uniform distribution of intensities, 
one recovers an inverted S-shaped (Dq,Q) spectrum which represents a signature of the object 
and of the contributions of its different densities. As the set which supports this probabilistic 
measure is a fractal, the box-counting dimension derived from the Rényi spectrum for 
moment Q = 0 (D0) is the same in all four cases (D0 = 1.8928). However, the rest of the Dq 
dimensions are function of the choice of probability p and of moment Q. As illustrated in 
section 4.2.2.4 for a mono-fractal object, the space-filling properties of the object are 
recovered for the spectrum of fractal dimensions Dq as        𝑄       
  . From the 2
nd
 
to the 4
th
 case, the difference in intensity weights attributed to the voxels increases, creating 
objects in which the total object intensity (TOI, sum of intensities) is more and more densely 
concentrated (Figure 4.7 B). As this difference increases, the area filled by the most active 
voxels decreases, which manifests in the plateau of the (Dq,Q) spectrum for Q>20 (Figure 
4.8) and the values obtained for AreaFD (Table 4.6). Notably, in the extreme case where the 
object reduces to the Sierpinski carpet with a uniform distribution (Figure 4.7 B, case 1), the 
area recovered using the multifractal spectrum is the area of the fractal set (64 voxels) and the 
associated mean intensity of the object is given by the total object intensity (TOI) (or sum of 
intensities) divided by AreaFD (Table 4.6). In the case of a high difference between the 
probabilities p and q (Figure 4.7 B, case 4), the mass is mainly concentrated in 16 voxels – 
the actual area can be recovered using the FD value reached for greater Q’s at the plateau, 
and used to indicate the mean intensity that is spread between these active areas – namely 
TOI / 16. The area recovered via the FD computation is 16.7 with a mean intensity of 0.54. 
The contribution of the other voxels to recovering the sum of intensities (TOI) is negligible in 
this case. 
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Figure 4.8 –Multifractal Rényi (Dq, Q) spectrum of modified Sierpinski carpets. Case 1 
corresponds to p = 1/2 (classical Cantor set, blue line), case 2 to p = 1/3 (red), case 3 to p = 1/10 
(magenta) and case 4 to p = 1/50 (black).  
 
 
 
Table 4.6 – Ground truth (GT) values for sum of intensities of the modified Sierpinski carpets 
(total object intensity, TOIGT) and FD estimates (AreaFD, IFD) recovered from the multifractal 
Rényi (Dq,Q) spectrum. Values are given for the plateau part of the curve. In this example, the sum 
of intensities: TOI = 9. 
 
Case number TOIGT AreaFD (pixels) IFD 
1 9 64 0.14 = (9/64) 
2 9 36.6 0.24 
3 9 19.8 0.45 
4 9 16.7 0.54 ≈ (9/16) 
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 18F-FLT PET FEC-chemotherapy dataset 4.3. 
 Breast cancer patients  4.3.1. 
The original PET data used in this analysis were collected by Dr Laura Kenny (Imperial 
College London, London, UK) (Kenny et al, 2005; Kenny et al, 2007). Fifteen patients with 
locally advanced or metastatic epithelial breast cancer who were to be treated with 
chemotherapy at Hammersmith & Charing Cross Hospitals, London, United Kingdom were 
included in the study (Table 4.7). Eligible patients were aged between 18 and 80 years with 
histologically proven breast cancer and had at least one lesion with a minimum diameter of 
2.5 cm. Patients had AJCC stage II to IV breast cancer. All patients but four were treatment 
naïve. Only patients who had not received cytotoxic or hormonal therapy for at least 3 weeks 
and radiotherapy for at least 4 weeks were eligible for the study. 
 
13 out of 15 patients had a primary breast tumour. Secondary breast cancer was detected prior 
to the study in lymph nodes of four patients (axillary, pre-tracheal and mammary). The cancer 
had also spread to other parts of the body (lung and bone metastases) in two patients prior to 
the study. 73% of patients (N=11) had ductal breast cancer disease while 20% (N=3) had 
lobular breast cancer disease and one had inflammatory disease. Patient 15 had multifocal 
disease.  
 
 Biological measurements 4.3.2. 
Direct measurements of proliferation were obtained for the original study from core biopsies 
taken within 3 months (median 18 days) before the start of the study. Formalin-fixed tumour 
samples were sectioned and immunostained with an anti-Ki-67 antibody, NCL-Ki-67-MM1 
(Novocastra Laboratories, Newcastle upon Tyne, UK). Ki-67 positive cells were counted 
manually in a total of eight fields of view selected randomly. The Ki-67 labelling index was 
calculated as the ratio of the number of Ki-67-positive cells to the total number of cells 
(Table 4.7). The procedure was carried out using a BX51 Olympus microscope (Olympus 
Optical, Tokyo, Japan) at x400 magnification and with the aid of Sigma Scan Pro 5 (Aspire 
Software International, Leesburg, VA, USA). ER and PgR status were measured on core 
biopsies. 
4.3 – 18F-FLT PET FEC-chemotherapy dataset  95 
 
 
 
Table 4.7 – Information about patients who took part in the 18F-FLT PET study. Hormone 
receptor status was classified as negative (-) or positive (+).  
  
Patient Lesions Grade 
Previous 
treatment 
Histological 
type 
ER 
(+ / -) 
PgR 
(+ / -) 
Ki-67 
labelling 
index (%) 
1 Breast tumour II Nil Lobular + + 4.91 
2 Lung metastasis III Chemotherapy Ductal - - ND 
3 Breast tumour III Endocrine Ductal + + ND 
4 
Breast tumour,  
Rib metastasis 
II Nil Ductal + + 45.22 
5 
Breast tumour, 
Axillary node,  
Mammary node 
III Nil Lobular - - 
3.02 
ND 
6 
Breast tumour,  
Axillary node 
III Nil Ductal - - 33.57 
7 Breast tumour III Nil Ductal + - 9.98 
8 Breast tumour II Nil Ductal + + 21.21 
9 Breast tumour II Nil Ductal + + 7.85 
10 
Axillary node,  
Pre-tracheal node 
III Chemotherapy Ductal - - ND 
11 Breast tumour III Nil Inflammatory - - 8.85 
12 Breast tumour II Nil Lobular + - 3.53 
13 
Breast tumour, 
Axillary node 
II Chemotherapy Ductal + 
+ 
 
28.87 
14 Breast tumour II Nil Ductal + + 29.70 
15 Breast tumour II Nil Ductal - - 13.21 
 
ND: not done 
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 Clinical response assessment 4.3.3. 
Patients received combination 5-fluorouracil (600mg/m
2
), epirubicin (600mg/m
2
) and 
cyclophosphamide (600mg/m
2
) (FEC) chemotherapy every 21 days for up to 8 cycles until 
surgery or disease progression.  
   
Clinical response was evaluated in 12 out of 15 patients at 60 days according to the RECIST 
criteria (Table 4.8). Tumours were measured using electronic calipers or by CT before each 
PET scan (baseline and at one week after treatment) and at 60 days. Response to treatment 
was assessed in the primary lesion for 8 patients, in both breast and axillary lesions for 2 
patients and axillary node only for one patient. 11 patients had a primary lesion, of which 6 
were classified as partial responders and 5 as stable disease. 3 patients were not measured for 
response: patient 2 developed brain metastases after the first cycle of chemotherapy and died 
before day 60; patient 12 withdrew from the study due to a viral infection; patient 15 had 
surgery (mastectomy) before the end of the study because of an abscess. Patient 5 was 
classified as a non-responder after two cycles of FEC chemotherapy due to a lack of response 
in the primary tumour. Her treatment was changed to docetaxel-trastuzumab thereafter. 
Patients 5 and 10 also had a mammary node and a pre-tracheal node (respectively) that had 
not been detected prior to the study. Similarly, patients 1, 13 and 15 had axillary nodes and 
patient 4 had a rib metastasis that could not be measured for response.  
 
All patients were either classified as having partial response (PR) or stable disease (SD). 
These two response groups are referred to as responder (R) and non-responder (NR) in the 
remainder of this thesis.  
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Table 4.8 – Anatomical response assessment (RECIST criteria). Lesions size (cm2) at baseline 
(Day 1), 1 week after FEC chemotherapy (Day 8) and 60 days after treatment  (Day 60), equivalent 
decrease of 30% in the sum of lesions’ longest diameters measured at baseline (Day 1) and clinical 
response classification (PR: partial response, SD: stable disease, R: responder, NR: non-responder). 
*
 This patient was classified as a non-responder based on the primary breast tumour although a response was 
observed in the axilla 
†
 This patient was classified as a responder by the clinician given the reduction in lesion size along the second 
diameter 
  
Patient 
Site of 
disease 
Dimensions (cm
2
)  Equivalent 30% 
decrease in the sum 
of longest diameters  
(cm) 
Clinical 
Response Day 1 Day 8  Day 60  
 
1 breast 8.0x6.4 7.5x6.7 1x1  5.6 PR (R) 
2 lung  3.0x3.0 - -  - - 
3 breast 7.7x10.1 6.7x10.7 6.5x8.6  7.07 SD (NR) 
4 breast 26x18 - 16x13  18.2 PR (R) 
5 breast 19x18 19x18 19x18  
16.1 SD (NR)
*
 
5 axilla 3x4 3x4 2x2  
6 breast 10.5x10 8.5x9 5x4  
10.5 PR (R) 
6 axilla 4.5x4.5 2.5x3 CR  
7 breast 4x4 4x4 3x1  2.8 PR (R)
†
 
8 breast 10x13 10x13 12x13  9.1 SD (NR) 
9 breast 3.7x3.4 3.5x2.8 3.5x3.2  2.59 SD (NR) 
10 axilla 3x2.9 3x2.9 3x3  2.1 SD (NR) 
11 breast 9.0x7.8 8.9x7.9 8x8  6.3 SD (NR) 
12 breast 6x3 - -  - - 
13 breast 2.7x3.5 2.6x2.9 2.2x2.2  2.45 PR (R) 
14 breast 5.8x7.8 5.7x7.7 3.5x3.5  5.46 PR (R) 
15 breast 3.1x3.2 3.1x2.4 -  - - 
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 Positron Emission Tomography imaging 4.3.4. 
 PET scans schedule 4.3.4.1. 
Three PET scans were planned for each patient: a baseline scan, a validation scan performed 
within 2 to 8 days of the first scan, and a scan at 1 week after the start of chemotherapy. All 
patients underwent one PET scan prior to the first cycle of chemotherapy treatment; 9 
patients out of 15, of whom 6 had a primary lesion, underwent an additional pre-treatment 
scan at 2-8 days. Details are given in Table 4.9. 
 
 
Table 4.9 – 18F-FLT PET scans. Scans performed for each patient (prior to treatment: Baseline 
and/or Validation (2-8 days) and at 1 week after the start of FEC chemotherapy: Post-treatment). (R: 
responder, NR: non-responder).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Patient Response Scans 
1 R Baseline
*
, Validation, Post-treatment 
2 - Baseline, Validation,  Post-treatment 
3 NR Baseline, Validation,  Post-treatment 
4 R Baseline, Validation,  Post-treatment 
5 NR Baseline,  Post-treatment 
6 R Baseline,  Post-treatment 
7 R Baseline, Validation,  Post-treatment 
8 NR Validation,  Post-treatment 
9 NR Validation,  Post-treatment 
10 NR Baseline
†
, Validation,  Post-treatment 
11 NR Baseline, Validation,  Post-treatment 
12 - Baseline 
13 R Validation,  Post-treatment 
14 R Baseline, Validation,  Post-treatment 
15 - Baseline, Validation,  Post-treatment 
*
 This scan was not used in subsequent analyses due to a problem of count 
during OSEM reconstruction 
†
 Patient 10 left the bed during the scan. Therefore the baseline scan was not 
used in subsequent analyses 
   
4.3 – 18F-FLT PET FEC-chemotherapy dataset  99 
 
 Image acquisition and reconstruction 4.3.4.2. 
18
F- FLT was synthetised by Hammersmith Imanet by radiofluorination of the 2,3V-anhydro-
5V-O-(4,4Vdimethoxytrityl)-thymidine precursor (Cleij et al, 2001). Imaging was performed 
using a single bolus injection. The planned dose was 370 MBq for each scan and the actual 
dose injected ranged from 153 to 380 MBq (specific activity from 25 to 465 GBq/Amol, 
determined by high-performance liquid chromatography).  
 
Dynamic PET scans were performed using an ECAT 962/HR+ scanner (CTI/Siemens, 
Knoxville, TN, USA) for 95 minutes (58 cm transaxial field of view). The 15.5 cm axial field 
of view allowed the simultaneous acquisition of 63 trans-axial planes. Data were binned into 
31 discrete frames (30 s×10, 60 s×5, 120 s×5, 180 s×5, 600 s×6). Image reconstruction was 
performed in the original study using FBP reconstruction. The PET data were reconstructed 
by Dr Katherine Gray for a subsequent study (Gray et al, 2010) using OSEM reconstruction 
method (360 iterations and 6 subsets). Full width at half maximum (FWHM) in-plane and 
axial resolutions were 5 mm. Images were reconstructed with a voxel size set to 2.615 x 
2.615 x 2.420 mm
3
. 
 
 Manual delineation 4.3.4.3. 
Regions of interest were manually drawn in different tissues (tumour, node, metastases, liver, 
normal breast) by an experienced clinician on each slice of the summed PET images using 
Analyze software (Version 7; Biomedical Imaging Resources). These regions were then 
added to obtain a single 3-dimensional Volume of Interest (VOI) for each lesion. Regions of 
interest were defined on the transverse plane. The procedure was visually guided by CT for 
patients with metastatic disease.  
 
 Blood and metabolite collection 4.3.4.4. 
Continuous arterial blood sampling was performed for the first 10 minutes, followed by 
discrete arterial samples taken at 0, 2.5, 5, 10, 20, 30, 45, 60, 75, and 90 minutes. Gamma 
counting was used to derive the total blood radioactivity, and high-performance liquid 
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chromatography was used to determine plasma parent fraction. Further details can be found 
in Kenny et al (2005). 
 
 Image pre-processing 4.3.4.5. 
Images were decay corrected by taking into account the duration of each frame (Turku PET 
Centre, 2011). 
 
 Kinetic analysis 4.3.4.6. 
Delivery of the radiotracer (K1) was estimated at the voxel level using spectral analysis 
(Turkheimer et al, 1994) and in-house software with the help of Dr Giampaolo Tomasi. K1 
parametric maps were averaged for each VOI to obtain the average delivery of radiotracer in 
the entire lesion (K1mean). In addition the retention of radiotracer (Ki) was evaluated using a 
modified Patlak analysis applied to the entire tumour volume. Further details of this method 
have been reported in previous work (Kenny et al, 2005). 
 
 Statistical analyses 4.4. 
Statistical analyses were performed using SPSS for Windows version 19 (IBM, Chicago, IL, 
USA). 
 
 Implementation 4.5. 
All methods were implemented using MATLAB (The Mathworks, Natick, MA, USA) in a 
vectorised fashion wherever possible in order to speed up the computation process. 
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Chapter 5.  Global textural feature measurements       
of intra-tumour proliferative heterogeneity 
 
 
5.1.  Introduction 
In this chapter, the use of statistical texture analysis methods to characterise intra-tumour 
heterogeneity is explored in breast cancer patients using 
18
F-FLT PET imaging. The aim of 
this work was to quantify tissue and intra-tumour heterogeneity of in vivo cell proliferation 
using intensity distribution and spatial texture descriptors of 
18
F-FLT PET imaging and to 
assess the repeatability of the measurements using test-retest data. Secondary aims were to 
explore the ability of a subset of well-behaved image descriptors to capture differences 
between responders and non-responders to neoadjuvant chemotherapy, and to study changes 
in intra-tumour heterogeneity one week after the start of therapy. Additional analyses were 
carried out to study the influence of volume size, injected dose, image reconstruction 
techniques and texture analysis parameter settings. 
 
5.2.  Materials and Methods 
5.2.1.  Dataset 
The 
18
F-FLT PET FEC-chemotherapy dataset on which this research was conducted was 
described in Chapter 4 (Materials and Research Methods, Section 4.3). Among the 15 
patients included in this study, all except two patients (patients 2 and 10) had a primary breast 
lesion. 12 patients were measured for response at 60 days using the RECIST criteria, of 
whom 11 had a primary breast lesion. Among these 11 patients, 6 were classified as 
responders (complete responder or partial responder) and 5 as non-responders (stable 
disease). Patient 15 had multifocal disease and was excluded from the analyses. 
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Primary analyses were performed on iteratively reconstructed images (Materials and 
Research Methods, Section 4.3.4.2). FBP reconstructed images (lower resolution) were used 
for comparison. The dynamic PET images were averaged over a window of time (from 32 to 
65 minutes) in order to obtain an average map of tumour heterogeneity once the tracer had 
entered the tumour tissue (Figure 5.1). A second time window (PET image averaged from 65 
to 95 minutes) was used for comparison.   
 
 
 
 
Figure 5.1 – Heterogeneous intra-tumour uptake of 18F-FLT in primary breast tumours. Images 
A to F were normalised for injected dose and body weight (OSEM, Gaussian post-filtering: FWHM = 
4mm, images summed between 32 and 65 minutes). Patient 14 (responder): baseline (A), validation 
(B) and post-treatment scan (C). Patient 3 (non-responder): baseline (D), validation (E) and post-
treatment scan (F).  
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5.2.2.  Textural feature analysis 
A total of 29 image descriptors were computed (Table 5.1). The features were derived from 
the methods introduced in Chapter 4: FOS, GLCM, GLSZM and NGTDM. The radiotracer 
concentration in each individual lesion was normalised prior to texture characterisation using 
a uniform quantisation method for a large range of number of quantisation levels: 8, 16, 32, 
64 and 128gl. This was a necessary step before applying statistical texture analysis methods 
(EntropyFOS and spatial texture features derived from GLCM, GLSZM and NGTDM 
techniques). 
 
Table 5.1 – List of computed image descriptors. Features were derived from FOS and spatial 
texture analysis techniques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Technique Features 
FOS 
(First Order Statistics) 
 
CV  (Coefficient of Variation) 
Skewness 
Kurtosis 
EntropyFOS 
GLCM 
(Grey Level 
Co-occurrence Matrix) 
Correlation 
InfCo2  (Information Measure of Correlation 2) 
Angsmo  (Angular Second Moment) 
EntropyGLCM 
ContrastGLCM 
Dissimilarity 
Homogeneity 
 Smallzone (Small Zone Emphasis) 
GLSZM 
(Grey Level 
Size-Zone 
Matrix) 
Largezone  (Large Zone Emphasis) 
Glnonunif  (Grey Level Non Uniformity) 
Sznonunif  (Size-Zone Non Uniformity) 
Szpcent  (Zone Percentage) 
Zonelogl  (Low grey level Zone Emphasis) 
Zonehigl  (High grey level Zone Emphasis) 
Szonelogl  (Small Zone Low grey level Zone Emphasis) 
Szonehigl  (Small Zone High grey level Zone Emphasis) 
Lzonelogl  (Large Zone Low grey level Emphasis) 
Lzonehigl  (Large Zone High grey level Emphasis) 
Glvariance  (Grey Level Variance) 
Szvariance  (Size-Zone Variance) 
NGTDM 
(Neighbourhood Grey-
Tone Difference 
Matrix) 
Coarseness 
ContrastNGTDM 
Complexity 
Strength 
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5.2.3.  Statistical analyses 
Lymph nodes and metastases were excluded from the statistical analyses because they are 
biologically different from primary tumours. 
 
According to the definition of the International Organization for Standardisation (ISO) as 
cited by Laking et al (2006), Repeatability was defined as the ability of the features to give 
consistent results for the same subject scanned twice without an intervening treatment and 
within a few days in our centre using the same PET scanner with images identically 
reconstructed. Repeatability of textural feature measurements was assessed in 5 patients who 
had a primary lesion. The variability of textural measurements within individual tumours 
prior to treatment was estimated by computing relative differences of textural features 
between baseline and validation scans: (featbaseline-featvalidation)/[( featbaseline+featvalidation)/2]. 
The normality of the relative differences was assessed using the Shapiro-Wilk Test. Mean 
and standard deviation (std) were estimated from the relative differences. Lower and Upper 
Limits of Repeatability which defined the 95% confidence interval (CI) of normal 
fluctuations of textural feature measurements prior to treatment were calculated as ±1.96×std. 
An Intra-Class Correlation Coefficient (ICC) was also used to assess the repeatability of the 
image descriptor measurements for the group of patients that was included in this study. 
 
A subset of textural features was selected from the repeatability study in order to explore 
associations with response to treatment. Features were selected if they had high repeatability 
(ICC ≥ 0.7) and a within-patient variability in the range of SUV measurements across the 
range of intensity normalisation parameters. The normality of feature distributions was 
assessed using the Shapiro-Wilk Test. For patients who underwent both a baseline and a 
validation scan before treatment, pre-treatment feature values were calculated as an average 
of these two scans. T-tests were performed to explore the ability of individual textural 
features measured on pre-treatment scans to differentiate between primary lesions of 
responders and non-responders. Bivariate correlations between pairs of textural features were 
investigated by computing Spearman rank correlation coefficients. 
Changes in feature values from baseline at 1 week after the start of therapy were explored 
using paired t-tests. In addition, the percentage change in feature values at 1 week was 
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calculated as: (featpost-treatment-featpre-treatment)/featpre-treatment. Percentage change was compared to 
the normal range of fluctuations obtained from test-retest data in both response groups. 
 
The scope of this study, aims and main statistical methods used are presented in Figures 5.2 
and 5.3.  
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Figure 5.2 – Scope of the texture analysis work and results presented in this chapter. Methods [M1, M2 and M3] are detailed in Figure 5.3. R and 
NR designated responder and non-responder patients respectively.  
Textural feature selection/ 
repeatability study [M1] 
 
 
Univariate associations 
between baseline feature 
values and response 
[M2] 
 
Main Study  
Can one derive a subset of textural features 
providing repeatable measurements of 
18
F-FLT 
PET uptake at baseline and within the same 
conditions of imaging? 
 
 
Do the selected features discriminate between R 
versus NR to therapy as measured with RECIST at 
60 days? 
Do baseline feature values 
predict response? 
Can one detect changes in 
feature values early on after 
the onset of chemotherapy? 
Changes in feature 
values at 1 week and 
association with 
response [M3] 
 
Do these features capture 
correlated/complementary 
information in the signal? 
METHOD: Bivariate 
Associations: Non-
parametric Spearman 
correlations between pairs of 
textural features. Mapping 
using strength of correlation 
for each individual 
quantisation level. 
 
Does time of imaging 
influence feature values 
and discriminatory 
power (R vs. NR)? 
 
METHODS: 
Comparison of feature values 
for two time window averaging 
(32-65min vs. 65-95min) 
- Pearson correlation and 
paired t-test 
- Comparison of feature 
association with response 
[M2] 
 
  
What are the influences of VOI size and Injected 
Dose on feature values? 
 
METHODS:  
- Pearson and Spearman Correlations [
18
F-FLT PET dataset] 
- Simulation study (same distribution, different VOI size) 
 
  
What is the influence of the 
method used for image 
reconstruction on feature 
selection and association with 
response to treatment? 
METHODS:  
Computation of texture analysis on 
FBP reconstructed images and 
comparison with results obtained on 
OSEM reconstructed images 
 
- Feature selection based on 
repeatability study [M1] 
- Discrimination between response 
groups at baseline [M2] 
 
 
 
What is the influence of the distance 
parameter d (between paired 
voxels) on the GLCM feature values 
and on the discrimination between R 
versus NR? 
 
METHODS: 
- Relationship between d and number of 
voxels in computation 
- Influence of d on repeatability results [M1] 
- Influence of d on feature values 
- Influence of d on the discrimination 
between response groups [M2] [M3] 
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*As commonly reported in the literature (Kottner et al, 2011), a value of 0.7 was used as the minimum cut-off value for feature selection. In addition a value of 0.9 was 
used to indicate high repeatability following feature selection (Kottner et al, 2011).   
Figure 5.3 – Main statistical methods, assumptions and selection criteria: for assessing repeatability [M1], studying associations between feature 
values measured at baseline and response to treatment [ M2] and early change in feature values (1week after the onset of therapy) and association with 
response to treatment [M3]. 
Textural feature selection/repeatability study [M1] 
 
 Selection criteria 
 ICC ≥ 0.7*  
 Relative differences within the order of 
magnitude of SUVs  
 
Features were selected only if these results were 
consistent across the range of image intensity 
quantisation parameters used (8 – 128gl) 
 
METHODS 
1. Variations at baseline within individual lesions 
(Index: % Diff and Bland-Altman). Calculation of 
limits of repeatability (mean ± 1.96 x std) 
 
2. Within lesion variability combined with 
separability between patients (Index: ICC 
coefficient) 
 
Assumptions:  
For [1] the normality of the relative differences were 
tested using Shapiro-Wilk Test 
 
 
METHODS 
Univariate analysis: 
1. Parametric (t-test)
 †
  
Or 
2. Non-parametric (Mann-Whitney U test) 
 
†
 If the feature values are normally 
distributed at baseline (Shapiro-Wilk Test) 
 
Selection criteria: p < 0.05 
 
 
 
Association between textural features 
computed at baseline and response to 
chemotherapy [M2] 
 METHODS 
 Global changes between baseline and 1 week 
assessed using paired t-test 
 
 “True” changes in feature values assessed 
using limit of repeatability calculated in [M1].  
 
Selection criteria: Features qualified if changes 
at 1 week were consistent: 
- Not on both sides of the limits of repeatability 
- Distinct trends for responders and non-
responders. 
Changes in textural feature values 
at 1 week after the start of therapy 
and association with response [M3] 
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5.3.  Results 
5.3.1.  Variation in range of textural features across tissue types 
The range of textural feature values varied across tissue types. The mean uptake of 
radiotracer (SUVmean) was lowest in normal breast (0.07 to 0.82 g.mL
-1
), medium in tumours 
and nodes (1.10 to 5.26 g.mL
-1
) and highest in liver (2.57 to 7 g.mL
-1
) and vertebra (2.83 to 
7.44 g.mL
-1
) (Figure 5.4 A). CV (Figure 5.4 B) and EntropyFOS (Figure 5.4 C) captured a 
greater proportion of voxels with low or no uptake of 
18
F-FLT in healthy breast compared to 
other tissues (tumour, liver, and vertebra) which displayed comparable shape in their intensity 
distributions. The area under the curve of the SUV-volume histogram (see AUC-CSH in 
Figure 5.4 D) was similar in tumour (0.16 to 0.38), nodes (0.15 to 0.36) and liver tissue (0.16 
to 0.38). Only slight variations in spatial textural features were observed across tissue types. 
ContrastGLCM (Figure 5.4 E) was generally greater in liver and vertebra compared to healthy 
breast and tumour. However, Complexity (Figure 5.4 G) was similar or slightly lower in 
tumours compared to liver and vertebra. The range of CV, EntropyFOS and Homogeneity 
feature values in healthy breast was larger than in primary breast tumour, node, liver and 
vertebra.  
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Figure 5.4 – Range of textural feature values: SUVmean (A), CV (B), EntropyFOS (C), AUC-CSH 
(D), ContrastGLCM (E), Homogeneity (F) and Complexity (G) in healthy breast, liver, metastasis, node, 
tumour and vertebra.   
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5.3.2.  95% confidence interval (CI) repeatability  
The assumption of normality of relative differences in textural feature estimates at baseline 
was not rejected (Shapiro-Wilk Test) for all but 4 textural features, for which the range of 
normal fluctuation was therefore not estimated: GlNonUnif, SzNonUnif, Szonehigl and 
Strength (Table 5.2). For all other textural features, 95% of the relative differences lay within 
the 95% Confidence Interval. CV and Complexity had a normal range of fluctuations (95% 
CI) below ± 10% (Table 5.3). Six additional features had a variability range below ± 30%, 
namely EntropyFOS, AUC-CSH, EntropyGLCM, Contrast, Dissimilarity and Homogeneity. 
SUV measurements as well as Skewness had wider limits of repeatability (SUVmean: -47.25% 
to 57.67%; SUVmax: -9.30% to 34.97%; and Skewness: -50.86% to 52.77%). A wider range 
of normal fluctuations was observed for textural features derived from the GLSZM method. 
 
5.3.3.  Intraclass correlation coefficient (ICC) repeatability 
Very high repeatability was found for 5 features (         across the range of intensity 
normalisation parameters: CV, InfCo2, ContrastGLCM, Dissimilarity and Complexity (Table 
5.3). 8 textural features had high repeatability (              : EntropyFOS, AUC-CSH, 
Correlation, Homogeneity, SzVariance, Coarseness, ContrastNGTDM and Strength. High 
repeatability was obtained for SUVmean and SUVmax measurements (             ). 
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Table 5.2 – Normality of relative differences in textural feature estimates at baseline. P-value 
associated with Shapiro-Wilk Test.  
Feature p-value 
SUVmean 0.26 
SUVmax 0.27 
CV 0.12 
AUC-CSH 0.82 
Skewness 0.44 
Kurtosis 0.47 
 Number of quantisation levels 
 8gl 16gl 32gl 64gl 128gl 
EntropyFOS 0.53 0.90 0.87 0.90 0.75 
Correlation 0.18 0.38 0.37 0.40 0.39 
InfCo2 0.73 0.24 0.96 0.83 0.64 
Angsmo 0.24 0.69 0.75 0.58 0.18 
EntropyGLCM 0.26 0.59 0.43 0.26 0.044 
ContrastGLCM 0.30 0.32 0.37 0.39 0.47 
Dissimilarity 0.45 0.75 0.78 0.76 0.84 
Homogeneity 0.19 0.75 0.94 0.85 0.87 
SmallZone 0.14 0.89 0.95 0.27 0.58 
LargeZone 0.98 0.60 0.37 0.40 0.097 
GlNonUnif 0.99 0.82 0.56 0.019 0.25 
SzNonUnif <0.01 0.62 0.58 0.51 0.62 
ZonePCent 0.53 0.81 0.59 0.22 0.37 
ZoneLogl 0.92 0.62 0.47 0.75 0.88 
Zonehigl 0.86 1.00 0.36 0.38 0.30 
Szonelogl 0.090 0.55 0.85 0.20 1.00 
Szonehigl 0.011 0.33 0.71 1.00 0.51 
Lzonelogl 0.27 0.27 0.25 0.17 0.13 
Lzonehigl 0.46 0.14 0.15 0.98 0.41 
Glvarianc 0.91 0.52 0.11 0.98 0.81 
Szvarianc 0.30 0.40 0.48 0.39 0.70 
Coarse 0.075 0.075 0.10 0.19 0.23 
ContrastNGTDM 0.42 0.68 0.21 0.91 0.57 
Complexity 0.15 0.77 0.85 0.34 0.64 
Strength 0.035 0.052 0.047 0.049 0.051 
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Table 5.3 - Repeatability results for SUVs and textural features. Mean and standard deviation 
(std) % variations, Lower and Upper Limits of Repeatability (95% confidence interval) and ICC 
values were given for 64gl. In addition the wider range of Limit of Repeatability and the ICC range 
were given across all intensity normalisation parameters. Features selected for studying association 
with response to treatment are highlighted in grey. 
 Features Mean Std 
Lower 
Limit of 
Repeatability 
Upper 
Limit of 
Repeatability 
Widest 95% CI ICC ICC range 
SUVmean 5.21 26.77 -47.25 57.67 -47.25 to 57.67 0.91 0.91 
SUVmax 12.84 11.29 -9.30 34.97 -9.30 to 34.97 0.88 0.88 
CV -1.47 4.20 -9.70 6.77 -9.70 to 6.77 0.95 0.95 
Skewness 0.95 26.44 -50.86 52.77 -50.86 to 52.77 0.60 0.60 
Kurtosis -4.03 18.81 -40.90 32.83 -40.90 to 32.83 0.59 0.59 
EntropyFOS 0.75 2.51 -4.18 5.67 -9.73 to 13.50 0.81 0.74 to 0.81 
AUC-CSH 11.15 11.07 -10.55 32.86 -10.55 to 32.86 0.88 0.88 
Correlation -8.10 55.54 -116.96 100.75 -127.23 to 123.69 0.88 0.86 to 0.88 
InfCo2 -0.18 2.90 -5.85 5.50 -34.06 to 7.24 0.99 0.94 to 1.00 
Angsmo -12.54 22.43 -56.51 31.43 -59.77 to 37.43 0.55 0.55 to 0.80 
EntropyGLCM 
* 2.03 3.43 -4.69 8.75 -8.16 to 15.81 0.74 0.62 to 0.93 
ContrastGLCM   14.00 9.05 -3.74 31.75 -7.15 to 29.67 0.91 0.90 to 0.91 
Dissimilarity 7.86 5.76 -3.42 19.15 -5.25 to 19.35 0.90 0.90 to 0.91 
Homogeneity -7.52 7.90 -23.01 7.97 -27.18 to 11.22 0.91 0.89 to 0.92 
SmallZone -1.92 56.55 -112.76 108.92 -381.22 to 360.98 0.58 0.21 to 0.86 
LargeZone -0.69 50.85 -100.36 98.98 -132.65 to 130.49 -0.19 -0.19 to 0.42 
Glnonunif 
†
 -3.11 11.66 / / -59.01 to 79.80 0.96 0.25 to 0.96 
Sznonunif ‡ -2.15 12.65 -26.94 22.64 -51.95 to 121.57 0.86 -0.33 to 0.89 
Zonepcent -0.07 25.85 -50.74 50.59 -122.17 to 85.27 0.48 0.23 to 0.96 
Zonelogl 1.25 80.31 -156.16 158.66 -173.38 to 159.71 0.34 -0.37 to 0.87 
Zonehigl -12.73 36.27 -83.82 58.37 -169.44 to 144.75 0.61 -0.88 to 0.61 
Szonelogl -1.96 78.05 -154.93 151.01 -358.37 to 388.47 0.47 0.12 to 0.98 
Szonehigl ‡ -13.56 61.57 -134.23 107.11 -346.40 to 256.41 0.48 -0.17 to 0.65 
Lzonelogl 10.66 56.01 -99.13 120.44 -171.17 to 157.63 0.84 0.46 to 0.97 
Lzonehigl -6.35 32.26 -69.59 56.89 -175.26 to 116.63 0.77 0.04 to 0.77 
Glvarianc -8.75 22.52 -52.88 35.39 -101.58 to 77.23 0.89 0.63 to 0.89 
Szvarianc -5.67 25.17 -55.00 43.67 -87.72 to 53.53 0.94 0.75 to 0.96 
Coarseness -8.65 18.38 -44.67 27.37 -51.87 to 32.88 0.90 0.87 to 0.91 
ContrastNGTDM 5.82 15.82 -25.18 36.83 -32.16 to 52.55 0.90 0.75 to 0.95 
Complexity 3.88 2.58 -1.18 8.95 -2.47 to 9.06 0.95 0.94 to 0.96 
Strength§ -12.55 28.55 / / / 0.78 0.77 to 0.78 
*  The limits of repeatability were not calculated for 128gl according to the results presented in Table 5.2 
†
  The limits of repeatability were not calculated for 64gl according to the results presented in Table 5.2   
‡  The limits of repeatability were not calculated for 8gl according to the results presented in Table 5.2   
§  The limits of repeatability were not calculated for this feature based on the results presented in Table 5.2 
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5.3.4.  Univariate analyses: association between textural feature 
measurements and response to treatment (RECIST) 
5.3.4.1.  Association between baseline and response to treatment 
The association between a subset of textural features, measured on scans before treatment, 
and clinical response measured at 60 days was studied. Textural features were selected if they 
had ICC values equal to or greater than 0.7 and the same variability range (95% confidence 
interval) as SUV measurements. Parametric tests were only performed on features for which 
the distribution was not statistically different from a normal distribution (Table 5.4). A non-
parametric test was used to study associations between response and SUVmax, InfCo2 (128gl) 
and Coarseness. Associations were studied for the following 10 textural features: CV, 
EntropyFOS, AUC-CSH, InfCo2, ContrastGLCM, Dissimilarity, Homogeneity, ContrastNGTDM, 
Coarseness and Complexity. 
 
Table 5.4 – Normality of feature distributions at baseline. P-value associated with Shapiro-Wilk 
Test. The statistical analysis was performed on a subset of features selected on repeatability study. 
 
  Features p-value 
SUVmean 0.17 
SUVmax 0.020 
CV 0.96 
AUC-CSH 0.14 
 Number of quantisation levels 
 8gl 16gl 32gl 64gl 128gl 
EntropyFOS 0.31 0.43 0.22 0.28 0.43 
InfCo2 0.81 0.38 0.34 0.21 <0.01 
ContrastGLCM 0.56 0.58 0.54 0.56 0.58 
Dissimilarity 0.76 0.87 0.88 0.88 0.89 
Homogeneity 0.56 0.40 0.39 0.30 0.48 
Coarseness 0.026 0.040 0.054 0.069 0.089 
ContrastNGTDM 0.38 0.72 0.64 0.82 0.57 
Complexity 0.91 0.67 0.72 0.72 0.70 
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Intensity histograms were visually positively skewed in both groups and the shift was on 
average greater in lesions of non-responders than in lesions of responders (Figures 5.5 A). 
AUC-CSH was significantly greater in lesions of responders versus non-responders (Figure 
5.5 B and Table 5.5). SUVmean was almost statistically significant (p = 0.067) in 
discriminating between the two responder groups (Figure 5.6 A and Table 5.5), whereas no 
difference in SUVmax was observed (Figure 5.6 B and Table 5.5).  CV was statistically greater 
(p < 0.05) in lesions of non-responders (Table 5.5 and Figure 5.7 A). EntropyFOS was 
statistically greater in lesions of responders across all intensity normalisation parameters 
(Figure 5.7 B). Complexity was significantly greater in lesions of non-responders versus 
responders for 8 and 16gl and almost statistically significant for 32 and 64gl (Table 5.5 and 
Figure 5.7 C).  
 
 
Figure 5.5 – Averaged activity distribution profiles in primary lesions of responder and non-
responder patients (A) and cumulative SUV-volume histograms of individual scans (B) for 
OSEM reconstructed images.  A: 
18
F-FLT uptake was normalised in each lesion using 16 
quantisation levels. Error bars represent standard deviations of the percentage of voxels for each grey 
level. An arbitrary intensity threshold, equal or just above the averaged third quartile for the responder 
group, was plotted to illustrate the relative difference of high 
18
F-FLT uptake values for the two 
groups.   
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Table 5.5 -  Associations between feature measurements and response to treatment at baseline: 
p-values (t-test) for a subset of features computed on baseline PET images and for VOI intensities 
normalised using different ranges of grey levels (gl; 8-128gl). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 – Dot plots representing SUVmean (A) and SUVmax (B) values computed on baseline 
PET images for responder (R) and non-responder (NR) patients   
Features  p-value 
SUVmean  0.067 
SUVmax  0.33
*
 
CV  0.006 
AUC-CSH  0.004 
  Number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.028 0.011 0.005 0.003 0.002 
InfCo2  0.031 0.12 0.27 0.51 0.54
*
 
ContrastGLCM  0.90 0.86 0.84 0.84 0.84 
Dissimilarity  0.84 0.75 0.73 0.74 0.73 
Homogeneity  0.81 0.70 0.66 0.66 0.55 
ContrastNGTDM  0.45 0.35 0.51 0.67 0.89 
Coarseness
*
  0.66 0.66 0.66 0.66 0.66 
Complexity   0.031 0.048 0.063 0.070 0.13 
*
Mann-Whitney U test 
A B 
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Figure 5.7 – Dot plots representing feature values computed on baseline PET images for 
responder (R) and non-responder (NR) patients: CV (A), EntropyFOS (16gl) (B), Complexity (16gl) 
(C) and Homogeneity (16gl) (D).  
 
5.3.4.2.  Association between feature change measured at 1 week and 
response to treatment 
Changes in feature values of the 10 textural descriptors and SUV measurements after 1 week 
of therapy were investigated in relation to measurements obtained at baseline. Differences 
between pairs of pre and post-treatment feature values were not statistically different from a 
normal distribution (Shapiro-Wilk Test). In addition, there was no statistical difference 
between pre- and post-treatment mean values for the 10 image descriptors.  
 
There was a true increase (outside the Limits of Repeatability) in dispersion from the mean 
(CV) (Figure 5.8A) along with a true increase in Homogeneity (Figure 5.8 B) for 4 out of 6 
responder patients (1, 6, 7 and 14) at 1 week after the start of therapy. No changes in these 
A B C 
D 
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features were observed outside the Limits of Repeatability for responder patients 4 and 13. 
There was a true decrease in CV for non-responder patient 5 and no changes for patients 3, 8, 
9 and 11. No true changes in Homogeneity were observed for any of the non-responders. 
There were no changes in EntropyFOS (Figure 5.8 C) for all patients except a true decrease in 
responder patient 1 and a true increase in non-responder patient 5. There was a true decrease 
in Dissimilarity and ContrastGLCM  (Figure 5.8 E and F) for responder patients 1, 6 and 14 and 
no changes outside the 95% CI for patients 7, 4 and 13. No changes in Dissimilarity or 
ContrastGLCM were observed for 4 out of 5 non-responders (3, 5, 8 and 9). A true increase in 
Dissimilarity and ContrastGLCM was observed for non-responder patient 11. Overall, these 
feature values changed much more in responders compared to non-responders following the 
onset of chemotherapy. A true decrease in AUC-CSH was measured in responder patients 1 
and 7 while a true decrease was measured in non-responder patients 5 and 9. No true changes 
from baseline were observed for SUVmean values (Figure 5.9 A) calculated on the whole 
tumour except for patient 1 (decrease). Changes in SUVmax (Figure 5.9 B) were observed for 
5 out of 11 patients but these were not associated with response to treatment. Similarly, true 
changes in Complexity (Figure 5.8D) and ContrastNGTDM were observed (in 6 and 3 out of 11 
patients respectively) across all intensity normalisation parameters, but were not associated 
with response measured at 60 days. True changes were also observed for InfCo2 for 
responder and non-responder patients, although results were not consistent across intensity 
normalisations. There was no visual association between true changes in Coarseness and 
response to treatment. In summary, a subset of features exhibited different trends in 
percentage change between responder and non-responder patients following the onset of 
chemotherapy.   
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Figure 5.8 -  Dot plots representing percentage change in textural feature values at 1 week after 
the start of therapy for responder (R) and non-responder (NR) patients: CV (A), Homogeneity 
(16gl) (B), EntropyFOS (C), Complexity (16gl) (D), Dissimilarity (E) and ContrastGLCM (F). Dashed 
lines represent the 95% Limits of Repeatability of normal fluctuations in feature values at baseline.  
A B 
C D 
E F 
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Figure 5.9 – Dot plots representing percentage change in SUV measurements at 1 week after the 
start of therapy for responder (R) and non-responder (NR) patients: SUVmean (A) and SUVmax (B) 
A B 
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5.3.5.  Bivariate feature associations at baseline  
Bivariate feature associations for the five intensity normalisations yielded 1 Spearman 
correlation for pairs of SUV measurements and FOS features computed on raw images and 5 
Spearman correlation coefficients for other pairs of features (Figure 5.10). CV was strongly 
negatively associated with SUVmean and very weakly to moderately associated with spatial 
textural features. GLCM features were generally very weakly to moderately associated with 
SUV measurements (except for Homogeneity which was strongly associated with SUVmax for 
16 to 128gl). Complexity was strongly negatively associated with SUVmean. Pairs of GLCM 
features were very strongly associated.  
 
Figure 5.10 – Strength and direction of bivariate Spearman correlations between statistically 
significant textural features for five intensity normalisations  
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5.3.6.  Associations between VOI size, textural features and injected dose 
The scans at baseline were split into two datasets in order to study associations between the 
size of primary breast lesions (measured as the size of the VOI delineated in the PET image) 
and textural features, such that only one scan per patient was used (Dataset 1: first scan or 
scan available at baseline and Dataset 2: second scan or scan available at baseline). VOI size 
was negatively associated with injected dose (Dataset 1: r = -0.664 and p-value = 0.026; 
Dataset 2: r = -0.615 and p = 0.044, Spearman correlation).  
 
5.3.6.1.  Associations between textural features and VOI size 
Associations between textural features and VOI size at baseline are presented in Table 5.6.  
ContrastGLCM and Dissimilarity were strongly negatively associated with VOI size (Spearman 
correlation). Similarly, Homogeneity was strongly positively correlated with VOI size. Other 
features such as EntropyFOS and Complexity were weakly to strongly correlated with VOI 
size (-0.73 ≤ r ≤ - 0.33, Spearman correlation) across grey level quantisation parameters. 
There were no associations between VOI size and CV and between VOI size and AUC-CSH. 
VOI size did not discriminate between responder groups (Dataset 1: p-value = 0.47 and 
Dataset 2: p-value = 0.28) nor did injected dose (Dataset 1: p-value = 0.82 and Dataset 2: p-
value = 0.60). There were no differences in the correlations between VOI size and textural 
features between responder groups (Table 5.7 and Figure 5.11). 
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Table 5.6 - Strength of the linear and non-linear associations between textural features and VOI 
size in primary tumours at baseline (N = 11) (Dataset 1: first scan or scan available at baseline; 
Dataset 2: second scan or scan available at baseline). Results are for textural features computed on 
images normalised using 16 grey levels (except for CV and AUC-CSH).  
 
  
Pearson Correlation 
Coefficient 
Spearman Correlation 
Coefficient 
Dataset 1 Dataset 2 Dataset 1 Dataset 2 
CV -0.067 -0.006 -0.018 0.036 
EntropyFOS -0.416 -0.349 -0.736
**
 -0.682
*
 
AUC-CSH -0.190 -0.159 -0.091 -0.200 
InfCo2 0.055 -0.418 -0.718* -0.636* 
ContrastGLCM -0.637
*
 -0.671
*
 -0.955
**
 -0.973
**
 
Dissimilarity -0.698
*
 -0.751
**
 -0.964
**
 -0.973
**
 
Homogeneity 0.771
**
 0.836
**
 0.909
**
 0.927
**
 
ContrastNGTDM -0.554 -0.569 -0.927
**
 -0.955
**
 
Coarseness -0.444 0.114 -1.000** -0.991** 
Complexity -0.532 -0.525 -0.582 -0.709
*
 
 
* 
p-value less than 0.05 
** 
p-value less than 0.01 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 – Scatterplot – Relationship between VOI size and feature values: EntropyFOS (A) 
and Complexity (B) (16gl) for responder (R) and non-responder (NR) patients (Dataset 1) 
 
 
  
A B 
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Table 5.7 – Strength of the linear and non-linear associations between textural features and VOI 
size in primary tumours at baseline in non-responder (NR) (N = 5) and responder (R) (N = 6) 
patients (Dataset 1: first scan or scan available at baseline; Dataset 2: second scan or scan available at 
baseline). Results are for textural features computed on images normalised using 16 grey levels 
(except for CV and AUC-CSH).  
 
  
 Pearson Correlation 
Coefficient 
Spearman Correlation 
Coefficient 
Response Dataset 1 Dataset 2 Dataset 1 Dataset 2 
CV R 0.288 0.343 -0.200 -0.029 
 NR -0.377 -0.400 -0.300 -0.300 
EntropyFOS R -0.846 -0.817
*
 -0.800 -0.600 
 NR -0.901
*
 -0.941
*
 -0.943
**
 -0.900
*
 
AUC-CSH R -0.717 -0.643 -0.200 -0.200 
 NR 0.277 0.138 0.600 0.200 
InfCo2 R -0.003 -0.059 -0.829* -0.657 
 NR -0.722 -0.742 -0.700 -0.600 
ContrastGLCM R -0.742 -0.818
*
 -0.886
*
 -0.943
**
 
 NR -0.942
*
 -0.930
*
 -1.000
**
 -1.000
**
 
Dissimilarity R -0.810 -0.889
*
 -0.886
*
 -0.943
**
 
 NR -0.969
**
 -0.965
**
 -1.000
**
 -1.000
**
 
Homogeneity R 0.895
*
 0.949
**
 0.771 0.829
*
 
 NR 0.964
**
 0.994
**
 1.000
**
 1.000
**
 
ContrastNGTDM R -0.711 -0.785 -0.943
*
 -0.886
*
 
 NR -0.905
*
 -0.969
**
 -0.900
*
 -1.000
**
 
Coarseness R -0.533 -0.519 -1.000* -0.943** 
 NR -0.865 -0.868 -1.000** -1.000* 
Complexity R -0.604 -0.611 -0.886
*
 -1.000
**
 
 NR -0.935
*
 -0.948
*
 -0.900
*
 -0.900
*
 
 
* 
p-value less than 0.05 
** 
p-value less than 0.01 
 
5.3.6.2.  Simulations to study the effect of VOI size 
In order to assess the influence of VOI size on feature values, a simulation consisting of a set 
of images of various sizes filled in with intensities drawn from a Gaussian distribution was 
generated using MATLAB. The widths of the 3D squared images varied between 5 and 33 
voxels (from 125 to 35,937 voxels) which covered the range of VOI sizes in the 
18
F-FLT 
dataset. The number of grey levels (quantisation levels) was set to 16 (from 0 to 15). Each 
image was filled in with intensities drawn from a normal distribution (mean intensity µ = 7.5 
and standard deviation σ = 2.5). By definition 99.7% of the values lay between 0         
and 15        . In addition, the process was repeated 100 times for each box size.  
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For all features which were computed, larger variations in feature values were observed for 
smaller VOIs (Figure 5.12). The theoretical Coefficient of Variation (CV) was σtheo/µtheo = 
2.5/7.5 = 0.3333. This value was recovered within ± 16% across all simulations (as measured 
using the relative error: |CVmeasured – CVtheo|/ CVtheo) (Figure 5.12 A), and the error was less 
for bigger VOI sizes. The expected value for Kurtosis was 3 (Figure 5.12 C). This value was 
recovered within ±52% across all simulations, with large errors occurring for small VOI sizes 
and smaller errors for larger VOI sizes. The theoretical EntropyFOS could be calculated as 
follows: 
EntropyFOS THEO = (1/2) x [log2 (2 x PI x e x σ
2
)] = 3.37 with e ≈ 2.71828183 (Euler’s 
number). 
The relative error in EntropyFOS across all simulations was ± 20% or less (Figure 5.12 D). 
 
5.3.7.  Influence of analysis parameters 
5.3.7.1.  Time window 
The influence of the time window on textural feature measurements was studied by 
comparing the measurements obtained for images averaged between 32 and 65 minutes with 
textural measurements obtained for images averaged between 65 and 95 minutes. Parametric 
tests were used except for InfCo2 (128gl) and Coarseness for which feature values were not 
normally distributed on both time windows (p > 0.05, Shapiro-Wilk Test). Non-parametric 
tests were used in the case of these two features.  
 
There were high paired sample correlation coefficients between both datasets (32-65min and 
65-95min) (Table 5.8). There was no statistically significant difference between the two 
datasets (paired sample t-test) except for Complexity and Coarseness (32 and 64gl) (Table 
5.9).  Although the correlation between Complexity for the two time windows was high, the 
feature values were higher on average for the 32-65min time window (Figure 5.13). The 
assumption of normality of feature distributions at baseline was not rejected except for 
Coarseness and InfCo2 (128gl). Associations between textural features measured at baseline 
and response to treatment were similar for 65-95min (Table 5.10) to the results for 32-65min 
(Table 5.5). 
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Figure 5.12 – Simulations - relationship between VOI size (in voxels) and 
feature values. CV (A), Skewness (B), Kurtosis (C), EntropyFOS (D), 
Homogeneity (E), Dissimilarity (F) and Complexity (G) 
G 
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Table 5.8 – Association between textural feature values across time windows. Paired samples 
correlation (Pearson Correlation Coefficient) between textural features values obtained using images 
averaged between 32-65min and 65-95min. All correlation coefficients were associated with a p-value 
< 0.05. 
  
 
 
 
 
 
 
 
 
 
 
 
Table 5.9 – Influence of time window on textural feature values. Paired samples t-test between 
textural features values obtained using images averaged between 32-65min and 65-95min. 
 
 
 
 
  
Features  Paired-sample correlation coefficient 
CV  0.98 
AUC-CSH  0.94 
  Number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.67 0.69 0.73 0.76 0.77 
InfCo2  0.95 0.93 0.96 0.98 0.97
*
 
ContrastGLCM  0.74 0.72 0.73 0.72 0.73 
Dissimilarity  0.76 0.74 0.75 0.75 0.75 
Homogeneity  0.80 0.77 0.80 0.80 0.80 
ContrastNGTDM  0.70 0.87 0.89 0.89 0.91 
Coarseness
*
  > 0.99 > 0.99 > 0.99 > 0.99 > 0.99 
Complexity   0.94 0.92 0.93 0.93 0.93 
*
Spearman Correlation Coefficient 
Features  p-value 
CV  0.10 
AUC-CSH  0.27 
  Number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.33 0.39 0.43 0.38 0.38 
InfCo2  0.26 0.38 0.40 0.68 > 0.99
*
 
ContrastGLCM  0.091 0.092 0.092 0.091 0.092 
Dissimilarity  0.11 0.13 0.12 0.12 0.12 
Homogeneity  0.14 0.23 0.27 0.28 0.28 
ContrastNGTDM  0.21 0.32 0.33 0.33 0.13 
Coarseness
*
  0.11 0.13 0.008 0.013 0.16 
Complexity   0.023 0.057 0.023 0.030 0.031 
*
Wilcoxon Rank Sum Test 
 
5.3 – Results   127 
 
 
 
Figure 5.13 – Plot of feature values for PET image averaged between 32-65min versus feature 
values for PET image averaged between 65-95min:  Complexity (8gl) (A) and Coarseness (32gl) 
(B). The plain line represents the line of unity. 
 
 
 
Table 5.10 - Associations between feature measurements (65-95min) and response to treatment 
at baseline p-values (t-test) for a subset of features computed on baseline PET images (averaged 
between 65-95 minutes) and for VOI intensities normalised using different ranges of grey levels (8-
128gl). 
 
 
 
 
  
Features  p-value 
CV  0.001 
AUC-CSH  0.003 
  number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.013 0.008 0.006 0.007 0.012 
InfCo2  0.022 0.017 0.10 0.36 0.33
*
 
ContrastGLCM  0.50 0.47 0.47 0.47 0.47 
Dissimilarity  0.54 0.46 0.46 0.45 0.45 
Homogeneity  0.59 0.46 0.44 0.38 0.34 
ContrastNGTDM  0.10 0.35 0.72 0.93 0.96 
Coarseness
*
  0.66 0.66 0.66 0.66 0.66 
Complexity  0.010 0.027 0.031 0.041 0.093 
*
Mann-Whitney U test 
A 
B A 
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5.3.7.2.  Influence of the image reconstruction method (FBP 
reconstruction) 
PET images were also reconstructed using a FBP approach. The results obtained in section 
5.3.4 were therefore compared to the same results computed on FBP reconstructed images. 
Repeatability measurements were carried out for the same patients as for OSEM images.  
The intensity distribution profiles computed on FBP images were visually different (Figures 
5.14 and 5.5). As obtained previously on OSEM reconstructed images, the intensity 
distribution profiles for the two groups indicated that on average there was a greater number 
of voxels with low 
18
F-FLT uptake in lesions of non-responders than in responders prior to 
treatment.  
Normality of feature values, repeatability and feature associations with response were tested 
as previously for OSEM images (Tables 5.11 to 5.14). The ability of the textural features to 
discriminate between responder and non-responder patients was less than on OSEM 
reconstructed images as confirmed by the statistical tests for the features computed on both 
FBP (Table 5.14) and OSEM images (Table 5.5). Kurtosis was selected based on the 
repeatability study using FBP images (Table 5.12) and it discriminated between response 
groups (p = 0.004) (Table 5.14). However, this feature did not produce reliable estimates on 
OSEM reconstructed images which suggests that it is more sensitive to stochastic noise than 
other textural features that characterised the radiotracer uptake distributions using iteratively 
reconstructed images. Correlation was highly repeatable on FBP images (Table 5.12) but did 
not discriminate between response groups (Table 5.14). This might be due to greater 
contamination of pixels’ intensities between neighbours on FBP reconstructed images. 
Similarly, ContrastNGTDM was not selected based on the repeatability study (Table 5.12) on 
FBP reconstructed images. AUC-CSH also poorly discriminated between response groups 
(ICC = 0.41).   
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Table 5.11 – Normality of relative differences in textural feature estimates at baseline (FBP 
images). P-value associated with Shapiro-Wilk Test. Features highlighted in grey show the main 
differences with OSEM images.  
Features p-value 
SUVmean 0.89 
SUVmax 0.49 
CV 0.045 
AUC-CSH 0.29 
Skewness 0.17 
Kurtosis 0.34 
 Number of quantisation levels 
 8gl 16gl 32gl 64gl 128gl 
EntropyFOS 0.32 0.29 0.21 0.10 0.34 
Correlation 0.62 0.59 0.65 0.66 0.66 
InfCo2 0.88 0.97 0.24 0.26 0.96 
Angsmo 0.64 0.52 0.35 0.43 0.24 
EntropyGLCM 0.39 0.035 0.071 0.12 0.065 
ContrastGLCM 0.27 0.164 0.23 0.30 0.31 
Dissimilarity 0.16 0.029 0.031 0.059 0.055 
Homogeneity 0.040 0.013 0.14 0.69 0.86 
SmallZone 0.53 0.081 0.85 0.13 0.034 
LargeZone 0.40 0.23 0.99 0.97 0.45 
GlNonUnif 0.72 0.031 1.00 0.65 0.44 
SzNonUnif 0.48 0.85 0.82 0.39 0.96 
ZonePCent 0.72 0.67 0.90 0.022 0.039 
ZoneLogl 0.52 0.57 0.82 0.52 0.74 
Zonehigl 0.53 0.064 0.99 0.90 0.82 
Szonelogl 0.12 0.18 0.18 0.90 0.60 
Szonehigl 0.030 0.23 0.69 0.59 0.99 
Lzonelogl 0.90 0.51 0.12 0.28 0.60 
Lzonehigl 0.79 0.30 0.62 0.18 0.077 
Glvarianc 0.98 0.092 0.50 0.50 0.20 
Szvarianc 0.96 0.39 0.75 0.33 0.87 
Coarse 0.020 0.43 0.66 0.90 0.98 
ContrastNGTDM 0.37 0.64 0.61 0.78 0.44 
Complexity 0.30 0.25 0.18 0.22 0.19 
Strength 0.39 0.33 0.35 0.36 0.34 
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Table 5.12 - Repeatability results for SUVs and textural features (FBP images). Mean and 
standard deviation (std) % variations, Lower and Upper Limits of Repeatability (95% Confidence 
Interval) and ICC values were given for 64gl. In addition the wider range of Limits of Repeatability 
and the ICC range were given across all intensity normalisation parameters. Features selected for 
studying associations with response to treatment are highlighted in light grey (using both OSEM and 
FBP images), dark grey (for FBP reconstruction only) or shaded (for OSEM only). 
 Features Mean Std 
Lower 
Limit of 
repeatability 
Upper 
Limit of 
repeatability 
Wider 95% CI ICC ICC range 
SUVmean -1.73 13.23 -27.67 24.21 -27.67 to 24.21 0.93 0.93 
SUVmax 4.29 22.28 -39.37 47.95 -39.37 to 47.95 0.93 0.86 
CV -3.78 12.42 -28.12 20.56 -28.12 to 20.56  0.77 0.77 
Skewness* 21.19 234.44 / / / 0.63 0.63 
Kurtosis 1.65 8.07 -14.16 17.46 / 0.8 0.8 
EntropyFOS 0.82 2.28 -3.65 5.29 -11.05 to 12.95 0.81 0.75 to 0.84 
AUC-CSH -9.29 10.14 -29.17 10.58 -29.17 to 10.58 0.41 0.41 
Correlation -3.18 10.36 -23.49 17.13 -25.68 to 18.63 0.92 0.91 to 0.92 
InfCo2 -1.54 1.17 -3.84 0.76 -21.68 to 13.60 0.96 0.87 to 0.96 
Angsmo -13.39 17.89 -48.46 21.68 -53.07 to 29.33 0.42 0.42 to 0.87 
EntropyGLCM 
†
 1.96 3.09 -4.10 8.02 -5.82 to 10.51 0.57 0.57 to 0.92 
ContrastGLCM   11.39 15.21 -18.43 41.21 -18.43 to 41.21 0.94 0.94 to 0.95 
Dissimilarity ‡ 6.48 7.07 / / / 0.95 0.95 to 0.95 
Homogeneity
†
 -6.79 5.99 -28.52 4.95 -21.09 to 6.17 0.95 0.95 to 0.96 
SmallZone
†
 23.71 86.22 -145.28 192.70 -132.59 to 312.42 0.85 0.13 to 0.87 
LargeZone -12.14 49.28 -108.72 84.44 -108.72 to 84.44 0.55 -0.28 to 0.91 
Glnonunif 
†
 -9.92 22.29 -53.60 33.76 -46.09 to 95.38 0.82 0.18 to 0.84 
Sznonunif  4.62 23.71 -41.86 51.09 -44.26 to 128.07 0.83 -0.19 to 0.90 
Zonepcent
†
 18.33 51.01 / / -62.66 to 111.45 0.86 0.53 to 0.98 
Zonelogl 7.56 51.44 -93.26 108.38 -104.66 to 138.06 0.42 0.083 to 0.70 
Zonehigl -9.24 32.53 -73.00 54.51 -89.43 to 62.41 -0.125 -0.293 to 0.09 
Szonelogl 85.37 104.25 -118.96 289.70 -187.25 to 364.07 0.068 0.068 to 0.53 
Szonehigl
†
 12.99 101.93 -186.80 212.77 -194.67 to 338.66 0.48 0.033 to 0.90 
Lzonelogl -9.56 62.51 -132.09 112.97 -132.09 to 112.97 0.43 0.32 to 0.95 
Lzonehigl -9.25 60.60 -128.02 109.52 -128.02 to 109.52 0.45 -0.98 to 0.79 
Glvarianc -11.38 21.43 -53.38 30.62 -61.74 to 55.01 0.83 0.74 to 0.98 
Szvarianc -10.96 16.06 -42.44 20.52 -36.89 to 88.08 0.83 0.75 to 0.89 
Coarseness
†
 -8.85 7.52 -23.59 5.89 -30.03 to 11.54 0.94 0.90 to 0.98 
ContrastNGTDM 6.52 32.68 -57.54 70.58 -78.29 to 92.52 0.78 0.66 to 0.88 
Complexity 2.97 20.66 -37.51 43.46 -39.68 to 45.42 0.85 0.81 to 0.88 
Strength -17.70 9.74 -36.79 1.40 -35.66 to 9.77 0.99 0.98 to 0.99 
*  Some of the feature values were negative so could not calculate the limits of repeatability 
†
  The limits of repeatability were not calculated for the grey level intensity quantisation for which the relative differences 
were  
   different from a normal distribution (p < 0.05, Shapiro-Wilk) according to the results presented in Table 5.11   
‡  The limits of repeatability were not calculated for this feature based on the results presented in Table 5.11 
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Figure 5.14 - Averaged activity distribution profiles in primary lesions of responder and non-
responder patients (FBP images). 
18
F-FLT uptake was normalised in each lesion using 16 
quantisation levels. Error bars represent standard deviations of the percentage of voxels for each grey 
level. An arbitrary intensity threshold, equal or just above the averaged third quartile for the responder 
group, was plotted to illustrate the relative difference of high 
18
F-FLT uptake values for the two 
groups.  
 
 
Table 5.13 - Normality of feature distributions at baseline (FBP images). P-value associated with 
Shapiro-Wilk Test. The statistical analysis was performed for the subset of features highlighted in 
table 5.12 
  
Features  p-value 
SUVmean  0.12 
SUVmax  0.066 
CV  0.10 
Kurtosis  0.038 
AUC-CSH  0.30 
  Number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.37 0.46 0.56 0.58 0.27 
InfCo2  0.80 0.36 0.89 0.063 0.027 
Correlation  0.81 0.76 0.75 0.74 0.74 
ContrastGLCM  0.44 0.53 0.53 0.53 0.54 
Dissimilarity  0.73 0.69 0.71 0.69 0.70 
Homogeneity  0.64 0.31 0.14 0.076 0.048 
Coarseness  0.053 0.12 0.14 0.19 0.35 
ContrastNGTDM  0.86 0.53 0.24 0.16 0.85 
Complexity   0.42 0.41 0.52 0.51 0.50 
Strength  0.16 0.24 0.25 0.26 0.26 
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normalised intensity 
responders
non-responders
averaged third quartile for 
responder group  
○ 21% ± 9% of voxels in R   
○ 10% ± 7% of voxels in NR 
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Table 5.14 - Associations between feature measurements and response to treatment at baseline 
(FBP images). P-values (t-test: responders versus non-responders) were given for the subset of 
features highlighted in table 5.12 and computed on baseline FBP reconstructed PET images and for 
VOI intensities normalised using different ranges of grey levels (8-128gl). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Features  p-value 
SUVmean  0.095 
SUVmax  0.87 
CV  0.21 
Kurtosis*  0.004 
AUC-CSH  0.14 
  Number of quantisation levels 
 
 
8gl 16gl 32gl 64gl 128gl 
EntropyFOS  0.075 .079 0.081 0.070 0.13 
InfCo2  0.17 0.07 0.014 0.13 0.54* 
Correlation  0.27 0.28 0.28 0.29 0.28 
ContrastGLCM  0.46 0.48 0.45 0.47 0.47 
Dissimilarity  0.45 0.49 0.46 0.48 0.47 
Homogeneity  0.45 0.52 0.50 0.53 0.50* 
Coarseness  0.53 0.44 0.43 0.40 0.36 
ContrastNGTDM  0.76 0.98 0.76 0.51 0.24 
Complexity   0.34 0.32 0.32 0.33 0.21 
Strength  0.42 0.36 0.34 0.33 0.33 
*
Mann-Whitney U test 
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5.3.7.3.  Distance parameter in GLCM calculation 
In the results presented in previous parts of this work, the distance d between paired voxels in 
the computation of the GLCMs was set to d = 1. The influence of this parameter setting on 
the GLCM computation (OSEM reconstructed images) and on the textural feature 
measurements was investigated, in terms of repeatability, values as a function of d, and the 
ability of the features to discriminate between response groups. The GLCM features listed in 
Table 5.1 were computed for a range of parameter settings d (from 1 to 5). 
 
5.3.7.3.1. Relationship between number of voxels and parameter d 
As expected the number of voxels included in the GLCM computations decreased as the 
distance d between paired voxels increases. Examples are given in Figures 5.15, 5.16 and 
5.17. This decrease was faster as a function of d in VOIs with a smaller number of voxels. 
For VOIs that comprised less than a thousand voxels (Figure 5.17), the actual number of 
voxels used in the GLCM computations was less than a hundred for d > 2 for patients 1, 5 
and 7 (VOIs with less than 600 voxels) and for d > 4 for patient 9 (886 voxels). As the 
proportion of voxels decreased dramatically for increasing distance d in small VOIs (patients 
1, 5 and 7), An arbitrary cut-off value of 100 voxels was used to look at repeatability of the 
GLCM features as a function of d. Therefore, in subsequent analyses, patient 7 was excluded 
from the repeatability analyses for d > 2. Patients 1, 5 and 7 (d > 2) and patient 9 (d > 4) were 
also excluded from statistical analysis of associations between GLCM features and response 
to treatment at baseline. Finally, patient 13 was excluded from the Percentage Change study 
for d > 1 as the size of the VOI at 1 week was too small (160 voxels). 
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Figure 5.15 – Relationship between parameter d and the % of voxels belonging to the VOI that 
are taken into account in the GLCMs calculation. Results are given for a subset of patients as the 
mean % voxels (o) across the 13 directions the GLCM is calculated for. Vertical bars represent the 
range between the minimum % voxels and maximum % voxels across the 13 directions.  
 
 
Figure 5.16 – Relationship between parameter d and the number of voxels belonging to the VOI 
that are taken into account in the GLCMs calculation. Results are given for a subset of patients as 
the Mean number of voxels (o) across the 13 directions the GLCM is calculated for. Vertical bars 
represent the range between the minimum and maximum number of voxels across the 13 directions.  
d 
d 
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Figure 5.17 – Relationship between parameter d and the number of voxels belonging to the VOI 
that are taken into account in the GLCMs calculation (for VOIs with less than 1,000 voxels). 
Results are given as the mean number of voxels (o) across the 13 directions the GLCM is calculated 
for. Vertical bars represent the range between the minimum and the maximum number of voxels 
across the 13 directions.  
 
5.3.7.3.2. Repeatability as a function of the distance between paired voxels 
The results of the repeatability study: normality of relative differences, % difference at 
baseline and ICC results are presented in Tables 5.15 and 5.16 for a range of distance d 
between paired voxels (from 1 to 5). Limits of repeatability were consistent with results 
obtained for d = 1.  The limits of repeatability were stable for the range of distance d, 
especially for d > 1 for EntropyGLCM, Contrast, Dissimilarity Homogeneity and InfCo2. 
Narrower limits of repeatability were observed for Angsmo for d > 1 compared with results 
previously obtained for d = 1. Wider limits of repeatability were observed for Correlation. 
ICC values were generally high to very high (0.7 ≤ ICC ≤ 1) except for Angsmo and 
EntropyGLCM (0.53 ≤ ICC ≤ 0.95, for d = 1 to 2). 
  
d 
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Table 5.15 - Normality of relative differences in GLCM textural feature estimates at baseline for 
different values of d. P-value associated with Shapiro-Wilk Test 
  
Features Distance d 
p-value 
Number of quantisation levels 
  8gl 16gl 32gl 64gl 128gl 
Correlation 1 0.18 0.38 0.37 0.40 0.39 
 2 0.67 0.75 0.66 0.63 0.47 
  3
*
 0.69 0.29 0.53 0.44 0.56 
   4
*
 0.33 0.23 0.60 0.34 0.38 
  5
*
 0.058 0.20 0.097 0.22 0.17 
InfCo2 1 0.73 0.24 0.96 0.83 0.64 
 2 0.70 0.61 0.48 0.79 0.67 
  3
*
 0.008 0.86 0.16 0.96 0.85 
  4
*
 0.35 0.010 0.016 0.77 0.67 
  5
*
 0.29 0.058 0.083 0.50 0.57 
Angsmo 1 0.24 0.69 0.75 0.58 0.18 
 2 0.19 0.54 0.59 0.19 0.056 
  3
*
 0.38 0.17 0.24 0.18 0.83 
  4
*
 0.54 0.31 0.50 0.30 0.74 
  5
*
 0.33 0.27 0.42 0.50 0.47 
EntropyGLCM 1 0.26 0.59 0.43 0.26 0.044 
                                                                                                                                                  2 0.19 0.39 0.27 0.084 0.010 
  3
*
 0.80 0.61 0.64 0.64 0.32 
  4
*
 0.73 0.68 0.71 0.76 0.21 
  5
*
 0.85 0.72 0.57 0.86 0.42 
ContrastGLCM 1 0.30 0.32 0.37 0.39 0.47 
 2 0.29 0.41 0.37 0.40 0.47 
  3
*
 0.49 0.47 0.51 0.55 0.60 
  4
*
 0.16 0.12 0.16 0.20 0.23 
  5
*
 0.96 0.89 0.92 0.94 0.93 
Dissimilarity 1 0.45 0.75 0.78 0.76 0.84 
 2 0.27 0.50 0.44 0.45 0.48 
  3
*
 0.83 0.77 0.77 0.78 0.79 
  4
*
 0.57 0.48 0.60 0.62 0.66 
  5
*
 0.63 0.81 0.72 0.71 0.66 
Homogeneity 1 0.19 0.75 0.94 0.85 0.87 
 2 0.14 0.42 0.45 0.34 0.61 
  3
*
 0.80 0.64 0.33 0.30 0.23 
  4
*
 0.75 0.71 0.87 0.75 > 0.99 
  5
*
 0.14 0.40 0.026 0.004 0.034 
* patient 7 was excluded from the calculation for d > 2 
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Table 5.16 - Repeatability results for GLCM textural features for different values of d. Mean and 
standard deviation (std) % variations, Lower and Upper Limits of Repeatability (95% Confidence 
Interval) and ICC values were given for 64gl. In addition the wider range of Limits of Repeatability 
and the ICC range were given across all intensity normalisation parameters.  
 Features 
Distance 
d 
Mean Std 
Lower 
Limit of 
Repeatability 
Upper 
Limit of 
Repeatability 
Wider 95% CI ICC ICC range 
Correlation 1 -8.10 55.54 -116.96 100.75 -127.23 to 123.69 0.88 0.86 to 0.88 
 2 -25.87 18.50 -62.12 10.38 -66.98 to 11.82 0.98 0.98 to 0.98 
 3
* -30.00 22.38 -73.87 13.87 -84.67 to 17.24 0.98 0.98 to 0.98 
 4
* -6.64 180.28 -359.99 346.71 -354.52 to 354.32 0.96 0.95 to 0.96 
 5* 14.50 90.82 -163.50 192.50 -212.48 to 238.08 0.98 0.98 to 0.98 
InfCo2 1 -0.18 2.90 -5.85 5.50 -34.06 to 7.24 0.99 0.94 to 1 
 2 -0.09 3.57 -7.08 6.90 -22.57 to 0.43 1 0.96 to 1 
 3
* 0.21 3.74 -7.12 7.53 -17.10 to 7.92 0.99 0.95 to 1 
 4
* -0.32 3.85 -7.86 7.23 -15.92 to 11.26 1 0.96 to 1 
 5* -0.66 3.89 -8.27 6.96 -23.67 to 9.42 1 0.88 to 1 
Angsmo 1 -12.54 22.43 -56.51 31.43 -59.77 to 37.43 0.55 0.55 to 0.80 
 2 0.47 9.43 -18.00 18.95 -24.24 to 26.61 0.64 0.53 to 0.81 
 3
* 1.21 10.12 -18.63 21.05 -25.41 to 29.13 0.80 0.80 to 0.97 
 4
* 1.65 9.38 -16.74 20.03 -23.95 to 28.17 0.80 0.80 to 0.98 
 5* 1.25 9.19 -16.75 19.25 -25.74 to 30.53 0.84 0.84 to 0.98 
EntropyGLCM 1
†
 2.03 3.43 -4.69 8.75 -8.16 to 15.81 0.74 0.62 to 0.93 
 2
†
 -0.05 1.28 -2.56 2.46 -5.44 to 5.41 0.83 0.59 to 0.95 
 3
* -0.18 1.30 -2.74 2.38 -5.56 to 5.46 0.79 0.79 to 0.99 
 4
* -0.23 1.21 -2.61 2.15 -5.77 to 5.37 0.85 0.85 to 0.99 
 5* -0.26 1.26 -2.73 2.21 -6.03 to 5.48 0.93 0.86 to 1 
ContrastGLCM   1 14.00 9.05 -3.74 31.75 -7.15 to 29.67 0.91 0.90 to 0.91 
 2 4.27 9.10 -13.57 22.10 -13.84 to 22.22 0.81 0.79 to 0.82 
 3
* 3.61 9.75 -15.50 22.72 -15.67 to 22.84 0.96 0.96 to 0.96 
 4
* 3.72 8.84 -13.61 21.04 -13.61 to 21.04 0.97 0.97 to 0.97 
 5* 0.65 9.05 -17.09 18.39 -17.28 to 18.67 0.96 0.96 to 0.96 
Dissimilarity 1 7.86 5.76 -3.42 19.15 -5.25 to 19.35 0.90 0.90 to 0.91 
 2 2.36 5.23 -7.89 12.61 -8.13 to 13.02 0.82 0.80 to 0.82 
 3
* 1.90 5.76 -9.40 13.20 -9.55 to 13.26 0.96 0.95 to 0.96 
 4
* 1.93 5.00 -7.87 11.74 -7.80 to 11.93 0.97 0.97 to 0.97 
 5
* 0.26 5.69 -10.89 11.42 -11.36 to 11.86 0.96 0.95 to 0.96 
Homogeneity 1 -7.52 7.90 -23.01 7.97 -27.18 to 11.22 0.91 0.89 to 0.92 
 2 -1.76 5.84 -13.21 9.69 -15.32 to 12.89 0.90 0.82 to 0.90 
 3
* -1.79 8.92 -19.27 15.68 -20.37 to 17.75 0.94 0.94 to 0.96 
 4
* -2.39 5.73 -13.61 8.84 -13.88 to 9.05 0.97 0.97 to 0.97 
 5*‡ 1.00 7.06 - - - 0.96 0.95 to 0.97 
* patient 7 was excluded from the calculation for d > 2 
†
 Excludes 128gl 
‡ The limits of repeatability were not calculated for this feature based on the results presented in Table 5.15 
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5.3.7.3.3. Feature values as a function of the distance between paired voxels 
Examples of feature values as a function of the distance between paired voxels are given in 
Figure 5.18. Relatively important variations in InfCo2 (non-linear correlation between paired 
voxels) were observed as a function of distance d between paired voxels. In most volumes 
(VOIs > 600 voxels), the correlation decreased or remained enhanced for small values of d 
and increased again for higher values of d. Similar trends were observed for Angsmo – an 
index of global texture uniformity - although the variations were less. In most volumes, 
EntropyGLCM, which is a measure of uncertainty in the intensities of paired voxels, increased 
for small values of d and decreased again for higher values of d. EntropyGLCM values were 
generally stable across the range of d values. The local Homogeneity between paired voxels 
generally decreased with increasing d values, reaching a plateau in some cases. 
 
In the case of patient 4 who had a large tumour volume, InfCo2 decreased from around 0.55 
to 0.35 for the range of parameter d. Similarly, the uniformity in the texture of the tumour 
volume of this patient was characterised by a steady decrease in uniformity (Angsmo), as 
well as a steady decrease in the local Homogeneity between paired voxels with increasing d. 
EntropyGLCM slightly increased for the range of d values for patient 4.   
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Figure 5.18 – GLCM feature values for a range of distance d between paired voxels (32-65min, 
16gl): InfCo2 (A), Angsmo (B), EntropyGLCM (C) and Homogeneity (D). 
  
A B 
C D 
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5.3.7.3.4. Associations between GLCM feature values and response to treatment 
Associations between GLCM feature values at baseline and percentage change at 1 week (for 
InfCo2, ContrastGLCM, Dissimilarity and Homogeneity) with response to treatment were 
investigated for a range of d values. Patients 1, 5 and 7 were excluded from the statistical 
analyses for d > 2 as too few voxels were used for the GLCMs computation. Therefore the 
associations at baseline were explored for 4 responders versus 4 non-responders for d > 2. 
Association at baseline with response to treatment was not computed for d = 5 as this would 
have meant excluding patient 9 from the analysis. There were no statistically significant 
associations between GLCM features and response to treatment at baseline (Table 5.17) 
across the range of d values, except for InfCo2 for one parameter (8gl).   
 
 
Table 5.17 – Associations between GLCM feature measurements and response to treatment at 
baseline for a range of distance d between paired voxels. p-values (t-test) for a subset of features 
computed on baseline PET images and for VOI intensities normalised using different ranges of grey 
levels (8-128gl). 
 
 
  Features Distance d 
 p-value 
 Number of quantisation levels 
   8gl 16gl 32gl 64gl 128gl 
InfCo2 1  0.031 0.12 0.28 0.51 0.54
*
 
 2  0.089 0.23 0.38 0.63 0.54
*
 
  3
†
  0.21 0.48 0.67 0.97 0.89
*
 
  4
†
  0.43 0.65 0.83 0.91 0.89
*
 
ContrastGLCM 
1  0.90 0.86 0.84 0.84 0.84 
 2  0.61 0.57 0.56 0.56 0.56 
  3
†
  0.90 0.84 0.81 0.82 0.82 
  4
†
  0.70 0.66 0.64 0.64 0.64 
Dissimilarity 1  0.84 0.75 0.73 0.74 0.73 
 2  0.53 0.48 0.47 0.47 0.46 
  3
†
  0.81 0.73 0.72 0.72 0.72 
  4
†
  0.64 0.59 0.58 0.57 0.57 
Homogeneity 1  0.81 0.70 0.66 0.66 0.55 
 2  0.48 0.41 0.42 0.47 0.45 
  3
†
  0.76 0.66 0.67 0.68 0.72 
  4
†
  0.60 0.55 0.55 0.57 0.56 
*
Mann-Whitney U test 
†
Without patients 1,5 and 7 (4 responders vs. 4 non-responders)  
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Percentage change in Homogeneity gave similar results for d = 2 as for d = 1 (Figure 5.19). 
Patient 13 was excluded for d > 1 as the size of the VOI at 1 week was too small (160 
voxels). Patients 1, 5 and 7 were excluded from the analyses for d > 2 and patient 9 for d > 4. 
A true change from the normal range of fluctuations was observed for d = 2 for patients 1, 7 
and 14. Patient 6, for which the percentage change was borderline for d = 1, fell within the 
limits of repeatability for d ≥ 2. A true change in Homogeneity was observed at 1 week for 
patient 14 for the range of distance d between paired voxels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 – Dot plots representing percentage change in Homogeneity feature values (16gl) at 
1 week after the start of therapy for responder (R) and non-responder (NR) patients for a range 
of distance d: d = 1 (A), d = 2 (B),  d = 3(C) d = 4 (D) and d = 5 (E). Dashed lines represent the 95% 
Limits of Repeatability of normal fluctuations in feature values at baseline. 
  
A B C 
D E 
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5.3.8.  Kinetic measurements 
K1mean derived from K1 parametric maps yielded no significant differences between the mean 
delivery for the two response groups of patients (t-test, p-value > 0.5). The retention 
parameter Ki approached statistical significance in differentiating between the two groups (t-
test, p-value = 0.054) (Figure 5.20). Due to a high noise level in the dynamic OSEM 
reconstructed PET images, collaborators (Dr Mattia Veronese and Dr Gaia Rizzo, University 
of Padova, Italy) were not able to compute kinetic parametric maps on the OSEM 
reconstructed dataset. Therefore, in the context of this study, it was not possible to further 
explore relationships between textural analysis computed on raw images and kinetic 
parametric maps.  
 
 
 
 
 
Figure 5.20 – Dot plots of kinetic parameters – K1mean (min
-1
) (A) and Ki (ml plasma/ml tissue/min) 
(B) for responder (R) and non-responder (NR) patients. 
  
A B 
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5.4.  Summary 
The present study aimed to investigate variations in textural feature values in 
18
F-FLT PET 
scans at baseline across tissues, assess repeatability and examine the discriminatory power of 
these image descriptors in 11 primary breast lesions (6 responders and 5 non–responders). To 
my knowledge, this is the first time that texture analysis has been applied to quantify intra-
tumour heterogeneity of a cell proliferation PET radiotracer. 
 
The range of textural feature values depended on tissue type and provided additional 
information to mean uptake concentration (SUVmean). ContrastGLCM was greater on average in 
liver and vertebra compared to normal breast and tumour, which is consistent with a higher 
18
F-FLT uptake. Eight textural features (CV, EntropyFOS, AUC-CSH, EntropyGLCM, 
ContrastGLCM, Dissimilarity, Homogeneity and Complexity) had variability below ± 30% 
indicating that a subset of textural features can provide relatively reliable numerical estimates 
of intra-tumour heterogeneity at baseline and with a limited effect of stochastic noise. Seven 
of these features were characterised by an ICC equal to or greater than 0.7, indicating that the 
within-patient variability in texture values was reasonably small compared to the between-
patient variability. This suggests that the subset of features can potentially be used to study 
associations with outcome.  
 
A subset of features selected on test-retest discriminated between responders versus non-
responders at baseline. Better visual and statistical separation of the groups was achieved 
using OSEM versus FBP reconstructed images. Visual inspection of the intensity distribution 
profiles for the two groups indicated that on average there was a greater number of voxels 
with low 
18
F-FLT uptake in lesions of non-responders than in lesions of responders prior to 
treatment. However, Skewness was not a robust image descriptor according to test-retest data 
and to previously published work (Tixier et al, 2012). CV captured this greater shift in the 
intensity distribution of non-responder patients. In addition, EntropyFOS indicated a greater 
proportion of voxels with similar intensities in lesions of non-responders at baseline. 
SUVmean at baseline, as well as the Ki-67 were greater in lesions of responders versus non-
responders (although statistical significance was not reached, p-value = 0.067 and 0.07, 
respectively). There was no statistically significant difference between the average rate 
constants for 
18
F-FLT tumour delivery (K1mean) in both response groups. Therefore, a 
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possible explanation for the observed differences in radiotracer distribution between the two 
groups at baseline is the presence of a lower proportion of highly proliferative tumour cells 
within lesions of non-responders compared with responders. There was a true increase in 
feature values at 1 week after the start of therapy for 4 out of 6 responder patients for CV and 
Homogeneity. Therefore the dispersion of radiotracer concentration from the mean increased 
while neighbouring voxels had a much more similar concentration to that at baseline. CV and 
Homogeneity were weakly associated at baseline (0 ≤ r ≤ 0.39, Spearman).  However, the 
percentage change at 1 week in these features was strongly correlated across analysis 
parameters (0.75 ≤ r ≤ 0.86, Spearman), suggesting that they capture different aspects of the 
same underlying process associated with the start of chemotherapy.  
 
There was a negative association between injected dose and VOI size, which is due to a 
negative effect of dose on the resolution of objects in the PET image. This indicates the 
necessity to inject as large a dose as possible to image tissue heterogeneity, while controlling 
for safety, co-injected cold effects, and linearity of the scanner. Although response to 
treatment was not associated with VOI size, there were some associations between textural 
feature measurements and VOI size. This is likely due to the influence of the number of 
voxels used on the accuracy of the statistics. Although VOI size has an effect on the textural 
feature values measured in tissue, the variability in textural features due to VOI size might be 
limited and small enough to detect biological differences between groups of patients. VOI 
size was generally greater in non-responders versus responders (except for one responder 
patient). As Complexity and VOI size were inversely related, one would have expected to see 
a positive association between Complexity and response to treatment if VOI size was 
responsible for the latter relationship. However the opposite is true.  
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Chapter 6.  Space-filling properties of a complex 
object: A fractal approach to correcting partial 
volume effects in oncological PET imaging 
 
  
6.1.  Introduction 
PVEs have been identified as one of the major sources of bias in PET. Different components 
contribute to PVEs; the first is the finite point spread function (PSF) of the imaging system 
which is responsible for the blur (PET physics: positron range, detectors, etc.) characteristic 
of reconstructed PET images. The second effect contributing to PVEs is the so-called “tissue 
fraction effect” which is introduced into any digital image, independently of the resolution of 
the system, when discretising the intensities onto a voxels’ grid. The discretisation process 
generates a mixture of intensities between adjacent structures (tissue types) within individual 
voxels. Additional PVEs can be introduced during pre-processing of the images, for instance 
when smoothing the images with a Gaussian kernel (after reconstruction) so as to reduce the 
noise level.  Heterogeneous uptake patterns of radiotracer in a region of interest (e.g. intra-
tumour heterogeneity) or density of the organ (e.g. lung, brain) can further impede 
visualisation and quantification in PET. For instance, a tumour with a necrotic centre will 
appear to contain more viable tumour tissue within its centre and with a less aggressive rim 
(active part), due to PVEs.  
 
The entropy-based Rényi FDs introduced in Chapter 4 (Section 4.2) provide a description of 
how an object fills space in a non-uniform fashion and across different scales of measurement 
(meshing of the image through the box-counting method). In PET imaging, this is equivalent 
to capturing how the radiotracer concentration in a neoplastic lesion is distributed in space 
from individual voxels, to regional and global scales. One expects the total lesion activity 
(TLA) to be re-distributed between neighbouring voxels at different image resolutions. The 
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resolution will affect the apparent spatial properties in the neoplastic lesion, which will 
appear more diffuse at lower resolutions with a decrease in mean spatial activity 
concentration. The main aim of this study was to assess whether these resolution effects are 
captured by the FD method, and (further) whether the total lesion activity, which will be 
more or less severely contaminated by PVEs, can be recovered within a reasonable range at 
different image resolutions typical in PET imaging. 
  
Two practical implementations of the technique are proposed for recovering the space-filling 
properties of an object embedded in background in 3D images. Estimates of AreaFD, IFD and 
TOIFD (total object intensity) were illustrated on simple objects such as modified Sierpinski 
carpets embedded in non-zero background and synthetic objects characterised by different 
uptake patterns. The influence of noise and Target to Background ratio (TBR) was also 
investigated. The performances of the technique were further validated on realistic PET 
simulations. The impact of PET reconstruction parameters, VOI size and TBR were studied. 
The effect of PVC on the FD estimates was also illustrated. The robustness of the technique 
was assessed on test–retest 18F-FLT dataset and SUVFD results were compared to SUVmean 
and SUVmax values computed on the mask that were originally manually delineated by a 
clinician.  
 
6.2.  Materials and Methods 
 Practical computation of the Rényi multifractal spectrum and 6.2.1. 
recovery of intensity-volume estimates 
In this section the terminology and framework proposed for recovering space-filling 
properties (see Section 4.2) are extended to application on real objects embedded in non-zero 
background. The square box defined around the object of interest and required for the Rényi 
multifractal spectrum computation is referred to as the FD computation box in the rest of this 
thesis (Figure 6.1). Because the object of interest is embedded in background in the FD 
computation box, the method also requires an estimate of the mean background intensity 
(IBG). IBG is subtracted from the voxels’ intensities in the FD computation box prior to the 
Rényi spectrum calculation. This is to minimise the contributions of the background when 
estimating the space-filling properties of the object, by only taking into account the sum of 
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mass in the FD computation box which belongs to the target. As described previously 
(Chapter 4), estimates of the object’s area and filling-factor within the FD computation box 
are then derived as follows: 
 
         ( )         
              (6.1) 
 
       ( )            
               (6.2) 
 
Where FF stands for Filling-Factor and         is the width of the FD computation box 
(FDbox).  
 
The mean background intensity estimate (IBG) is also used to recover other FD estimates: 
namely the mean object intensity (         ) in the FD computation box, as well as the total 
sum of intensities (        ) of the object in the FD computation box. Two practical 
approaches, described in the following paragraphs, are proposed for defining the FD 
computation box and estimating IBG, AreaFD,           and         . These methods were 
implemented as part of a software solution, the Filling-Factor Software (see brief overview in 
the following section). 
 
 
 
 
 
 
 
 
 
 
 
` 
Figure 6.1 – Computation of the (Dq, Q) Rényi multifractal spectrum and          ( ) of an 
object embedded in background 
   
Define a square box (FD computation box) 
around the target embedded in background 
Subtract IBG (mean background intensity) from the 
image intensities in FD computation box 
Estimate the (Dq,Q) spectrum 
 
Estimate          ( ) 
Q 
Dq 
AreaFDbox(Q) 
Q 
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6.2.1.1.  Filling-Factor Software 
The Filling-Factor Software (written in MATLAB) consists of a graphical user interface 
(GUI) to collect input variables from the user, and an algorithm for computing the (Dq,Q) 
Rényi multifractal spectrum and deriving the FD estimates (         ,          ,         ). 
Two practical implementations of the method were proposed to recover the estimates of 
interest. The advantage of each of these methods will become clearer in the results and 
discussion sections of this chapter. The first approach, the FD_BGbox implementation, 
consists of positioning square boxes around the object of interest (for each slice in the case of 
a 3D image) and in the background. The second approach, the FD_Delin implementation, 
consists of defining a rough contour around the target. Each of these implementations is 
described in more detail in the following paragraphs. A visualisation of the software and a 
general outline of the different steps involved are given in Figures 6.2 to 6.3. 
 
Figure 6.2 – Filling-Factor Software –User’s input in graphical user interface. FD_BGbox 
implementation (A) and FD_Delin implementation (B) 
  
6.2 – Materials and Methods              149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 – In-slice recovery of intensity-volume features (         ( ),          ( ), and 
        ( )) using both the FD_BGbox and FD_Delin implementations (Filling-Factor 
Software) for each FD computation box 
 
User draws a “biggest” bounding square box around the object 
User draws a “smallest” bounding 
square box around the object 
User draws a rough contour around 
the object 
FD_BGbox implementation FD_Delin implementation 
User draws one or more square 
boxes in the background (BG_box) 
Software estimates mean 
background intensity (IBG) 
For each FD computation box  
(Containing “smallest” and contained within  
“biggest” bounding square box) 
Software generates “smallest” 
bounding square box 
Subtract IBG from all voxels  
in FD computation box 
Software estimates IBG  
in the FD computation box  
outside the rough contour (not 
including “excluded voxels”) 
Estimate (Dq,Q) spectrum  
and          ( ) 
Recover Space-Filling properties 
User excludes any other 
structures by contouring 
Software substitutes intensities of “excluded 
voxels” in the FD computation box by IBG 
Calculate sum of 
intensities  
(∑     ) in rough 
contour  
Calculate sum of 
intensities  
(∑      ) in FD 
computation box 
Estimate other in-slice intensity-
volume features:  
         ( ) and         ( ) 
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6.2.1.2.  Implementation of FD_BGbox and recovery of in-slice estimates 
As mentioned in the preceding paragraphs, in this implementation the user is asked to draw 
two square boxes (a “smallest” and a “biggest”) around the object. By defining two bounding 
square boxes around the object instead of one (which would be arbitrary and user-dependent), 
estimates can be computed for a range of FD computation box sizes and positions, and the 
variability of the estimates can be studied. The FD computation boxes derived (across 
available sizes and positions, as further discussed in Section 6.2.1.4) all contain the 
“smallest” square box and are contained within the “biggest” square box. In addition, the user 
is asked to position a square box (BG_box) elsewhere in the image with intensities 
resembling the background around the target (e.g. same tissue type and/or with similar 
radiotracer uptake), so as to derive an estimate of the mean background intensity (IBG).  
 
In each FD computation box used for the computation, IBG is subtracted from the image 
intensities prior to the Rényi spectrum calculation. Further the IBG estimate is used to recover 
in-slice         ( ) and          ( ) estimates. All other structures in the FD computation 
boxes (different from background and lesion) can be removed by using delineation tools also 
provided in the interface (and for which the voxels’ values are replaced by the estimated IBG). 
For each FD computation box the in-slice estimates (in addition to          ( ) [6.1] 
and        ( ) [6.2]) are obtained as follows: 
 
         ( )       
           
       ( )
  
       ( )  
       ( )
            (6.3) 
 
        ( )       ∑        (         ( )        
 )           (6.4) 
  
where FF stands for Filling-Factor,             and ∑        are the mean intensity and the 
sum of intensities in the FD computation box (respectively), and         is the width of the 
FD computation box.  
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6.2.1.3.  Implementation of FD_Delin and recovery of in-slice estimates 
FD_Delin is an alternative method based on the user drawing a contour around the object of 
interest that includes some background (so as to include the whole object, voxels 
contaminated by PVEs and some background voxels). Similar to the FD_BGbox 
implementation, the user is also asked to draw a “biggest” bounding box around the target. 
The Filling-Factor Software then automatically calculates the positions of the “smallest” 
bounding box coordinates. In this implementation, there is no need to define the background 
elsewhere in the image – instead the mean background intensity is estimated in each FD 
computation box outside of the object boundaries that have been drawn by the user. For each 
FD computation box the in-slice estimates (in addition to          ( ) [6.1] 
and        ( ) [6.2]) are obtained as follows: 
 
         ( )        
∑     
         ( )
  (   
        
         ( )
)            (6.5) 
 
        ( )         ∑       (         ( )          )            (6.6) 
  
Where ∑       is the sum of intensities in the mask (rough contour),          is the number 
of pixels in the mask, and           is the background mean estimate in the FD computation 
box. 
6.2.1.4.  FD computation box size and position 
The possible sizes for the square boxes (“smallest”, “biggest” and FD computation box) were 
constrained so that the resulting squared-image in which the (Dq,Q) spectrum was computed 
(FD computation box) could always be partitioned into sub-squares of equal size across a 
minimum number of three scales (including the voxel width and the FD computation box 
width). Sizes available were 4, 6, 8, 9, 12, 14, 15, 18, 24, etc.  
 
For an FD computation box of given width, all possible partitioning of the image into 
identical sub-squares were used. This ensured that as many points as possible were used in 
the estimation of FD (Kinsner, 2006).  
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6.2.1.5.  Mean in-slice estimates and standard deviation 
The mean and standard deviation of in-slice estimates for the features (Feat):         ( ) and 
           ( ),      ( ) and         ( ),      ( ) and           ( ) across FD computation 
boxes were obtained as follows:  
 
        ( )   ∑          ( )                 ⁄       (6.7) 
 
           ( )  √
 
           
 ∑ (         ( )          ( ))
 
        (6.8) 
 
where           is the number of FD computation boxes used. 
 
In the remainder of this thesis, IFD and TOIFD are exclusively used to describe the fractal 
objects employed to validate the FD method. For PET images, including synthetic 
simulations, SUVFD and TLAFD are used instead of IFD and TOIFD (respectively), to designate 
the normalised uptake value and total lesion activity recovered via the FD method.  
 
6.2.1.6.  Volumetric features 
In the 3D case (PET images), the procedures described in the previous paragraphs (using 
either the FD_BGbox or FD_Delin implementation) were successively repeated on each 
individual slice of the image in which the object (or target) was visible. From the in-slice 
mean estimates obtained across FD computation boxes (Section 6.2.1.5) on SUV normalised 
images, 3D estimates (VOLFD, SUVFD and TLAFD) were recovered as follows: 
 
     ( )   ∑         ( )              (6.9) 
 
     ( )   
∑        ( )                   ( ) 
∑         ( )     
       (6.10) 
 
     ( )   ∑                 ( )             (6.11) 
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Where in-slice mean total lesion activity computed on a SUV normalised PET image, 
                ( ), is equivalent to TOIFD ( ) computed on 2D images. 
 
 Datasets 6.2.2. 
6.2.2.1.  Fractal objects 
A set of two modified Sierpinski carpets (9x9 pixels) was generated (Figure 6.4). The objects 
were obtained as previously described in Chapter 4 (with IFS probabilities set to p =1/2 and 
1/3). The objects were generated using a range of arbitrary total object intensity (TOI; 250, 
350 and 450) and then embedded in an image of size 64x64 pixels filled with constant mean 
background intensity (IBG = 0, 1 or 2) (Table 6.1). A supplementary noisy dataset was 
obtained by adding Gaussian white noise to the images generated (std = 1). Smoothed 
versions of the images were generated using Gaussian filtering (2 and 3 pixels FWHM, 
kernel size = 7x7 pixels).  
 
A        B 
 
Figure 6.4 – Modified Sierpinski carpet objects embedded in constant background. The objects 
were generated using TOI = 250 and embedded in an image of size 64x64 pixels filled in with 
constant background intensity (IBG = 1): case f.1.2 (A)  and case f.2.2 (B). Images were cropped to 
24x24 pixels. 
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Table 6.1 – Ground truth (GT) values for lesion size (AreaGT) in pixels, and TOIGT, mean 
intensity value (IGT) and minimum and maximum intensity values for all modified Sierpinski 
carpets embedded in background 
 
 
 
  
Case 
Probability 
p (IFS) 
IBG TOI GT AreaGT IGT 
[min – max] object 
intensities 
f.1.1 1/2 0 250 64 3.91 3.91 
f.1.2 1/2 1 250 64 3.91  3.91  
f.1.3 1/2 2 250 64 3.91 3.91 
f.1.4 1/2 0 350 64 5.47 5.47 
f.1.5 1/2 1 350 64 5.47 5.47 
f.1.6 1/2 2 350 64 5.47 5.47 
f.1.7 1/2 0 450 64 7.03 7.03 
f.1.8 1/2 1 450 64 7.03 7.03 
f.1.9 1/2 2 450 64 7.03 7.03 
f.2.1 1/3 0 250 N/A N/A [1.72 to 6.94] 
f.2.2 1/3 1 250 N/A N/A [1.72 to 6.94] 
f.2.3 1/3 0 350 N/A N/A [2.41 to 9.72] 
f.2.4 1/3 1 350 N/A N/A [2.41 to 9.72] 
f.2.5 1/3 2 350 N/A N/A [2.41 to 9.72] 
f.2.6 1/3 0 450 N/A N/A [3.13 to 12.5] 
f.2.7 1/3 1 450 N/A N/A [3.13 to 12.5] 
f.2.8 1/3 2 450 N/A N/A [3.13 to 12.5] 
N/A = non-applicable 
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6.2.2.2.  Synthetic simulations 
Synthetic simulations were generated to illustrate algorithm performance for different uptake 
patterns: homogeneous pattern uptakes (cases s.1); rim-core-like pattern uptakes (cases s.2); 
and hot-spot-like pattern uptakes (cases s.3). Details and examples of objects generated are 
given in Figure 6.5 and Table 6.2. Arbitrary contours were manually drawn in 32x32 pixel 
images using MATLAB. The same contour was used in cases s.1 and s.2 as the external 
boundary between lesion and surrounding background. An additional contour was drawn in 
case s.2 to define a boundary between rim and core. A total of 3 hotspot contours were drawn 
in a separate image in case s.3. All contours were then converted into binary masks. The 
background was filled in with SUVBG = 1 and the different lesions were filled in with a range 
of different values (see Figure 6.5 and Table 6.2). An additional noisy dataset was obtained 
by adding white Gaussian noise (std = 1) to the images. All datasets were subsequently 
smoothed with a Gaussian filter (2 and 3 pixels FWHM, kernel size = 7 pixels). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 – Examples of synthetic simulations: homogeneous uptake pattern (A), rim-core-like 
uptake pattern (B), hot-spot-like uptake pattern (C). The original images (no PVEs) are displayed 
in the first column. Examples of corresponding smoothed (3 voxels FWHM Gaussian filter) noiseless 
and noisy images are given in the middle and right column respectively. (A) represents case s.1.2 
(Table 6.2), (B) case s.2.2 and (C) case s.3.1. 
A D G
G 
B E H 
C F I 
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Table 6.2 – Ground truth (GT) values for lesion size (AreaGT) in pixels, intensity (SUVGT) and 
TLAGT for all synthetic simulated cases.  
 
   Ground truth (GT) 
Description Case SUVBG 
Lesion size 
AreaGT 
(in pixels) 
SUVGT TLAGT 
Homogeneous 
uptake pattern 
s.1.1 1 
(Rim + core) 
46 pixels 
6 276 
s.1.2 1 4 184 
s.1.3 1 2 92 
Rim-core-like 
uptake pattern 
s.2.1 1 
Rim = 35 pixels 
Core =11 pixels 
Rim: 6 
Core: 4 
254 
s.2.2 1 
Rim: 6 
Core: 2 
232 
s.2.3 1 
Rim: 6 
Core: 1 
210 
Hot-spot-like  
uptake pattern 
s.3.1 1 Hs1 = 4 pixels 
Hs2 = 6 pixels 
Hs3 = 7 pixels 
All Hs: 6 102 
s.3.2 1 
Hs1: 6 
Hs2: 4 
Hs3: 2 
62 
 
6.2.2.3.  Realistic PET simulations  
Realistic simulations (Polycarpou et al, 2012) generated by collaborators Dr C. Tsoumpas 
and Mrs I. Polycarpou (King’s College London, London, UK) were used in order to validate 
the multifractal method against ground truth in the context of PET imaging. The fast analytic 
simulation toolkit (FAST) employed to generate the functional images has been described 
elsewhere (Tsoumpas et al, 2011; Tsoumpas et al, 2013). Briefly, real MR images were 
segmented and used for generating PET images using typical physiological uptake values 
(SUVBW) of 
18
F-FDG in thorax. Spherical lesions of different size and characterised by 
different homogeneous radiotracer uptakes were inserted into lung and liver. Dynamic MR 
images were used, so as to retrieve information during the full respiratory cycle, to simulate a 
4D PET dataset and originally, to study the impact of motion and motion correction 
techniques in PET imaging (Tsoumpas et al, 2011). All PET images were simulated using a 
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PET Gemini TF Scanner. PET images were reconstructed using OSEM (23 subsets) for a 
range of iterations (1, 2, 3, 5, 10, 15 and 20), using open source software for tomographic 
image reconstruction (STIR) (Thielemans et al, 2012). Image size was 250x250x87 voxels 
and voxel size was set to 2x2x2 mm
3
. Results were computed on both images generated using 
motion-compensated image reconstruction (MCIR) and on non-motion-corrected images. 
Images were post-filtered (4 and 5 mm Gaussian smoothing). A total of 6 lesions were 
studied (Figure 6.6 and Table 6.3). The theoretical total lesion activity (       ) of the 
inserted spherical lesions (in grams) was derived from ground truth values for diameter (in 
cm) and SUVmean (equivalent to g/mL) as follows: 
 
                  
 
 
  (
  (  )
 
)
 
, 
Where d is the diameter of the lesion. 
 
 
Figure 6.6 – Lesions manually inserted into realistic PET simulations. Lung (lesions 1, 2 and 3) in 
reference image (A) and reconstructed image (B), Liver (lesions 4, 5 and 6) in reference image (C) 
and reconstructed image (D). Images were reconstructed using 15 iterations (MCIR) and were post-
filtered (4mm FWHM).  
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Table 6.3 - Ground truth (GT) values – realistic PET simulations: lesion size (VOLGT) (cm
3
), 
SUVGT (SUVmean in lesion), SUVBG (SUVmean in background tissue), and TLAGT 
 
 
 
 
 
 
 
 
 
 
 
All the FD analyses were performed using the Filling-Factor Software described in the 
practical implementation section (6.2.1) of this chapter. Both the FD_BGbox and FD_Delin  
implementations were used. For the FD_BGbox implementation the background boxes 
(BG_boxes), as well as the “biggest” and “smallest” bounding square boxes were drawn on 
non-motion-corrected images reconstructed using 15 iterations and post-filtered (5mm 
FWHM, Gaussian Filter). For the FD_Delin implementation, the 6 lesions were grossly 
delineated on a 5 mm FWHM smoothed image (motion corrected, 15 iterations) and the 
“biggest” FD computation box was drawn around each lesion.  
 
Further, the influence of PVC on FD estimates was studied for the FD_BGbox 
implementation. The PVC technique employed was based on the Lucy-Richardson iterative 
deconvolution methodology (Boussion et al, 2006; Boussion et al, 2009), with incorporated 
wavelet denoising using Bayeshrink filtering (Chang et al, 2000). The PVC technique 
assumed a spatially invariant PSF for the scanner and was implemented as a C++ in-house 
console application written by Dr Adrien Le Pogam (Imperial College London, London, UK). 
For comparison, a PSF of both 4.3mm and 5mm were used. The analyses were performed on 
motion-corrected images. For this study, the “biggest” and “smallest” square boxes were 
drawn on MCIR reconstructed images (15 iterations, 5mm FWHM Gaussian smoothing). 
  
 
Lesion size 
 
SUVmean 
 
TLAGT (g) 
lesion 
number 
Location 
diameter 
(cm) 
VOLGT  
(cm3) 
 SUVGT 
(g/mL) 
lesion 
SUVBG 
(g/mL) 
BG 
 
1 Lung 1.0 0.52  4.5 0.50  2.36 
2 Lung 1.6 2.14  4.5 0.50  9.65 
3 Lung 1.6 2.14  7.5 0.50  16.08 
4 Liver 1.0 0.52  6.5 2.50  3.40 
5 Liver 1.6 2.14  6.5 2.50  13.94 
6 Liver 1.6 2.14  9.5 2.50  20.37 
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6.2.2.4.  Test-retest clinical dataset 
The 
18
F-FLT PET FEC-chemotherapy dataset described in Chapter 4 (Materials and Research 
Methods, Section 4.3) was used to assess the robustness of the method proposed (test-retest 
dataset). Analyses were performed on iteratively reconstructed images (see Chapter 4, 
Section 4.3.4) on one time frame (at 60 minutes for 10 minutes duration). PET images were 
post-filtered using a 5mm FWHM Gaussian filter. All FD analyses were performed using the 
Filling-Factor Software and the FD_BGbox implementation. The variability of the FD 
measurements within individual tumours prior to treatment was estimated by computing 
relative differences between baseline and validation scans: (featbaseline-
featvalidation)/[(featbaseline+featvalidation)/2] . An ICC was also calculated to assess the repeatability 
of the image descriptor measurements for the group of patients included in this study. For the 
repeatability study, a “smallest” and a “biggest” bounding square box were defined in all the 
slices in which the lesion was visible. SUVFD values were recovered as the normalised 
version of IFD (SUV normalisation for body weight).  
 
In addition, SUVFD values were compared to SUVmean and SUVmax values derived from the 
contour drawn by the clinician. Notably, there was sometimes a discrepancy between the 
slices in which the tumour volume was visible and the slices in which the clinician had drawn 
the contour. Indeed, because of pronounced PVEs in the first and last slices, the clinician 
often excluded these slices from the mask. Therefore it was not possible to directly compare 
VOLFD and TLAFD to VOI size and TLA (respectively) derived from the manual contour 
drawn by the clinician. Instead, the actual SUVmean and SUVmax values derived from the mask 
drawn by the clinician were compared to SUVFD values (by only including those slices in 
which the lesion was contoured by the clinician for the purpose of comparison). 
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6.3.  Results 
 Recovery of FD estimates in noiseless images: example with 6.3.1. 
modified Sierpinski carpets 
On noiseless and non-blurred images, the modified Sierpinski carpets in the homogeneous 
case (p = 1/2, cases f.1.1 to f.1.9) yielded objects with intensities distinct from the 
background, regardless of the total object intensity (TOI) and background intensity. For these 
objects, the area recovered via the FD method (AreaFD) was independent of TOIGT (ground 
truth) and/or the mean background intensity (IBG) the object was embedded in (Table 6.4). 
The object size was recovered within an error of 5%. However, the error in IFD and TOIFD 
recovery varied with the Target to Background Ratio (TBR). All intensity-volume features 
(AreaFD, IFD, and TLAFD) were recovered within ± 6% (Table 6.4). The estimates of AreaFD 
recovered across TBRs for cases f.2.1 to f.2.8 (p = 1/3) were in reasonable agreement with 
the values obtained previously (Chapter 4, Table 4.6). However, the area estimates recovered 
in cases f.2 depended on IBG as well as on TOIGT. For an identical object (same TOIGT), 
AreaFD was diminished when the object was embedded in a hotter background. Similarly, 
when embedded in the same background, AreaFD was greater for objects with greater TOIGT 
(Table 6.4). 
 
The error in TOIGT recovery was much greater for f.2 (≤ 20% across all cases) than for f.1 (≤ 
3% across all cases). In the case of f.2, this error increased with lower TBR due to either a 
lower TOIGT or to greater IBG. Results for the other estimates (Table 6.4) suggest that this is a 
direct consequence of the AreaFD sensitivity to TBR. Notably, the estimates of AreaFD were 
derived from the plateau of the (Dq, Q) spectrum that emphasises denser regions of the 
object. Additionally, in some cases the object’s minimum intensity (in 16 pixels of the 
modified Sierpinski carpet, per construction) was closer to IBG than to the object’s maximum 
intensity (e.g. cases f.2.2 and f.2.5, Tables 6.1 and 6.4). Therefore, it is possible that, in this 
type of images (no PVEs) for heterogeneous objects, lower/medium intensities (with values 
between IBG and the object’s maximum intensity) are disregarded at low TBR.   
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Table 6.4 – Recovery of estimates (AreaFD, IFD and TOIFD) on modified Sierpinski carpet 
embedded in constant background. Mean and std for FD estimates (FD_BGbox implementation) 
were given for Q=50 and across FD computation boxes size and position. Relative errors (%) were 
given for AreaFD and IFD for case 1 only (AreaGT = 64 pixels and IGT = TOI/ AreaGT).  
 
 
  
Case 
Probability 
p (IFS) 
IBG TOIGT AreaFD (voxels) IFD TOIFD 
f.1.1 1/2 0 250 60.8 ± 5.8 (-4.9%) 4.1 ± 0.4 (6.2%) 250.0 ± 0.0 (0.0%) 
f.1.2 1/2 1 250 60.8 ± 5.8 (-4.9%) 4.1 ± 0.3 (4.6%) 246.8 ± 5.8 (-1.3%) 
f.1.3 1/2 2 250 60.8 ± 5.8 (-4.9%) 4.0 ± 0.2 (3.0%) 243.7 ± 11.5 (-2.5%) 
f.1.4 1/2 0 350 60.8 ± 5.8 (-4.9%) 5.8 ± 0.6 (6.2%) 350.0 ± 0.0 (0.0%) 
f.1.5 1/2 1 350 60.8 ± 5.8 (-4.9%) 5.7 ± 0.5 (5.0%) 346.8 ± 5.8 (-0.9%) 
f.1.6 1/2 2 350 60.8 ± 5.8 (-4.9%) 5.7 ± 0.4 (3.9%) 343.7 ± 11.5 (-1.8%) 
f.1.7 1/2 0 450 60.8 ± 5.8 (-4.9%) 7.5 ± 0.7 (6.2%) 450.0 ± 0.0 (0.0%) 
f.1.8 1/2 1 450 60.8 ± 5.8 (-4.9%) 7.4 ± 0.6 (5.3%) 446.8 ± 5.8 (-0.7%) 
f.1.9 1/2 2 450 60.8 ± 5.8 (-4.9%) 7.3 ± 0.5 (4.4%) 443.7 ± 11.5 (-1.4%) 
f.2.1 1/3 0 250 37.9 ± 3.3 6.6 ± 0.6 250.0 ± 0.0 (0.0%) 
f.2.2 1/3 1 250 32.8 ± 2.8 6.7 ± 0.5 218.8 ± 2.8 (-12.5%) 
f.2.3 1/3 0 350 37.9 ± 3.3 9.3 ± 0.8 350.0 ± 0.0 (0.0%) 
f.2.4 1/3 1 350 34.4 ± 2.9 9.4 ± 0.7 320.4 ± 2.9 (-8.4%) 
f.2.5 1/3 2 350 30.1 ± 2.5 9.4 ± 0.6 282.1 ± 5.0 (-19.4%) 
f.2.6 1/3 0 450 37.9 ± 3.3 12.0 ± 1.0 450.0 ± 0.0 (0.0%) 
f.2.7 1/3 1 450 35.3 ± 3.0 12.0 ± 0.9 421.3 ± 3.0 (-6.4%) 
f.2.8 1/3 2 450 32.1 ± 2.7 12.1 ± 0.8 386.3 ± 5.4 (-14.2%) 
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 Effect of image resolution and noise: example with modified 6.3.2. 
Sierpinski carpets 
Examples of modified Sierpinski carpets smoothed with a Gaussian filter (2 and 3 pixels 
FWHM, kernel width 7 pixels) are given in Figures 6.7 (noiseless dataset), 6.8 and 6.9 (noisy 
dataset). Smoothing the images has the effect of spreading the intensities in space. In other 
words the sum of intensities (TOIGT) became much less “concentrated” with increased 
smoothing. This was captured by the FD method in all cases (f1.1 to f.1.9 and f.2.1 to f.2.8) 
with an increase in the fractal dimension value (Dq) and the area recovered (AreaFD) for a 
greater moment Q (plateau, Figure 6.10), as well as a decrease in the mean intensity (IFD) 
(Tables 6.5 to 6.8). This trend was observed independently of TBR and IBG in both noiseless 
and noisy datasets. In contrast, TOIFD was stable across resolutions (no PVEs, 2 and 3 voxels 
FWHM smoothing) in noiseless datasets (Tables 6.5 and 6.6). TOIFD was also reasonably 
stable on noisy datasets (Tables 6.7 and 6.8). In case f.1 (noiseless dataset, Table 6.5) for 
which all objects’ intensities were always distinct from the background intensity in the 
original images, the values recovered for AreaFD were independent of TBR (TOIGT as well as 
IBG) across resolutions (no PVEs, 2 and 3 voxels FWHM smoothing). The background noise 
made the Sierpinski carpet less detectable in certain cases (e.g. low TBR due to low TOIGT 
and high background intensity for instance), which led to an underestimation of AreaGT and 
TOIGT (see for instance non-smoothed images: cases f.1.2 and f.1.3 in Figure 6.8 and f.2.2 in 
Figure 6.9). In case f.2, for which the intensity uptake pattern was heterogeneous, TOIFD 
estimates were recovered within a smaller error of the ground truth on noiseless smoothed 
images, compared with the noiseless, non-smoothed original images. For case f.2 (noiseless 
and noisy datasets) and case f.1 (noisy dataset), AreaFD slightly decreased with an increasing 
IBG (for the same TOI and smoothing). This indicates that, except for case f.1 (noiseless 
datasets) in which the object’s intensity is noticeably different from the background, the 
background has an influence on the space-filling properties of the object that are recovered.   
 
On noisy images and in contrast with noiseless images, the area occupied by the object was 
largely underestimated (e.g. case f.1, Table 6.7). AreaFD estimates recovered on smoothed 
images (2 and 3 voxels FWHM Gaussian Filtering) were in contrast much more similar 
between noisy and noiseless datasets (Tables 6.5 to 6.8, Figure 6.10). However, AreaFD 
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dropped with lower TBR for noisy datasets. The error in TOI recovery on images 
contaminated by PVEs (2 or 3 voxels FWHM smoothed) was less than 9% in all cases.  
 
Notably, the variation in FD estimates across moment Q (for the plateau) between 30 and 100 
was negligible (mean and std coefficients of variation) across all FD computation boxes (N = 
12,204): Dq = 0.33% ± 0.20%; AreaFD(Q) = 1.22% ± 0.75%; TOIFD(Q) = 0.18% ± 0.23%; 
and IFD(Q) = 1.03% ± 0.66%. The maximum variability (for one individual FD computation 
box) was 2.6% (Table 6.9). 
 
Figure 6.7 – Examples of modified Sierpinski carpets at different resolutions (noiseless 
datasets). Original Sierpinski carpet object with probability p = 1/2 (A), smoothed with a 2-voxel (B) 
and 3-voxel (C) FWHM Gaussian filter. Original Sierpinski carpet object with probability p = 1/3 (D), 
smoothed with a 2-voxel (E) and 3-voxel (F) FWHM Gaussian filter.  
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Figure 6.8 – Example of modified Sierpinski carpet (case f.1) at different resolutions (noisy 
dataset). Original Sierpinski carpet object with probability p = 1/2. The objects without PVEs are 
displayed in the left column, with a 2-voxel FWHM smoothing in the middle column and a 3-voxel 
FWHM smoothing in the right column. (A, B and C) are original and smoothed versions of case f.1.2 
(TOIGT = 250, IBG = 1), (D, E and F) of case f.1.3 (TOIGT = 250, IBG = 2), (G, H, I) of case f.1.9 
(TOIGT = 450, IBG = 2). 
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Figure 6.9 – Example of modified Sierpinski carpet (case f.2) at different resolutions (noisy 
dataset). Original Sierpinski carpet object with probability p = 1/3. The objects without PVEs are 
displayed in the left column, with a 2-voxel FWHM smoothing in the middle column and with a 3-
voxel FWHM smoothing in the right column. (A, B and C) were original and smoothed versions of 
case f.2.2 (TOIGT = 250, IBG = 1), (D, E and F) of case f.2.7 (TOIGT = 450, IBG = 1), (G, H, I) of case 
f.2.8 (TOIGT = 450, IBG = 2).  
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Figure 6.10 – (Dq, Q) spectrums for the examples given in Figures 6.8 and 6.9. Results are given 
for one FD computation box of size 15x15 pixels positioned around the target. In each graph, (Dq, Q) 
spectrums of noiseless and noisy datasets, with no PVEs and smoothed images are shown. Panels: 
case f.1.2 (A), case f.1.3 (B), case f.1.9 (C), case f.2.2 (D), case f.2.7 (E) and case f.2.9 (F). 
 
 
 
6
.3
 –
 R
es
u
lt
s 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 1
6
7
 
  
Table 6.5 – FD estimates recovered via FD_BGbox implementation across smoothing on noiseless datasets (case f.1). Estimates (mean ± std) are 
given for Q = 50 across FD computation box size and position. Percent errors are given relative to GT values.  
 
  
Case TOIGT Smooth IBG AreaFD (voxels) IFD TOIFD 
f.1.1 250 no PVEs 0 60.8 ± 5.8 (-4.9%) 4.1 ± 0.4 (6.2%) 250.0 ± 0.0 (0.0%) 
f.1.1 250 2 voxels 0 69.4 ± 4.4 (8.5%) 3.6 ± 0.2 (-7.4%) 250.0 ± 0.0 (-0.003%) 
f.1.1 250 3 voxels 0 82.9 ± 5.3 (29.5%) 3.0 ± 0.2 (-23.2%) 247.6 ± 0.0 (-1.0%) 
f.1.4 350 no PVEs 0 60.8 ± 5.8 (-4.9%) 5.8 ± 0.6 (6.2%) 350.0 ± 0.0 (0.0%) 
f.1.4 350 2 voxels 0 69.4 ± 4.4 (8.5%) 5.1 ± 0.3 (-7.4%) 350.0 ± 0.0 (-0.003%) 
f.1.4 350 3 voxels 0 82.9 ± 5.3 (29.5%) 4.2 ± 0.3 (-23.2%) 346.6 ± 0.0 (-1.0%) 
f.1.7 450 no PVEs 0 60.8 ± 5.8 (-4.9%) 7.5 ± 0.7 (6.2%) 450.0 ± 0.0 (0.0%) 
f.1.7 450 2 voxels 0 69.4 ± 4.4 (8.5%) 6.5 ± 0.4 (-7.4%) 450.0 ± 0.0 (-0.003%) 
f.1.7 450 3 voxels 0 82.9 ± 5.3 (29.5%) 5.4 ± 0.3 (-23.2%) 445.7 ± 0.0 (-1.0%) 
f.1.2 250 no PVEs 1 60.8 ± 5.8 (-4.9%) 4.1 ± 0.3 (4.6%) 246.8 ± 5.8 (-1.3%) 
f.1.2 250 2 voxels 1 69.4 ± 4.4 (8.5%) 3.7 ± 0.2 (-5.5%) 255.4 ± 4.4 (2.2%) 
f.1.2 250 3 voxels 1 82.9 ± 5.3 (29.5%) 3.2 ± 0.1 (-17.5%) 266.3 ± 5.3 (6.5%) 
f.1.5 350 no PVEs 1 60.8 ± 5.8 (-4.9%) 5.7 ± 0.5 (5.0%) 346.8 ± 5.8 (-0.9%) 
f.1.5 350 2 voxels 1 69.4 ± 4.4 (8.5%) 5.1 ± 0.3 (-6.1%) 355.4 ± 4.4 (1.5%) 
f.1.5 350 3 voxels 1 82.9 ± 5.3 (29.5%) 4.4 ± 0.2 (-19.1%) 365.3 ± 5.3 (4.4%) 
f.1.8 450 no PVEs 1 60.8 ± 5.8 (-4.9%) 7.4 ± 0.6 (5.3%) 446.8 ± 5.8 (-0.7%) 
f.1.8 450 2 voxels 1 69.4 ± 4.4 (8.5%) 6.6 ± 0.3 (-6.4%) 455.4 ± 4.4 (1.2%) 
f.1.8 450 3 voxels 1 82.9 ± 5.3 (29.5%) 5.6 ± 0.3 (-20.0%) 464.4 ± 5.3 (3.2%) 
f.1.3 250 no PVEs 2 60.8 ± 5.8 (-4.9%) 4.0 ± 0.2 (3.0%) 243.7 ± 11.5 (-2.5%) 
f.1.3 250 2 voxels 2 69.4 ± 4.4 (8.5%) 3.8 ± 0.1 (-3.6%) 260.8 ± 8.8 (4.3%) 
f.1.3 250 3 voxels 2 82.9 ± 5.3 (29.5%) 3.4 ± 0.1 (-11.8%) 285.0 ± 10.5 (14.0%) 
f.1.6 350 no PVEs 2 60.8 ± 5.8 (-4.9%) 5.7 ± 0.4 (3.9%) 343.7 ± 11.5 (-1.8%) 
f.1.6 350 2 voxels 2 69.4 ± 4.4 (8.5%) 5.2 ± 0.2 (-4.7%) 360.8 ± 8.8 (3.1%) 
f.1.6 350 3 voxels 2 82.9 ± 5.3 (29.5%) 4.6 ± 0.2 (-15.1%) 384.0 ± 10.5 (9.7%) 
f.1.9 450 no PVEs 2 60.8 ± 5.8 (-4.9%) 7.3 ± 0.5 (4.4%) 443.7 ± 11.5 (-1.4%) 
f.1.9 450 2 voxels 2 69.4 ± 4.4 (8.5%) 6.7 ± 0.3 (-5.3%) 460.8 ± 8.8 (2.4%) 
f.1.9 450 3 voxels 2 82.9 ± 5.3 (29.5%) 5.8 ± 0.2 (-16.9%) 483.0 ± 10.5 (7.3%) 
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Table 6.6 – FD estimates recovered via FD_BGbox implementation across smoothing on noiseless datasets (case f.2). Estimates (mean ± std) are 
given for Q = 50 across FD computation box size and position. Percent errors are given relative to GT values. 
 
 
  
Case TOIGT Smooth IBG AreaFD (voxels) IFD TOIFD 
f.2.1 250 no PVEs 0 37.9 ± 3.3 6.6 ± 0.6 250.0 ± 0.0 (0.0%) 
f.2.1 250 2 voxels 0 59.3 ± 3.8 4.2 ± 0.3 250.0 ± 0.0 (-0.003%) 
f.2.1 250 3 voxels 0 74.5 ± 5.0 3.3 ± 0.2 247.6 ± 0.0 (-1.0%) 
f.2.3 350 no PVEs 0 37.9 ± 3.3 9.3 ± 0.8 350.0 ± 0.0 (0.0%) 
f.2.3 350 2 voxels 0 59.3 ± 3.8 5.9 ± 0.4 350.0 ± 0.0 (-0.003%) 
f.2.3 350 3 voxels 0 74.5 ± 5.0 4.7 ± 0.3 346.6 ± 0.0 (-1.0%) 
f.2.6 450 no PVEs 0 37.9 ± 3.3 12.0 ± 1.0 450.0 ± 0.0 (0.0%) 
f.2.6 450 2 voxels 0 59.3 ± 3.8 7.6 ± 0.5 450.0 ± 0.0 (-0.003%) 
f.2.6 450 3 voxels 0 74.5 ± 5.0 6.0 ± 0.4 445.7 ± 0.0 (-1.0%) 
f.2.2 250 no PVEs 1 32.8 ± 2.8 6.7 ± 0.5 218.8 ± 2.8 (-12.5%) 
f.2.2 250 2 voxels 1 54.1 ± 3.5 4.5 ± 0.2 240.1 ± 3.5 (-4.0%) 
f.2.2 250 3 voxels 1 70.3 ± 4.8 3.6 ± 0.2 253.8 ± 4.8 (1.5%) 
f.2.4 350 no PVEs 1 34.4 ± 2.9 9.4 ± 0.7 320.4 ± 2.9 (-8.4%) 
f.2.4 350 2 voxels 1 55.8 ± 3.6 6.1 ± 0.3 341.8 ± 3.6 (-2.3%) 
f.2.4 350 3 voxels 1 71.8 ± 4.9 5.0 ± 0.3 354.3 ± 4.8 (1.2%) 
f.2.7 450 no PVEs 1 35.3 ± 3.0 12.0 ± 0.9 421.3 ± 3.0 (-6.4%) 
f.2.7 450 2 voxels 1 56.7 ± 3.6 7.8 ± 0.4 442.7 ± 3.6 (-1.6%) 
f.2.7 450 3 voxels 1 72.5 ± 4.9 6.3 ± 0.4 454.1 ± 4.9 (0.9%) 
f.2.5 350 no PVEs 2 30.1 ± 2.5 9.4 ± 0.6 282.1 ± 5.0 (-19.4%) 
f.2.5 350 2 voxels 2 50.9 ± 3.3 6.4 ± 0.3 323.8 ± 6.6 (-7.5%) 
f.2.5 350 3 voxels 2 67.6 ± 4.7 5.2 ± 0.2 353.8 ± 9.3 (1.1%) 
f.2.8 450 no PVEs 2 32.1 ± 2.7 12.1 ± 0.8 386.3 ± 5.4 (-14.2%) 
f.2.8 450 2 voxels 2 53.3 ± 3.4 8.1 ± 0.4 428.6 ± 6.9 (-4.7%) 
f.2.8 450 3 voxels 2 69.7 ± 4.8 6.6 ± 0.3 456.9 ± 9.5 (1.5%) 
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Table 6.7 – FD estimates recovered via FD_BGbox implementation across smoothing on noisy datasets (case f.1). Estimates (mean ± std) are given 
for Q = 50 across FD computation box size and position. Percent errors are given relative to GT values.  
 
Case TOIGT Smooth IBG AreaFD (voxels) IFD TOIFD 
f.1.1 250 no PVEs 0 38.6 ± 4.1 (-39.62%) 6.6 ± 0.6 (68.60%) 252.1 ± 6.8 (0.86%)  
f.1.1 250 2 voxels 0 62.8 ± 3.9 (-1.94%) 4.0 ± 0.3 (3.68%) 253.1 ± 4.6 (1.26%) 
f.1.1 250 3 voxels 0 77.9 ± 5.1 (21.79%) 3.2 ± 0.2 (-17.08%) 251.4 ± 4.3 (0.56%) 
f.1.4 350 no PVEs 0 43.7 ± 4.4 (-31.68%) 8.1 ± 0.8 (48.57%) 352.0 ± 6.8 (0.56%) 
f.1.4 350 2 voxels 0 65.4 ± 4.1 (2.20%) 5.4 ± 0.4 (-0.92%) 353.0 ± 4.6 (0.85%) 
f.1.4 350 3 voxels 0 79.7 ± 5.1 (24.52%) 4.4 ± 0.3 (-19.27%) 350.3 ± 4.3 (0.10%) 
f.1.7 450 no PVEs 0 47.2 ± 4.7 (-26.27%) 9.7 ± 0.9 (37.46%) 451.8 ± 6.8 (0.41%) 
f.1.7 450 2 voxels 0 66.7 ± 4.1(4.29%) 6.8 ± 0.4 (-3.11%) 452.9 ± 4.6 (0.65%) 
f.1.7 450 3 voxels 0 80.6 ± 5.2 (25.93%) 5.6 ± 0.4 (-20.38%) 449.3 ± 4.3 (-0.15%) 
f.1.2 250 no PVEs 1 33.9 ± 3.7 (-47.02%) 6.6 ± 0.5 (69.12%) 222.2 ± 9.5 (-11.11%) 
f.1.2 250 2 voxels 1 59.6 ± 3.8 (-6.83%) 4.2 ± 0.2 (7.20%) 248.9 ± 6.0 (-0.42%) 
f.1.2 250 3 voxels 1 75.8 ± 5.0 (18.39%) 3.5 ± 0.2 (-10.81%) 263.2 ± 6.5 (5.28%) 
f.1.5 350 no PVEs 1 40.7 ± 4.2 (-36.37%) 8.1 ± 0.7 (48.84%) 328.8 ± 9.7 (-6.06%) 
f.1.5 350 2 voxels 1 63.9 ± 4.0 (-0.10%) 5.5 ± 0.3 (1.29%) 353.0 ± 5.8 (0.86%) 
f.1.5 350 3 voxels 1 78.7 ± 5.1 (23.01%) 4.7 ± 0.2 (-14.94%) 365.0 ± 6.4 (4.28%) 
f.1.8 450 no PVEs 1 45.1 ± 4.5 (-29.51%) 9.7 ± 0.8 (37.66%) 433.0 ± 9.8 (-3.77%) 
f.1.8 450 2 voxels 1 66.0 ± 4.1 (3.11%) 6.9 ± 0.4 (-1.62%) 454.9 ± 5.7 (1.10%) 
f.1.8 450 3 voxels 1 80.1 ± 5.1 (25.13%) 5.8 ± 0.3 (-17.08%) 465.3 ± 6.3 (3.40%) 
f.1.3 250 no PVEs 2 27.1 ± 3.3 (-57.68%) 6.6 ± 0.4 (70.12%) 178.7 ± 12.3 (-28.50%) 
f.1.3 250 2 voxels 2 54.0 ± 3.5 (-15.62%) 4.3 ± 0.2 (10.98%) 233.6 ± 9.0 (-6.55%) 
f.1.3 250 3 voxels 2 71.4 ± 4.8 (11.62%) 3.7 ± 0.1 (-4.31%) 266.5 ± 10.8 (6.61%) 
f.1.6 350 no PVEs 2 36.8 ± 3.9 (-42.56%) 8.2 ± 0.6 (49.14%) 297.7 ± 12.9 (-14.93%) 
f.1.6 350 2 voxels 2 61.6 ± 3.9 (-3.77%) 5.7 ± 0.2 (3.71%) 348.4 ± 8.8 (-0.47%) 
f.1.6 350 3 voxels 2 77.2 ± 5.0 (20.55%) 4.9 ± 0.2 (-10.53%) 376.5 ± 10.7 (7.58%) 
f.1.9 450 no PVEs 2 42.5 ± 4.3 (-33.58%) 9.7 ± 0.7 (37.87%) 409.0 ± 13.4 (-9.11%) 
f.1.9 450 2 voxels 2 64.8 ± 4.0 (1.32%) 7.0 ± 0.3 (0.01%) 454.7 ± 8.8 (1.05%) 
f.1.9 450 3 voxels 2 79.3 ± 5.1 (23.94%) 6.1 ± 0.3 (-13.74%) 479.8 ± 10.6 (6.61%) 
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Table 6.8 – FD estimates recovered via FD_BGbox implementation across smoothing on noisy datasets (case f.2). Estimates (mean ± std) are 
given for Q = 50 across FD computation box size and position. Percent errors are given relative to GT values. 
 
  
Case TOIGT Smooth IBG AreaFD (voxels) IFD TOIFD 
f.2.1 250 no PVEs 0 28.4 ± 3.0 9.0 ± 0.8 252.5 ± 6.9 (1.01%) 
f.2.1 250 2 voxels 0 53.3 ± 3.5 4.8  ± 0.3 253.7 ± 4.6 (1.46%)  
f.2.1 250 3 voxels 0 70.7 ± 4.9 3.6 ± 0.3  251.8 ± 4.3 (0.73%) 
f.2.3 350 no PVEs 0 31.0 ± 3.1 11.5 ± 1.0 352.4 ± 6.9 (0.69%) 
f.2.3 350 2 voxels 0 55.3 ± 3.6 6.4 ± 0.4 353.5 ± 4.6 (1.01%) 
f.2.3 350 3 voxels 0 72.1 ± 4.9 4.9 ± 0.3 350.8 ± 4.3 (0.23%) 
f.2.6 450 no PVEs 0 32.6 ± 3.1 14.0 ± 1.2 452.4 ± 6.9 (0.53%) 
f.2.6 450 2 voxels 0 56.4 ± 3.6 8.1 ± 0.5 453.5 ± 4.6 (0.77%) 
f.2.6 450 3 voxels 0 72.8 ± 4.9 6.2 ± 0.4 449.8 ± 4.3 (-0.05%) 
f.2.2 250 no PVEs 1 23.5 ± 2.6 9.1 ± 0.8 212.2 ± 8.6 (-15.12%) 
f.2.2 250 2 voxels 1 47.5 ± 3.3 5.0 ± 0.3 237.5 ± 5.6 (-5.01%) 
f.2.2 250 3 voxels 1 65.7 ± 4.7 3.9 ± 0.2 253.8 ± 6.3 (1.51%) 
f.2.4 350 no PVEs 1 27.4 ± 2.8 11.6 ± 1.0 316.0 ± 8.5 (-9.72%) 
f.2.4 350 2 voxels 1 51.5 ± 3.4 6.7 ± 0.4 341.2 ± 5.5 (-2.51%) 
f.2.4 350 3 voxels 1 68.9 ± 4.8 5.2 ± 0.3 355.8 ± 6.2 (1.67%) 
f.2.7 450 no PVEs 1 29.8 ±2.9 14.1 ± 1.2 418.3 ± 8.5 (-7.04%) 
f.2.7 450 2 voxels 1 53.6 ± 3.4 8.3 ± 0.5 443.2 ±5.4 (-1.50%) 
f.2.7 450 3 voxels 1 70.5 ± 4.8 6.5 ± 0.4 456.4 ± 6.1 (1.42%) 
f.2.5 350 no PVEs 2 23.2 ± 2.5 11.8 ± 0.9 271.2 ± 10.3 (-22.52%) 
f.2.5 350 2 voxels 2 46.2 ± 3.1 6.9 ± 0.4 318.5 ± 7.6 (-9.01%) 
f.2.5 350 3 voxels 2 64.4 ± 4.6 5.5 ±0.3 352.0 ± 10.0 (0.57%) 
f.2.8 450 no PVEs 2 26.7 ± 2.6 14.3 ± 1.1 378.0 ± 10.3 (-16.00%) 
f.2.8 450 2 voxels 2 50.0 ± 3.3 8.6 ± 0.4 425.8 ± 7.6 (-5.39%) 
f.2.8 450 3 voxels 2 67.5 ± 4.7 6.8 ± 0.3 457.0 ± 9.9 (1.56%) 
6.3 – Results              171 
 
 
Table 6.9 – Coefficients of variation of FD estimates for a range of moments Q between 30 and 
100 (modified Sierpinski carpets). Statistics were computed across all cases, image types (noiseless 
and noisy) and smoothing used in this section (N = 12,204 FD computation boxes). 
  
 
 
 
 
 Recovery of total lesion activity (TLA) for different uptake patterns 6.3.3. 
The algorithm was then tested on different uptake patterns: homogeneous, rim-core-like and 
hot-spot-like. Results of the analyses are presented for objects embedded in constant 
background with no added noise (Table 6.10) and with added white Gaussian noise (Table 
6.11). The FD estimates recovered via the FD_BGbox implementation are compared to 
ground truth. The dependency of AreaFD and SUVFD estimates on resolution was previously 
shown (Section 6.3.2). The same effect is observed for synthetic simulations in both noiseless 
(Table 6.10) and noisy datasets (Table 6.11). The magnitude with which image resolution 
affects AreaFD and SUVFD estimates depends on the object (shape and size) as well as on the 
Target to Background Ratio activities (TBR) and noise in the images. The percent errors in 
AreaGT and SUVGT recovery are only given as indicative values in Tables 6.10 and 6.11. For 
the noiseless dataset, the maximum VOI size underestimation was -13%. Area overestimation 
(due to smoothing or low resolution) was object dependent: up to +12% in the case of rim-
core-like uptake patterns with a core intensity different from the background intensity, up to 
+45% in the case of a rim-core-like uptake pattern with a core intensity identical to 
background, and up to +90% in the case of a hot-spot-like pattern. For the noiseless dataset, 
TLAGT was recovered within a few percent (± 7%) for the homogeneous and rim-core-like 
uptake patterns, and the technique distinguished between different uptake values (e.g. 
different rim-core uptakes). More variability was observed for the hot-spot-like objects (up to 
± 16%).  
Feature mean std min max 
Dq 0.33% 0.20% 0.00% 0.68% 
Area(Q) 1.22% 0.75% 0.00% 2.59% 
TOI(Q) 0.18% 0.23% 0.00% 1.30% 
I(Q) 1.03% 0.66% 0.00% 2.54% 
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Table 6.10 –FD estimates (AreaFD, SUVFD and TLAFD) recovered using FD_BGbox implementation (noiseless dataset). Estimates (mean ± std) were 
given for moment Q=50 across FD computation box sizes and positions. Images were smoothed using a 2- or 3-voxel FWHM Gaussian Filter. 
 
  
   Ground truth (GT)  Recovered 
Case 
(description) 
Case 
number 
Smooth TLAGT 
AreaGT 
(voxels) 
SUVGT 
 
TLAFD AreaFD (voxels) SUVFD 
Homogeneous  
uptake pattern 
s.1.1 
2 voxels 276 46 6.0  271.3 ± 4.6 (-1.7%) 41.3 ± 4.6 (-10.3%) 6.6 ± 0.6 (10.7%) 
3 voxels 276 46 6.0  270.0 ± 4.5 (-2.2%) 42.6 ± 4.5 (-7.4%) 6.4 ± 0.6 (6.6%) 
s.1.2 
2 voxels 184 46 4.0  179.3 ± 4.6 (-2.6%) 41.3 ± 4.6 (-10.3%) 4.4 ± 0.4 (9.6%) 
3 voxels 184 46 4.0  178.9 ± 4.5 (-2.8%) 42.6 ± 4.5 (-7.4%) 4.2 ± 0.3 (5.9%) 
s.1.3 
2 voxels 92 46 2.0  87.3 ± 4.6 (-5.1%) 41.3 ± 4.6 (-10.3%) 2.1 ± 0.1 (6.4%) 
3 voxels 92 46 2.0  87.7 ± 4.5 (-4.6%) 42.6 ± 4.5 (-7.4%) 2.1 ± 0.1 (3.6%) 
Rim-core-like 
uptake pattern 
s.2.1 
2 voxels 254 46 5.5  251.2 ± 4.6 (-1.1%) 43.2 ± 4.6 (-6.1%) 5.9 ± 0.5 (6.3%) 
3 voxels 254 46 5.5  254.1 ± 4.8 (0.04%) 48.6 ± 4.9 (5.6%) 5.3 ±0.4 (-4.5%) 
s.2.2 
2 voxels 232 46 5.0  225.9 ± 4.0 (-2.6%) 39.9 ± 4.0 (-13.2%) 5.7 ± 0.5 (13.1%) 
3 voxels 232 46 5.0  235.0 ± 4.8 (1.3%) 51.3 ± 4.9 (11.6%) 4.6 ±0.3 (-8.6%) 
s.2.3 
2 voxels 210 35 6.0  212.8 ± 3.7 (1.3%) 37.8 ± 3.7 (7.9%) 5.7 ±0.4 (-5.4%) 
3 voxels 210 35 6.0  223.5 ± 4.6 (6.4%) 50.7 ± 4.6 (44.8%) 4.4 ± 0.3 (-26.0%) 
Hot-spot-like 
uptake pattern 
s.3.1 
2 voxels 102 17 6.0  104.6 ± 1.8 (2.6%) 19.6 ± 1.8 (15.3%) 5.4 ± 0.4 (-10.5%) 
3 voxels 102 17 6.0  116.2 ± 2.7 (13.9%) 32.3 ± 2.7 (90.2%) 3.6 ± 0.2 (-39.8%) 
s.3.2 
2 voxels 62 17 3.6  60.7 ± 1.7 (-2.1%) 15.7 ± 1.7 (-7.8%) 3.9 ± 0.3 (7.0%) 
3 voxels 62 17 3.6  71.8 ±2.6 (15.9%) 27.5 ± 2.6 (62.0%) 2.6 ± 0.1 (-28.1%) 
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Table 6.11 –FD estimates (AreaFD, SUVFD and TLAFD) recovered using FD_BGbox implementation (noisy dataset). Estimates (mean ± std) were 
given for moment Q=50 across FD computation box sizes and positions. Images were smoothed using a 3 voxels FWHM Gaussian Filter.  
   Ground truth (GT)  Recovered 
Case 
(description) 
Case 
number 
Smooth TLAGT 
AreaGT 
(voxels) 
SUVGT 
 
TLAFD AreaFD (voxels) SUVFD 
Homogeneous  
uptake pattern 
s.1.1 
2 voxels 284.2 46.0 6.2  281.2 ± 4.8 (-1.1%) 40.2 ± 4.0 (-12.6%) 7.1 ± 0.6 (14.2%) 
3 voxels 284.2 46.0 6.2  285.4 ± 4.6 (0.4%) 43.8 ± 4.1 (-4.8%) 6.6 ± 0.5 (6.3%) 
s.1.2 
2 voxels 192.2 46.0 4.2  187.3 ± 4.5 (-2.6%) 38.3 ± 3.5 (-16.8%) 4.9 ± 0.4 (17.9%) 
3 voxels 192.2 46.0 4.2  194.8 ± 4.4 (1.4%) 44.3 ± 3.7 (-3.6%) 4.4 ± 0.3 (5.8%) 
s.1.3 
2 voxels 100.2 46.0 2.2  88.5 ± 5.8 (-11.7%) 31.6 ± 2.6 (-31.4%) 2.8 ± 0.2 (29.1%) 
3 voxels 100.2 46.0 2.2  102.7 ±5.9 (2.5%) 43.3 ± 3.2 (-5.9%) 2.4 ± 0.1 (9.1%) 
Rim-core-like 
uptake pattern 
s.2.1 
2 voxels 262.2 46.0 5.7  261.1 ±4.8 (-0.4%) 42.0 ± 3.9 (-8.6%) 6.3 ± 0.5 (9.8%) 
3 voxels 262.2 46.0 5.7  269.1 ± 4.7 (2.6%) 49.4 ± 4.2 (7.3%) 5.5 ± 0.4 (-3.8%) 
s.2.2 
2 voxels 240.2 46.0 5.2  237.9 ± 4.5 (-1.0%) 40.9 ± 3.6 (-11.2%) 5.9 ± 0.4 (12.2%) 
3 voxels 240.2 46.0 5.2  250.6 ± 4.8 (4.3%) 52.7 ±4.3 (14.6%) 4.8 ± 0.3 (-8.5%) 
s.2.3 
2 voxels 218.7 35.0 6.2  225.0 ± 4.4 (2.9%) 39.0 ± 3.3 (11.4%) 5.8 ± 0.4 (-7.1%) 
3 voxels 218.7 35.0 6.2  239.7 ± 4.7 (9.6%) 52.7 ± 4.0 (50.5%) 4.6 ± 0.3 (-26.8%) 
Hot-spot-like 
uptake pattern 
s.3.1 
2 voxels 106.8 17.0 6.3  101.1 ± 8.2 (-5.3%) 18.8 ± 2.5 (10.5%) 5.4 ± 0.4 (-13.5%) 
3 voxels 106.8 17.0 6.3  111.9 ± 7.3 (4.8%) 30.1 ± 3.0 (77.2%) 3.7 ± 0.2 (-40.6%) 
s.3.2 
2 voxels 66.8 17.0 3.9  58.4 ± 9.1 (-12.6%) 16.1 ±3.1 (-5.5%) 3.7 ± 0.2 (-6.7%) 
3 voxels 66.8 17.0 3.9  73.1 ± 9.7 (9.4%) 30.9 ± 4.7 (81.7%) 2.4 ± 0.1 (-39.5%)  
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On the noisy dataset, the underestimation of VOI size varied between a few percent and as 
low as -31% in case s.1.3 (homogeneous uptake pattern, lowest TBR). The lower the TBR, 
the more the overlap between background and target intensity due to noise which 
contaminated both object and background and prevented recovering the totality of the ground 
truth area of the target. In the case of noisy homogeneous uptake patterns, smoothing the 
images much more (3 voxels vs. 2 voxels) yielded better results in terms of area recovery, 
which might be due to the reduction in noise level. TLAGT was recovered within a few 
percent (± 13%) in all cases. 
 
As previously in the case of the modified Sierpinski carpets, the variation in FD estimates 
across moment Q (for the plateau) between 30 and 100 was negligible (mean and std 
coefficients of variation) across all FD computation boxes (N = 1,152) (Table 6.12). 
 
 
Table 6.12 – Coefficients of variation of FD estimates for a range of moments Q between 30 and 
100 (synthetic simulations). Statistics were computed across all cases, image types (noiseless and 
noisy) and smoothing used in this section (N = 1,152, FD computation boxes). 
 
 
 
 
 
 
  
Feature mean std  min max 
Dq 0.42% 0.20% 0.00% 0.70% 
Area(Q) 1.43% 0.67% 0.00% 2.31% 
TLA(Q) 0.31% 0.22% 0.00% 0.98% 
I(Q) 1.10% 0.53% 0.00% 1.93% 
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 Effects of noise and FD_BGbox parameters on recovery of 6.3.4. 
intensity-volume features 
On noiseless datasets IBG (or SUVBG) can be perfectly estimated by positioning a square box 
(BG_box) in background (FD_BGbox implementation). Therefore, one is merely dealing with 
recovering the actual spatial area filled in by the object and the effect of resolution (and/or 
PVEs). However, when considering more realistic synthetic simulations, which incorporate 
noise, the FD estimates (AreaFD, SUVFD and TLAFD) might be affected by errors in the mean 
background intensity estimation (SUVBG). This error might also propagate differently as a 
function of how the user defines the square box in background (BG_box). 
 
This was illustrated on the noisy synthetic simulation datasets smoothed with a 3-voxel 
FWHM Gaussian filter. For the purpose of this study, a wider “biggest” box (32x32 pixels) 
was defined so as to cover a bigger range of possible FD computation boxes and to measure 
the propagation of ΔSUVBG on the estimates as a function of the size of the FD computation 
boxes. The same BG_box (of size 8x8 pixels) was positioned at three locations in the 
synthetic images so as to study how the error propagates as a function of the percent error in 
SUVBG estimate (Table 6.13). The FD estimates (AreaFD, SUVFD and TLAFD) were also 
computed on noiseless images but with an error introduced in the mean background intensity 
estimate (using IBG estimates at each of the three BG_box locations on noisy images), so as to 
study the impact of this error alone. Results were compared to the FD_Delin implementation. 
 
Table 6.13 – SUVBG estimates computed in a BG_box of size 8x8 pixels at three locations in the 
images and percent error (SUVBG (GT) = 1). The same regions were used for homogeneous and 
rim-core-like uptake patterns. Different regions were used for hot-spot-like uptake patterns.   
 
 BG_box in position 1 BG_box in position 2 BG_box in position 3 
homogeneous  
and rim-core-like 
uptake patterns 
1.04 (+3.7%) 0.94 (-5.9%) 1.00 (-0.15%) 
hot-spot-like  
uptake pattern 
1.05 (+5.1%) 0.98 (-2.3%) 0.93 (-6.7%) 
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Figure 6.11 – Percent error in TLA recovery for BG_box at three different locations (left, 
middle, right columns) and as a function of FD computation box size. In each graph, results are 
given as mean TLA estimates recovered over FD computation boxes of identical size and for Q = 50. 
Results are compared for the FD_BGbox implementation in noiseless images (plain black line) and 
noisy images (plain dark-grey line). Results from the noiseless dataset but with a biased estimate of 
SUVBG (FD_BGbox implementation) are shown by the black dashed line. Results are compared to 
TLA estimates recovered using the FD_Delin method on both noiseless (light grey dotted line) and 
noisy (light grey continuous line) datasets. Results for case s.1.1 (A, B and C), case s.1.3 (D, E and 
F), case s.2.2 (G, H and I) and for case 3.1(J, K and L) for BG_box_pos1, BG_box_pos2 and 
BG_box_pos3 (respectively). 
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Results (Figure 6.11 and Appendix C) showed that the error in the recovery of TLA, for the 
FD_BGbox implementation, depended on the error in mean background estimate (SUVBG) 
(see Figure 6.11: left, middle and right columns). The absolute error increased with the 
percent error in SUVBG estimate. When this error was minimal, very similar results were 
obtained across techniques (FD_BGbox and FD_Delin implementations), across FD 
computation box sizes and on noisy and noiseless datasets. For instance, TLA was recovered 
within ± 15% (for FD computation box widths of 14 to 28 pixels) for both the homogeneous 
and rim-core-like uptake patterns for BG_box in position 3 (ΔSUVBG = - 0.15%) (Figure 
6.11: C, F and I and Appendix C: C, F and I). For larger errors in SUVBG, (e.g. Figure 6.11: 
A, B, D, E, G and H), the absolute error in TLAFD increased with FD computation box size as 
the ratio of background to lesion voxels increased. The error was largely explained by the 
error in SUVBG estimate (see results for noiseless images with biased SUVBG estimates in 
Figure 6.11, black dashed-line). In the case of an initial underestimation of SUVBG mean 
intensity, the error in TLA increased to greater positive errors for greater FD computation 
box sizes (e.g. Figure 6.11, A, D and G) – and in the case of an initial overestimation of 
SUVBG, decreased to greater negative errors for greater FD computation box sizes (e.g. 
Figure 6.11, B, E and H). The errors sometimes became very large for big box sizes. 
However, the FD_BGbox implementation generally gave good results for small FD 
computation boxes (within 15% error). The FD_Delin implementation yielded the same 
results (or very similar) to FD_BGbox implementation on noiseless datasets. Unlike the 
FD_BGbox implementation, the FD_Delin implementation minimised the percent error in 
TLA recovery on noisy images and was not affected by the size of the FD computation 
boxes.  
 
In conclusion, in order to recover TLA with reasonable accuracy using the FD_BGbox 
technique, it is necessary to minimise the amount of background voxels in the FD 
computation boxes, and therefore the size of the “biggest” square-box, to a reasonable size 
around the target. In addition, it is advisable to define more than one background box to 
obtain a more reliable estimate of the mean background intensity; this would be particularly 
easy to implement on 3D images (where at least one background box can be defined in each 
slice). Finally, the alternative implementation, the FD_Delin method, can be used to derive 
the FD estimates while overcoming the limitations described above. It has two main 
advantages: it only takes into account those voxels inside the contour and corrects their 
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intensity for PVEs. Further, it removes the subjectivity in defining a BG_box elsewhere in the 
image.  
 
 Effect of object size and image resolution 6.3.5. 
The dual effects of object size and image resolution on the recovery of FD estimates were 
investigated using the hot-spot-like uptake pattern (case s.3.1, see Table 6.2). A magnified 
version of s.3.1 was obtained by splitting each pixel of the original image (s.3.1) into four 
identical pixels (Figure 6.12). This resulted in an object of size AreaGT_mag = 4 x AreaGT_origi = 
68 pixels and of TLAGT_ mag = 4 x TLAGT_origi. Previously, the error in TLA recovery was 
much more for the hot-spot-like uptake pattern objects than for other objects (around 15-
20%). Results presented in Figure 6.13 illustrate the effect of object size/image resolution 
dependency on the accuracy of the recovery. TLAGT was recovered within ± 15% for a 
smoothing between 1 and 6 pixels (FWHM). The results also suggest that TLA slightly 
increases with a decrease in resolution for an object embedded in non-zero background.  
  
Figure 6.12 – Effect of object size and image resolution on synthetic hot-spot-like uptake 
patterns. Hot-spots were filled in with intensity SUVGT = 6 and embedded in constant background 
(SUVBG = 1). Original images (first row, case s.3.1) of size 64x64 pixels were cropped to 14x14 
pixels. Magnified images (second row) of size 128x128 pixels were cropped to 28x28 pixels. (A) and 
(B) are the original and magnified images (no blur). (B) and (E) were obtained by smoothing the 
images (A) and (B) respectively with FWHM = 2 voxels. (C) is image (A) blurred with FWHM = 3 
voxels and (F) is image (D) with FWHM = 6 voxels.  
6.3 – Results               179 
 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
C 
 
 
 
 
 
 
Figure 6.13 – Percent error in recovery of mean FD estimates (A: TLAFD, B: AreaFD, C: SUVFD) 
as a function of object size and image resolution (smoothing from 1 to 6 voxels FWHM), for the 
same object of size 17 pixels (case s.3.1, 64x64 pixels image) and (4x) magnified size 68 pixels 
(128x128 pixels). Results are given as mean estimate values computed across a range of FD 
computation box sizes and positions (from 14 to 20 pixels width in the 64x64 pixels image and from 
28 to 40 pixels width in the 128x128 pixels image).  
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 Realistic PET simulations 6.3.6. 
Next the method was evaluated on more realistic PET simulations with inserted neoplastic 
lesions (see Section 6.2.2.3).  The impact of reconstruction parameters (number of iterations), 
VOI size and TBR on the results are presented in this section. Further, the results obtained via 
the FD_BGbox and FD_Delin implementations are compared. A reference image also 
provided the opportunity to study the tissue fraction effect and the error of the method itself 
on the results. 
  
6.3.6.1.  Recovery of FD estimates 
Examples of users’ input parameters on the realistic PET simulations in one slice of lesion 2 
are given in Figure 6.14 (FD_BGbox implementation) and Figure 6.15 (FD_Delin 
implementation), alongside an example of multifractal Rényi (Dq, Q) spectrum and 
AreaFD(Q) and TLAFD(Q) estimates.  
 
On the reference image, all GT estimates (VOLGT, SUVGT and TLAGT) were recovered 
within less than 15% error (Table 6.14). The biggest relative errors in volume recovery were 
for the smallest lesions of 10mm diameter (lesions 1 and 4). This purely illustrated the 
performance of the method on an image that is affected by PVEs due to the grid sampling 
(tissue-fraction effect) and the error of the method itself. On the reference image, the method 
underestimated all volumes which were contaminated by PVEs, resulting in overestimation of 
the SUVmean values (up to 6.5% for lesions 2 to 6 and 12.22% for lesion 1). Relative errors 
for TLA were less than ± 7% in all cases. No trends were observed with regard to TBR. 
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Figure 6.14 – Example of user’s inputs and Filling-Factor Software outputs (FD_BGbox 
implementation).  PET images were reconstructed using 15 iterations (MCIR) and post-filtered using 
a 4mm FWHM Gaussian filter. Examples are given for slice 50 of lesion 2. Example of user’s input: 
“biggest”, “smallest” bounding square boxes and “BG_box” (A). Mean and std (Dq, Q) spectrum for 
FD computation boxes of size 15x15 pixels (B). Mean and std estimates of in-slice AreaFD(Q) (C) and 
TLAFD(Q) (D) computed across all FD computation box sizes and positions used. Vertical axes for 
(C) and (D) are in logarithmic scale for display.  
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Figure 6.15 – Example of user’s inputs and Filling-Factor Software outputs (FD_Delin 
implementation).  PET images were reconstructed using 15 iterations (MCIR) and post-filtered using 
a 4mm FWHM Gaussian filter. Examples are given for slice 50 of lesion 2. Example of user’s input: 
“biggest” bounding square boxes and “Mask”: rough lesion manual contouring (A). Mean and std 
(Dq, Q) spectrum for FD computation boxes of size 15x15 pixels (B). Mean and std estimates of in-
slice AreaFD(Q) (C) and TLAFD(Q) (D) computed across all FD computation box sizes and positions 
used. Vertical axes for (C) and (D) are in logarithmic scale for display.  
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Table 6.14 – FD estimates (BG_box implementation) recovered on the reference image. Results 
were given for Q = 50. 
 
 
Results of the recovery of TLA estimates on reconstructed PET images are presented in 
Figure 6.16. The PVEs in the PET images in this case were due to the tissue fraction effect, 
the finite resolution of the scanner and the post-filtering applied to the images. A plateau was 
reached after 5 iterations for all datasets yielding stable results in the recovery of TLA 
estimates. The percent error was less than 10% for lesions 2 to 6 on images post-filtered and 
motion-corrected and around 15% for lesion 1. PET images not corrected for motion (NMC) 
yielded larger errors in the estimates recovered.  
 
The variation in FD estimates across moment Q (for the plateau) between 30 and 100 was 
negligible across all FD computation boxes, lesions and reconstruction parameters (Table 
6.15). 
 
  
  Ground truth (GT) 
 
Recovered (mean and % error) 
Lesion  Location 
VOLGT 
(cm3) 
SUVmean GT 
(g/mL) 
TLAGT 
(g) 
 
VOLFD (cm
3) 
SUVFD 
(g/mL) 
TLAFD 
(g) 
Lesion 1 Lung 0.52 4.5 2.36  
0.45 
(-14.41%) 
5.05 
(+12.22%) 
2.26 
(-3.99%) 
Lesion 2 Lung 2.14 4.5 9.65  
2.14 
(-0.41%) 
4.66 
(+3.45%) 
9.94 
(+3.02%) 
Lesion 3 Lung 2.14 7.5 16.08  
2.01 
(-6.25%) 
7.93 
(+5.67%) 
15.93 
(-0.94%) 
Lesion 4 Liver 0.52 6.5 3.40  
0.46 
(-12.05%) 
6.88 
(+5.85%) 
3.15 
(-6.95%) 
Lesion 5 Liver 2.14 6.5 13.94  
1.90 
(-11.21%) 
6.92 
(+6.46%) 
13.18 
(-5.48%) 
Lesion 6 Liver 2.14 9.5 20.37  
19.52 
(-9.00%) 
10.07 
(+6.01%) 
19.66 
(-3.53%) 
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Figure 6.16 – Mean percent error in TLA recovery relative to ground truth (realistic PET 
simulations, FD_BGbox implementation). Results are presented for images reconstructed for a 
range of iterations using the OSEM reconstruction method both without motion correction (NMC) and 
incorporating the motion-compensated image reconstruction (MCIR) method. Images were post-
filtered using a 4mm Gaussian FWHM filter. Lesion 1 (A), Lesion 2 (B), Lesion 3 (C), Lesion 4 (D), 
Lesion 5 (E) and Lesion 6 (F). 
 
 
Table 6.15 – Coefficients of variation of FD estimates for a range of moments Q between 30 and 
100 (realistic PET simulations). Statistics were computed across all cases and image reconstruction 
types (MCIR, NMC, number of iterations) (N = 19,250 FD computation boxes). 
  
Feature mean std min max 
Dq 0.52% 0.12% -1.05% 0.98% 
Area(Q) 1.82% 0.29% 0.02% 2.79% 
TLA(Q) 0.57% 0.34% 0.00% 1.69% 
I(Q) 1.21% 0.24% 0.01% 2.05% 
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Results obtained with the FD_Delin implementation on images reconstructed with 15 
iterations are presented in Table 6.16. Results indicated that TLA was recovered within 16% 
error across all lesions. Using the same regions (rough mask contour and “biggest” square 
box) on 4mm Gaussian post-filtered images led to equally good results. VOLFD estimates 
were significantly lower on 4mm versus 5mm post-filtered images (paired t-test, p = 0.003), 
SUVFD was significantly higher (paired t-test, p = 0.001), while no statistical difference was 
observed for TLAFD (Paired t-test, p = 0.068).  
 
Table 6.16 – TLAFD, VOLFD and SUVFD mean values recovered (and percent error) using the 
FD_Delin implementation. Results are given for Q = 50 on PET images (MCIR) reconstructed using 
15 iterations and post-filtered using a 4mm or 5mm FWHM Gaussian Filter.  
 
Lesion Post-Filt 
TLAFD 
(g) 
TLAFD 
% error 
VOLFD 
(cm
3
) 
VOLFD 
% error 
SUVFD 
(g/mL) 
SUVFD 
% error 
Lesion 1 4 mm 2.03 -13.75% 0.58 11.47% 3.48 -22.61% 
 
5 mm 1.93 -18.07% 0.64 23.16% 2.99 -33.47% 
Lesion 2 4 mm 9.33 -3.37% 2.14 -0.37% 4.36 -3.01% 
 
5 mm 9.16 -5.13% 2.29 6.88% 3.99 -11.24% 
Lesion 3 4 mm 15.32 -4.74% 2.10 -2.14% 7.30 -2.65% 
 
5 mm 15.12 -5.98% 2.28 6.11% 6.65 -11.39% 
Lesion 4 4 mm 3.22 -5.31% 0.50 -4.42% 6.44 -0.91% 
 
5 mm 3.23 -5.10% 0.60 14.13% 5.41 -16.84% 
Lesion 5 4 mm 12.23 -12.25% 1.78 -16.96% 6.87 5.67% 
 
5 mm 12.48 -10.49% 2.04 -4.96% 6.12 -5.83% 
Lesion 6 4 mm 18.42 -9.54% 1.93 -10.06% 9.55 0.50% 
 
5 mm 18.45 -9.36% 2.16 0.58% 8.55 -9.96% 
 
6.3.6.2.  Effects of partial volume correction (PVC) on FD estimates  
Previous results indicated that AreaFD and SUVFD were affected by resolution (and/or PVEs) 
in the images as illustrated on fractal and synthetic simulations (Sections 6.3.2 and 6.3.3). 
The finite spatial resolution of the scanner is one of the main sources of PVEs in 
reconstructed PET images. The influence of PVE correction (PVC, based on Lucy-
Richardson deconvolution with wavelet denoising) on the FD estimates recovered via the 
Filling-Factor Software (FD_BGbox implementation) was studied. The effect of PVC on 
lesion 2 (MCIR, 15 iterations) is illustrated in Figure 6.17. Inversely to the effect of increased 
smoothing, applying PVC by specifying successive larger point spread functions (PSF) for 
the scanner (4.3mm and 5mm) led to the radiotracer uptake being increasingly concentrated.  
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These visual observations were confirmed by the feature value recovered for VOLFD and 
SUVFD (Table 6.17) across image resolutions (no PVC, 4.3mm PSF and 5mm PSF), with a 
consistent decrease in VOLFD (and increase in SUVFD) for increasing PSF. Percent error in 
VOLFD only decreased with PVC for lesions inserted into low activity background (lesions 1 
and 2 in lung tissue). Percent error in VOLFD increased for lesions inserted into a hotter 
background (liver tissue) leading to greater underestimation of the ground truth lesion size for 
greater PSFs. Reasonably stable values of TLAFD were obtained for all lesions across the 
different image resolutions. The ground truth TLA was recovered within ± 15% in all cases. 
Figure 6.17 – Realistic PET images corrected for PVEs. Illustration with one slice of lesion 2. 
Images were reconstructed with OSEM using 15 iterations with incorporated motion-correction 
(MCIR) and were post-filtered (4mm FWHM Gaussian filter). Original image (no PVC) (A), image 
corrected for PVEs (PSF = 4.3mm) (B) and C: image corrected for PVEs (PSF = 5mm) (C).  
 
A statistically significant difference in VOLFD was observed between original images (no 
PVC) and corrected images (4.3mm PSF) (paired-sample t-test, p = 0.010), while statistical 
significance was almost reached between corrected images using a 4.3mm and 5mm PSF (p = 
0.055) illustrating the sensitivity of VOLFD to even small changes in resolution. Similarly, a 
statistically significant difference was measured in SUVmean between original images and 
corrected images (4.3mm PSF) (paired-sample t-test, p = 0.005) as well as between 4.3mm 
and 5mm PSF corrected images (p = 0.014). In contrast, no statistically significant 
differences were observed for TLAFD between original and corrected images (4.3mm PSF), 
and between 4.3mm and 5mm PSF corrected images (p = 0.7 and p = 0.72 respectively). 
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Table 6.17 – Impact of image resolution (PVC) on FD estimates and percent error. Estimates are given for Q = 50.  Images were reconstructed with 
OSEM using 15 iterations, motion-corrected (MCIR) and post-filtered (4mm FWHM Gaussian Filter).    
 
Lesion 
VOLFD (cm
3
)  SUVFD (g/mL)  TLAFD (g) 
No PVC 4.3 mm 
PSF 
5mm 
PSF 
 No PVC 4.3 mm 
PSF 
5mm 
PSF 
 No PVC 4.3 mm 
PSF 
5mm 
PSF 
1 
0.62 
(+17.7%) 
0.60 
(+14.0%) 
0.55 
(+5.7%) 
 
3.3  
(-27.8%) 
3.7  
(-18.4%) 
4.0  
(-12.2%) 
 
2.00 
(-15.0%) 
2.19  
(-7.0%) 
2.19 
(-7.1%) 
2 
2.46 
(+14.9%) 
2.24 
(+4.6%) 
2.06 
(-4.2%) 
 
4.1  
(-8.0%) 
4.7  
(+4.2%) 
5.1  
(+12.4%) 
 
10.20 
(+5.6%) 
10.53 
(+9.1%) 
10.39 
(+7.7%) 
3 
2.30 
(+7.1%) 
2.05 
(-4.4%) 
1.85 
(-13.6%) 
 
7.0  
(-7.1%) 
8.1  
(7.7%) 
8.9  
(19.0%) 
 
16.02 
(-0.40%) 
16.60 
(+3.2%) 
16.53 
(+2.8%) 
4 
0.56 
(+7.4%) 
0.42 
(-20.4%) 
0.42 
(-19.4%) 
 
6.4  
(-1.9%) 
8.1  
(+24.4%) 
8.2  
(+26.2%) 
 
3.58 
(+5.31%) 
3.37 
(-1.1%) 
3.46  
(+1.7%) 
5 
1.72 
(-19.9%) 
1.32 
(-38.7%) 
1.29 
(-39.9%) 
 
7.4 
(+13.4%) 
9.0 
(+38.1%) 
9.2  
(+41.8%) 
 
12.67 
(-9.1%) 
11.80 
(-15.4%) 
11.87 
(-14.9%) 
6 
1.89 
(-11.7%) 
1.53 
(-28.5%) 
1.48 
(-31.0%) 
 
9.4  
(-0.6%) 
11.3  
(+18.7%) 
11.7  
(+22.9%) 
 
17.88 
(-12.3%) 
17.30  
(-15.1%) 
17.27 
(-15.3%) 
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 Clinical validation of the method 6.3.7. 
6.3.7.1.  Robustness of the approach 
The FD algorithm was applied to the clinical 
18
F-FLT PET dataset described previously. A 
total of 10 lesions (6 primaries, 1 lung and 1 rib metastasis, 1 axillary and 1 pre-tracheal 
node) in 8 patients could be included in this study. FD estimates (VOLFD, SUVFD and TLAFD) 
for individual lesions and scans, as well as relative differences between baseline and 
validation scans are given in Table 6.18. 
 
All volumes were recovered within a variability of approximately ±15%, except for patient 7 
(+ 33%), for whom the tumour volume was hardly visible. Repeatability results (relative 
differences and ICC coefficients) for the three estimates (VOLFD, SUVFD and TLAFD) are 
given in Table 6.19. The results were stratified as follows: including/excluding patient 7 for 
whom large variations in SUV uptake were observed both with the FD method (+44%, Table 
6.18) and using the mask delineated by the clinician (+50%, Table 6.20). This variability at 
baseline might be due to either some biological change that happened in this lesion between 
the two successive scans, and/or to a problem of detectability with the PET scanner. ICC 
results are presented both including and excluding the primary lesion of patient 4 for TLAFD 
and VOLFD as the lesion was very large in comparison to other primary tumours (Table 6.19). 
When excluding patient 7, the variability across all lesions (mean ± std) was 4.8% ± 6.0% for 
VOLFD, 4.7% ± 12.2% for SUVFD and 9.5% ± 13.0% for TLAFD (Table 6.19). 
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Table 6.18 – FD estimates (VOLFD, SUVFD and TLAFD) recovered in individual lesions and relative differences (baseline versus validation 
scan). The estimates were computed on OSEM reconstructed PET images at 60 minutes and 5mm post-filtered images. The analyses were computed on 
all slices in which the tumour volumes were visible.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Table 6.19 - Repeatability results for FD estimates (VOLFD, SUVFD and TLAFD).  
 
 
VOLFD (cm
3
)  SUVFD (g/mL)  TLAFD (g) 
Patient Tissue 
Relative 
Differences (%) ICC 
 Relative 
Differences (%) ICC 
 Relative 
Differences (%) ICC 
mean std  mean std  mean std 
with  
patient 7 
tum + met 4.93% 12.74% 1 (0.99 w/o p4)  8.58% 17.62% 0.94  16.68% 23.35% 1 (0.96 w/o p4) 
tum 9.3% 12.9% 1 (0.99 w/o p4)  7.6% 20.4% 0.95  16.4% 30.5% 1 (0.98 w/o p4) 
without 
patient 7 
tum + met 1.81% 8.55% 1 (0.99 w/o p4)  4.62% 13.15% 0.94  10.25% 12.21% 1 (0.96 w/o p4) 
tum 4.6% 6.3% 1 (0.99 w/o p4)  0.2% 10.8% 0.98  4.8% 12.4% 1 (0.96 w/o p4) 
tum = tumour, met = metastasis, w/o p4 = without patient 4 
  
VOLFD (cm
3
)  SUVFD (g/mL)  TLAFD (g) 
Patient Tissue Baseline Validation 
Rel. 
Diff. 
(%) 
 Baseline Validation 
Rel. 
Diff. 
(%) 
 Baseline Validation 
Rel. 
Diff. 
(%) 
3 primary 72.3 72.0 0.4%  2.64 2.87 -8.6%  190.6 207.0 -8.3% 
4 primary 477.4 494.9 -3.6%  6.35 6.01 5.4%  3,031.7 2,976.3 1.8% 
11 primary 69.8 63.7 9.2%  2.22 2.55 -13.9%  154.7 162.2 -4.7% 
14 primary 31.7 28.2 11.8%  4.12 3.76 9.1%  130.7 106.1 20.8% 
15 primary 20.0 19.0 5.2%  3.69 3.36 9.2%  73.9 64.0 14.3% 
7 primary 11.4 8.2 33.0%  2.53 1.61 44.2%  28.9 13.2 74.5% 
2 lung met 15.0 13.5 10.7%  2.76 2.5 10.0%  41.4 33.6 20.7% 
4 rib met 38.4 38.3 0.1%  6.53 5.24 21.9%  250.5 200.9 22.0% 
10 axillary node 14.9 12.8 -15.2% 
 7.40 8.29 -11.5%  110.2 106.2 3.72% 
10 pre-tracheal node 5.2 5.1 -2.3%  5.36 4.38 20.0%  27.8 22.3 21.95% 
met = metastasis, Rel. Diff. = Relative Differences ( baseline vs. validation scans) 
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6.3.7.2.  SUVFD versus SUVmean and SUVmax (mask) 
Because of pronounced PVEs in the first and last slices in which the tumour is visible, 
clinicians often omit these slices in the delineation process. Therefore it was not possible to 
compare VOLFD and TLAFD to the same metrics (VOI size and TLA) derived from the 
manual contour drawn by the clinician. Rather the actual SUVmean and SUVmax values in the 
mask delineated by the clinician were compared to the SUVFD values recovered (Table 6.20). 
 
For all lesions, SUVFD was greater than SUVmean and less than SUVmax (with the exception of 
the lung metastasis for which SUVFD and SUVmean were almost equal). The large difference 
between SUV recovered and SUVmean for the primary breast tumour of patient 4 can be 
explained by a large necrotic core (which was included in the mask used in this section). 
Relative differences in feature values within individual lesions on successive scans (baseline 
and validation) were consistent for SUVFD and SUVmean. Lesion 7 was hardly visible. The 
relative difference between the two successive scans was +40.4% and +50.3% for SUVFD and 
SUVmean respectively. This might be due to lesion detectability (low uptake) and/or to some 
biological change that occurred in this lesion between the two scans without any intervening 
treatment.  
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Table 6.20 – Comparison of SUVFD with SUVmean and SUVmax (manual delineation). For the purpose of comparison, only those slices in which the 
tumour was delineated by the clinician were used for SUVFD estimation in this Table. “Dev from SUVmean (%)” and “Dev from SUVmax (%)” were the 
percent deviations of SUVFD from the traditional metrics (SUVmean and SUVmax). Repeatability metrics were given as the relative differences (%) between 
baseline and validation scans for individual lesions.  
  FD method  Traditional method 
    SUVFD  SUVmean SUVmax 
Patient 
Scan 
number 
Tissue 
 
Value 
Dev from  
SUVmean 
(%) 
Dev from  
SUVmax 
(%) 
Repeatability 
Relative 
Differences 
(%)  
 
Value  
Repeatability 
Relative 
Differences 
(%) 
Value 
Repeatability 
Relative 
Differences 
(%) 
3 1 primary  2.83 + 32.9% - 47.1% 
-2.4% 
 2.13 
-16.0% 
5.35 
-5.8% 
3 2 primary  2.90 + 16.0% - 48.9%  2.50 5.67 
4 1 primary  6.50 + 76.6% - 29.3% 
-3.3% 
 3.68 
-3.2% 
9.20 
-17.4% 
4 2 primary  6.72 + 76.8% - 38.6%  3.80 10.95 
7 1 primary  2.53 + 10.5% - 46.1% 
+ 40.4% 
 2.29 
+ 50.3% 
4.69 
+ 54.9% 
7 2 primary  1.68 + 22.6% - 37.1%  1.37 2.67 
11 1 primary  2.30 + 25.0% - 40.6% 
-12.6% 
 1.84 
-15.5% 
3.87 
-20.8% 
11 2 primary  2.61 + 21.4% - 45.3%  2.15 4.77 
14 1 primary  4.39 + 2.8% - 44.1% 
+ 5.9% 
 4.27 
+ 11.4% 
7.85 
+ 13.6% 
14 2 primary  4.14 + 8.7% - 39.6%  3.81 6.85 
15 1 primary  4.90 + 78.8% - 18.6% 
+ 12.8% 
 2.74 
+ 5.2% 
6.02 
+ 9.6% 
15 2 primary  4.31 + 65.8% - 21.2%  2.60 5.47 
2 1 lung met  2.76  - 2.8% - 51.2% 
+ 9.9% 
 2.84 
+ 14.3% 
5.66 
+ 31.3% 
2 2 lung met  2.50 + 1.6% - 39.5%  2.46 4.13 
4 1 rib met  8.46 + 5.1% - 36.5% 
+ 29.9% 
 8.05 
+ 32.5% 
13.33 
+ 31.3% 
4 2 rib met  6.26 + 7.9% - 35.6%  5.80 9.72 
10 1 axilla  8.05 + 71.0% -3.2% 
-9.1% 
 4.71 
-10.5% 
8.32 
-10.8% 
10 2 axilla  8.82 + 68.7% -4.8%  5.23 9.26 
10 1 pre-tracheal  5.90 + 50.7% -1.0% 
+ 25.8% 
 3.92 
+ 19.7% 
5.96 
+ 17.4% 
10 2 pre-tracheal  4.56 + 41.7% -9.1%  3.21 5.01 
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6.4.  Summary 
The results in this chapter have demonstrated that a method based on a fractal approach is 
useful to estimate the space-filling properties of neoplastic lesions in PET. The approach can 
be used to recover the TLA in a neoplastic lesion.    
 
The technique was validated on a range of fractal objects (modified Sierpinski carpets) and 
showed that for images with a resolution comparable to PET images (smoothed with a 2- to 
3- voxel FWHM Gaussian filter) the TOI was recovered within less than 10%. On noisy 
synthetic simulations, realistic PET simulations and the clinical 
18
F-FLT PET dataset, TLA 
was generally recovered within 16%. 
 
The results suggested that using the plateau of the (Dq, Q) spectrum is a sufficient 
approximation for images characterised by a resolution similar to PET (blurred Sierpinski 
carpets, synthetic simulations, and PET images). However, results showed that in the case of 
heterogeneous objects not contaminated (or less contaminated) by PVEs, using the plateau, 
which only takes into account the most concentrated uptake regions, could lead to 
underestimation of the actual apparent volume of the object, leading to an underestimation of 
the TLA. Therefore this means that the technique as proposed in this chapter should only be 
applied to regularised PET images (as is often the case).  
 
Results demonstrated that AreaFD (and VOLFD in 3D images) systematically increased (and 
IFD or SUVFD decreased) with a lowering of the image resolution (on Sierpinski objects, 
synthetic simulations and realistic PET simulations) and with different levels of PVEs 
(through image smoothing, post-filtering and PVC). The FD method provided stable 
estimates of TOI (or TLA) across smoothing and/or for a range of resolutions typical of PET 
imaging. This was demonstrated on realistic PET images with ground truth. In thoracic 
lesions, TLA estimates were recovered with good accuracy only after motion correction. The 
method proved to be robust and provided within-lesion variability comparable to manual 
delineation (or slightly better), while the values recovered for SUVFD were between SUVmean 
and SUVmax. 
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Results suggest that the method performs reasonably well in recovering the TLA on 
regularised PET images, while not requiring accurate delineation of the target (no delineation 
for the FD_BGbox implementation and gross delineation for the FD_Delin implementation). 
Further, the results suggest that TLA might be a more robust index than other traditional 
metrics such as SUVmean or MATV measurements across image protocols, institutions, 
scanner type, reconstruction parameters, post-filtering, etc. The method proposed needs to be 
compared to existing methods, especially to a traditional framework: motion correction and 
PVC followed by a robust automatic target segmentation method prior to quantification both 
in terms of accuracy and performance in the clinical setting.   
 
As with any other quantification method, such as volume recovery through a segmentation 
method, the performance of the FD method was affected by TBR, tumour size and noise in 
the images. For instance, for the realistic PET dataset, the sizes of lesions 5 and 6 were 
systematically underestimated, despite the low PET imaging resolution and application of 
PVC. This is likely due to a problem of detectability (low TBR). 
 
Another limitation of the technique is that it does not overcome the limited resolution of PET. 
If an object is too small compared to the image resolution, the FD algorithm performs poorly 
in terms of accuracy of recovery of estimates. Although practical, and not requiring a pre-
processing delineation step, the FD_BGbox implementation should also be used with caution 
– drawing a “biggest” and a “smallest” bounding square box of reasonable size compared to 
the object. BG_box(es) also need(s) to be defined carefully by the user: reasonable size and 
number, and filled in with intensity values similar to the background surrounding the object, 
so as to minimise possible bias in IBG estimates. The technique will need to be validated on 
other PET simulations and clinical datasets, especially on complex cases of heterogeneous 
uptake. 
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Chapter 7.  Discussion 
 
 
 
In this final chapter, the main strengths and weaknesses of the research presented in this 
thesis are discussed within the wider context of PET quantification in oncology. 
Contributions to PET quantification and implications of these findings for future research are 
also discussed.  
 
7.1.  Study strengths 
In Chapter 5, statistical texture analysis was applied to an 
18
F-FLT PET breast cancer patient 
dataset. One of the main strengths of this study was the possibility to select textural features 
at baseline, based on a test-retest dataset, prior to studying associations with clinical 
outcomes. A subset of textural features, selected on test-retest and computed at baseline, 
discriminated between responder and non-responder to neoadjuvant chemotherapy (RECIST 
measurement at 60 days). In addition, a subset of features was able to detect early changes 
associated with the start of therapy that discriminated between the two response groups. This 
is the first time that texture analysis has been applied to a tracer different from 
18
F-FDG and 
to breast cancer patients. Textural features performed better than SUV measurements 
computed on the whole tumour in discriminating between the two response groups. This 
work contributes to the growing literature supporting the potential of texture analysis as a 
useful quantification tool in PET oncology.  
 
In Chapter 6, a new methodology was proposed to recover the apparent space-filling 
properties of lesions in PET imaging affected by PVEs, and for deriving other volume-
intensity features such as SUVmean and TLA. The implementations proposed only required 
limited input from the user and did not require perfect delineation of the tumour lesion. One 
of the main strengths of the method was to provide stable results for TLA at different 
resolutions (given by PVEs contamination and corrections and post-filtering) for a range of 
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datasets including PET images and realistic PET simulations. Results suggest that TLA, 
derived from the FD method, might be a robust index across imaging protocols. In the case of 
the fractal method (Chapter 6), the impact of the number of iterations (OSEM reconstruction) 
on volume, SUV and TLA estimates could be studied on realistic 
18
F-FDG PET simulations. 
Results showed that a plateau was reached after 5 iterations (23 subsets). 
  
7.2.  Study limitations 
7.2.1.  Sample size 
One of the main limitations of the 
18
F-FLT PET and texture analysis study was the small 
sample size, due to the nature of the data that were used (collected for research purpose 
exclusively). As a consequence, it is important to stress that all the results obtained need to be 
confirmed in a bigger dataset for clinical relevance. It was not possible to explore differences 
between histological subtypes, or treatment history (9 patients were treatment naïve and 2 had 
received previous treatment).    
 
The small sample size also meant that the performance of the textural features in 
differentiating between response groups to chemotherapy could only be assessed using 
univariate statistical analyses for a subset of features. This excluded any multivariate analyses 
to control for confounding factors and test which features and combination of features might 
be strong independent predictors of response to treatment and other clinical outcomes. To 
address these limitations, the technique should be further validated on independent and larger 
datasets.  
 
Because of the small sample size, it was also not possible to thoroughly study the impact of 
texture analysis parameter settings on the results. For instance, the influence of the grey level 
quantisation parameter on results was not investigated in this study. Only those variables that 
yielded good repeatability results across the range of quantisation levels on test-retest were 
selected to study associations with response to treatment. It is important to note that statistical 
textural methods such as the GLCM provide average measurements of a textural 
characteristic over the VOI (e.g. ContrastGLCM). In addition, textural features were averaged 
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over the different directions between pairs of voxels in 3D. Therefore if the discriminatory 
power of the features lies between particular pairs of the GLCM matrix, or along specific 
spatial orientations of the images, it could be lost by averaging.  Alternative strategies might 
be more powerful. For instance, Walker et al (1995), suggested weighting each entry of the 
GLCM matrix not only according to a certain textural property to be derived, but also 
according to its discriminatory power in terms of class separability. Such investigations might 
be possible on large 
18
F-FDG PET datasets. Nevertheless results could be specific to dataset, 
patient groups, disease, and image protocol. 
 
The results contained in this work need to be expanded via multi-centre studies for a range of 
diseases, imaging protocols and types of treatment.  
 
7.2.2.  Effects of PET imaging parameters on the results 
7.2.2.1.  Effects of image resolution and PVEs 
As mentioned in Chapter 4, by definition textural features, with the exception of the fractal 
dimension, are resolution dependent. In other words, the PET scanner, imaging protocol, 
acquisition, reconstruction and corrections applied, as well as the pre-processing applied to 
the PET images which have an impact on image resolution (Rousset et al, 2007; Soret et al, 
2007; Erlandsson et al, 2012), are expected to have an impact on textural feature values. 
Therefore, the results obtained in Chapter 5 are parameter specific. In this study, exact 
measurements of the local and varying PSF were not available. PVEs could also constitute a 
confounding factor when assessing percentage change in textural feature values between 
successive PET scans, due to the change in tumour size and shape following therapy.  
 
In Chapter 6, the space-filling properties of an object or a lesion (as measured with AreaFD or 
VOLFD) were shown to be resolution dependent. Therefore, whether the “real” target size is 
recovered depends on the resolution of the images (PVEs, reconstruction parameters, post-
filtering etc.), as well as on other factors such as noise level and TBR. 
  
198  Chapter 7 – Discussion 
 
7.2.2.2.  Effects of patient motion and positioning 
In Chapter 6, the realistic PET simulation study (inserted lesions in thorax area) suggested 
that TLA could be recovered within 15% error on motion corrected images with the FD 
method, whereas the error was quite large when using non-motion-corrected images (up to 
40%). Thus one needs to apply robust corrections in order to recover feature values close to 
the “real” lesion characteristics (ground truth). As a consequence, although the estimates 
recovered via the FD method produced good results in terms of repeatability (
18
F-FLT PET 
dataset) (e.g. mean TLA difference of 10.25% ± 12.21% and ICC ≥ 0.96, excluding patient 
7), it is likely that the recovered TLA values contained other sources of bias (imaging 
protocol, including motion) that could not be corrected for in this study. Similarly, although 
good repeatability was obtained for a subset of textural features (Chapter 5), regular motion 
might have had an effect on textural feature values. 
 
McCall et al (2010) studied the effect of positioning on the apparent PET radiotracer uptake 
in heterogeneous lesions using a phantom and a head and neck simulation study. They 
showed that there was a trade-off between recovering the “true activity” (SUVmax), as 
measured with the recovery coefficient (RC) using iterative reconstruction with minimal 
post-filtering, and minimising the impact of patient (or lesion) positioning on recovery 
through increased smoothing of the images (resulting in lower RC). Lesion position might 
have a strong impact when heterogeneity is used for accurate target segmentation in multi-
modality imaging, for instance to inform dose planning in radiotherapy. Although absolute 
voxel activity values will be affected by patient positioning in the PET scanner, the impact 
might be more limited when intra-tumour heterogeneity is quantified through a global 
approach (e.g. texture analysis), for lesions of reasonable size. By contrast, patient 
positioning is not expected to have an impact on TLA recovered using the FD method.  
 
7.2.2.3.  Effects of image reconstruction parameters (texture analysis) 
Iterative reconstruction algorithms, such as OSEM, require sufficient number of iterations for 
convergence to occur. The rate of convergence of OSEM depends on the activity distribution, 
and as a consequence, the number of iterations necessary is application dependent 
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(Mustafovic et al, 2002). The dependency of SUV measurements on the number of iterations 
has been investigated in the literature (Jaskowiak et al, 2005). One can expect that sufficient 
number of iterations is needed in order to recover intra-tumour heterogeneity and for OSEM 
to provide better spatial information than FBP. This study used PET images that had been 
reconstructed with a large number of iterations. By contrast, FBP did not yield such good 
results, both visually and in terms of statistical discrimination between responders and non-
responders to therapy (Chapter 5). Because of the noise level, it was not possible to compute 
textural analysis on individual time frames for the dynamic scans. Instead, using an average 
of the 
18
F-FLT radiotracer uptake between 30 and 60 minutes provided an average map of 
heterogeneity in the tumour. On the test-retest dataset, eight textural features (CV, 
EntropyFOS, AUC-CSH, EntropyGLCM, Contrast, Dissimilarity, Homogeneity and Complexity) 
had variability below ±30%. This indicates that a subset of textural features could provide 
relatively reliable numerical estimates of intra-tumour heterogeneity at baseline and with a 
limited effect of stochastic noise. However, it was not possible to study the impact of number 
of iterations on textural feature values or on discrimination between clinical outcomes 
(Chapter 5), as raw data for the 
18
F-FLT PET scans were not available.  
 
7.2.2.4.  Target segmentation 
In Chapter 5, textural features were computed on lesions manually delineated by a clinician, 
with the aim of including the whole lesion (full extent of intra-tumour heterogeneity). 
However, manual segmentation has been shown to suffer from intra- and inter-observer 
variability (Hatt et al, 2010). In addition, heterogeneity (Hatt et al, 2011b) and imaging 
parameters (Cheebsumon et al, 2011) have been shown to affect delineation results 
depending on the technique employed, which is likely to affect textural feature values. One 
would expect automated segmentation methods such as FLAB (Hatt et al, 2009), which can 
be used on heterogeneous lesions, to be the best techniques currently available for this task 
(e.g. in contrast with thresholding approaches). Studies are needed to assess the impact of 
tumour contouring method on the predictive and prognostic performance of textural 
descriptors.   
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In Chapter 6, the target volumes (VOLFD) and TLAFD recovered via the FD method were 
essentially compared to ground truth values. It would be of interest to study how the results 
compare to robust automatic segmentation methods at different resolutions.  
  
7.2.3.  VOI size and target to background ratio 
The results in Chapter 5 demonstrated an association between VOI size and textural results 
(Section 5.3.6.1). This association is likely due to two causes: lesions have to be large enough 
so that heterogeneity is both detectable at the resolution of PET imaging and is present at the 
biological level (i.e. at the scale of the whole lesion). In addition, due to the statistical nature 
of the textural analysis techniques, estimates of textural features are also expected to be more 
robust when an increased number of points are used in the computation (see results in Section 
5.3.6.2). Results also showed that injected dose was negatively associated with VOI size. One 
can expect that a lower injected dose results in reduced contrast (or TBR), leading to lower 
resolution in the PET images and therefore an increase in VOI size.  This effect might be 
more important for tracers targeting specific functions (e.g. such as 
18
F-FLT) than for 
18
F-
FDG because of a lower uptake. Use of a greater injected dose, such as 15.21 MBq/kg, has 
been reported in the literature (e.g. Everaert et al, 2003). A typical European adult patient 
weighing 70.8 kg (Walpole et al, 2012) would require an injected dose of around 1,077 MBq, 
which is 3.5 times more than the average injected dose in this 
18
F-FLT PET study (302 MBq). 
The low resolution of PET also limits parameter settings such as the distance d between 
paired voxels in the GLCM method. As illustrated in the section on GLCM distance d 
(Section 5.3.7.3), it is not practical to set this parameter to values greater than 1 for VOIs of 
less than 1,000 voxels in size – otherwise the computation includes too few voxels from the 
original VOI and one risks obtaining meaningless feature values.    
 
Lesion size also affected the FD estimates (Section 6.3.5). FD estimates were recovered with 
a better accuracy for higher TBR, while lower TBR and noise could lead to underestimation 
of Area and TLA. 
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7.3.  Comparison with existing Literature 
7.3.1.  Texture analysis  
Texture analysis has shown potential for the non-invasive monitoring and assessment of 
intra-tumour heterogeneity and response to treatment, across radiotracers, cancer types and 
therapies. Tixier et al (2012) found that 3 of 24 features they studied (namely EntropyGLCM, 
Homogeneity and Dissimilarity) were characterised by repeatability limits below ±30%. 
These features fell within the same limits of repeatability in this study, along with 4 other 
textural features. Tixier et al also found that limits of repeatability for SUV measurements 
and Skewness fell below ±60%, similar to the findings presented in Chapter 5. However, CV 
yielded superior results in this study (limits of repeatability: -9.70% to +6.77% versus -43.2% 
to +51.3%). Repeatability of the GLSZM features SmallZone, Zonelogl and Szonelogl was 
poor in both studies (limits of repeatability ≥ ±100%). Tixier et al (2012) obtained better 
repeatability results for other GLSZM features in contrast to this study. This might suggest 
that repeatability of a subset of textural features is independent of the radiotracer, cancer type 
and protocols used. However, different textural features were associated with response to 
treatment and survival in this study (Chapter 5) and in 
18
F-FDG PET studies applied, for 
instance, to oesophageal cancer (Tixier et al, 2011) or NSCLC (Vaidya et al, 2012; Cook et 
al, 2013). It is important to note that 
18
F-FLT and 
18
F-FDG target two different biological 
processes. In a recent study comparing the uptake of the two radiotracers in tumours grown in 
mice, Bass et al (2012) found a low spatial correlation between the two radiotracers. This 
suggests that the underlying spatial heterogeneity of the two functional processes in these 
tumours differed. If this is the case, we can reasonably expect textural feature measurements 
(as indices of this heterogeneity) to depend on the biological function (and radiotracer) being 
imaged.  
 
7.3.2.  Fractal method 
Sophisticated methods have been proposed to try to outline a target lesion reliably in an 
automatic and repeatable fashion (e.g. Hatt et al, 2009; Hatt et al, 2010). However, these are 
not extensively used (Visvikis et al, 2012) and other metrics that are potentially less 
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informative of the functional extent of disease have been suggested to avoid PVEs while 
using simple methods to delineate the targets (Mertens et al, 2012).   
 
Hatt et al (2012b) reported similar trends with regard to lesion size and SUVmean variation 
following partial volume corrections using FLAB, as obtained with the FD method on 
realistic PET simulations (Section 6.3.6.2). However in their case, the total glycolytic volume 
was much more strongly affected by resolution than in our case, suggesting that the fractal 
approach might be more robust to changes in resolution. However the FLAB method might 
be more robust in the case of low TBR according to repeatability results (Section 6.3.7). The 
difference in repeatability in this study (Chapter 6), compared to what was reported by Hatt et 
al (2010) using the same 
18
F-FLT PET dataset, suggests that in one patient, the volume of the 
tumour (hardly visible in the PET image) might have been underestimated with the FD 
method in the second scan. However, Hatt et al (2010) did not specify which part of the 
dynamic PET acquisition was used in their study.  
 
Mertens et al (2012) recently proposed to derive an index related to TLA which does not 
depend on accurate delineation. They considered the context of the lesion with respect to 
background tissue. However their approach was merely based on recovering the differential 
activity due to the lesion embedded in background. In their approach, the actual TLA due to 
the lesion activity could not be recovered. In Chapter 6, the same lesion was shown to have a 
different apparent active volume depending on the background it is embedded in (exemplified 
by the modified Sierpinski carpet). Therefore the recovery is context-dependent as far as the 
background intensity is concerned. However, the FD method recovers the TLA rather than a 
differential sum of activity between background and object. In this sense, the FD method is 
more similar to the approach of Hatt et al (2009), in that they both recover the metabolically 
active tumour volume (MATV).  
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7.4.  Perspectives and Future work 
The complexity of radiotracer uptake captured by PET is, at best, a distorted representation of 
the underlying biology which is being monitored, due to the limitations of the physics 
(detectors and annihilation process), motion, reconstruction algorithms and parameters, image 
processing, etc. The limited resolution of PET (a few mm) means that this heterogeneity 
cannot be recovered at smaller scales. Still, characterising the complexity of PET radiotracer 
uptake in neoplastic lesions (e.g. its extent and intra-tumour heterogeneity) using image 
descriptors has shown promising results with regard to predicting clinical outcomes. Imaging 
intra-tumour heterogeneity is also potentially useful for dose-painting in radiotherapy 
planning (e.g. monitoring hypoxia using 
18
F-FMISO) (Le Maitre et al, 2010) and for 
investigating in vivo intra-tumour biological heterogeneity (Zhao et al, 2005). Nevertheless, 
imaging factors (reconstruction, resolution, motion, and PVEs) could severely limit potential 
comparisons in multi-centre studies or between different imaging and analysis settings, which 
could impede the generalisation of these techniques.  
 
7.4.1.  PET intra-tumour heterogeneity and underlying biology 
More studies are needed to understand the extent to which intra-tumour PET heterogeneity 
metrics can truly capture the underlying intra-tumour biological heterogeneity. Different 
methodologies have already been proposed: investigating for instance the relationship of 
spatial PET radiotracer uptake with resected tumour volumes and independent clinical and 
biological variables of relevance (Zhao et al, 2005; Van Baardwijk et al, 2008), using multi-
modality (Ng et al, 2012) or multi-tracer imaging  (Lohith et al, 2009; Nyflot et al, 2012). 
These investigations are essential to capture the different aspects of the heterogeneous 
landscape of tumour biology, and to understand the limitations and source of variability of 
the techniques used.  
 
For instance, Zhao et al (2005) explored associations between the spatial expression of 
several immunohistochemical markers and 
18
F-FDG intra-tumour heterogeneity in seven rats. 
They compared the uptake of radiotracer (autoradiography) across sub-regions of the lesion 
(core, peripheral and necrotic/apoptotic areas) in sectioned tumour slices with the expression 
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of glucose transporter 1 (Glut1), glucose transporter 3 (Glut3) and hexokinase 2 (HK2) on 
adjacent stained tumour sections. The greatest 
18
F-FDG accumulation was measured in the 
core region. This area of the lesion was also associated with significantly greater expression 
of Glut1, Glut3 and HK2 compared to peripheral regions (p <0.001). In addition, the 
researchers found a significant correlation between expression of the immunohistochemical 
markers and 
18
F-FDG accumulation across the different sub-regions (r = 0.923, P < 0.001 for 
Glut1; r = 0.829, p < 0.001 for Glut3; and r = 0.764, p < 0.01 for HK2).  
 
Other authors have investigated the spatial interactions between different biological functions 
in multi-tracer PET studies (Nyflot et al, 2012; Lohit et al, 2009). For instance, Lohit et al 
(2009) correlated metabolic (
18
F-FDG) and hypoxic (
62
Cu-ATSM) spatial activities within 
individual lesions, by defining small tumour sub-regions in lung cancer patients. PET images 
were co-registered using CT imaging. The authors found that the uptakes of 
18
F-FDG and 
62
Cu-ATSM were in visual agreement in adenocarcinomas, whereas an inverse relationship 
was observed between the spatial uptakes of the radiotracers at the periphery and towards the 
centre of lesions in squamous cell carcinomas. A correlation coefficient (
18
F-FDG versus 
62
Cu-ATSM spatial uptake computed in individual lesions) yielded a statistically significant 
difference between the two lung cancer types. Similarly, Nyflot et al (2012) used voxel-wise 
spatial correlations to investigate the relationship between metabolism (
18
F-FDG), 
proliferation (
18
F-FLT) and hypoxia (
18
F-FMISO) in patients with cancer of the oropharynx 
within the context of radiotherapy. The authors proposed that this approach, yielding a more 
thorough characterisation of tumour phenotypes, might help to reach a consensus on 
biological targeting strategies in radiotherapy, help to improve patient prognosis and inform 
treatment failure.  
 
Computational simulations are yet another necessary approach to understanding which 
characteristics of the underlying biological intra-tumour heterogeneity can be captured (or 
conversely cannot be monitored) by the imaging system (Bauer et al, 2012).  
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7.4.2.  Informative biomarkers of intra-tumour biological heterogeneity in 
the clinical context 
It is essential to understand which aspects of this complexity, in particular intra-tumour 
heterogeneity, are relevant to the clinical context: which descriptors summarise this 
heterogeneity sufficiently and which analytic parameters can be used in order to provide 
clinicians with the most reliable and informative summary of heterogeneity. Imaging intra-
tumour heterogeneity for biological investigations and for the purpose of deriving image 
biomarkers of response to treatment and clinical outcome might require separate approaches, 
feeding each other through new discoveries. This necessitates a comprehensive and 
incremental process between developing quantification methods to characterise PET signal 
variability, choosing and understanding the biological processes that need to be monitored in 
relation to intra-tumour heterogeneity within a specific context, as well as the usefulness, 
relevance and specificity of such approaches in the clinical context.  
 
7.4.3.  Optimal parameters to image heterogeneity with PET 
Galavis et al (2010) studied the dependence of textural features on reconstruction parameters. 
They showed that certain textural features displayed small variations, while other textural 
features were much more dependent on reconstruction type and parameters. This latter 
finding is to be expected as textural features are resolution dependent and so would capture 
different aspects of heterogeneity at different resolutions in the PET images. The study 
conducted by Galavis et al (2010) could be used to select features that are less sensitive to 
image protocols in multi-centre studies and for comparison across centres. However, the 
authors did not investigate the discriminatory power of individual features in relation to 
clinical endpoints or their biological relevance. Further studies are needed to determine which 
reconstruction parameters might be optimal to image intra-tumour heterogeneity using PET.  
Although textural feature values are affected by imaging protocols, it is critical to assess 
whether this also affects the ability of the features to discriminate between patient and disease 
or diagnostic groups, and whether the more stable features are the best discriminators across 
studies and image protocols. On the contrary, features that are more dependent on 
reconstruction parameters might also provide the best discrimination between patients for 
optimal parameter settings. It is therefore essential to study the influence of those parameters 
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in relation to clinical endpoints. Such investigations might help to provide guidance for image 
protocols and normalisations, which could facilitate comparisons across centres. 
 
Improvements in the spatial resolution of imaging systems (Baghaie et al, 2010) will also 
help to detect and more accurately characterise spatial intra-tumour heterogeneity in the 
future.  
 
7.4.4.  Monitoring dynamic and adaptive biological complexity with PET  
PET might also help researchers to understand, monitor and quantify the dynamic and 
adaptive landscape of intra-tumour biological heterogeneity which contributes to tumour 
resistance, cancer growth and progression. Frameworks are needed in order to compare 
imaging at multiple time points using robust methods for registration, PVEs, and correction 
of breathing and motion artefacts. For instance, David et al (2012) recently proposed a multi-
observation approach to assess successive PET scans and classify local changes following 
therapy.  
 
Expanding on the work of Norton (2005), monitoring the dynamic and changing space-filling 
properties of a lesion imaged with PET, might also be informative of tumour growth and 
therapy response. For instance, one can hypothesise that the filling factor associated with a 
specific biological function (ratio between the fraction of space filled by the object and the 
volume of the tumour in a Euclidian sense) measured at different time points might provide 
additional information to existing descriptors. However, the amplitude of those changes for a 
specific image protocol would need to be more than the variability introduced by factors such 
as PVEs.  
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Chapter 8.  Conclusion 
 
 
 
Texture analysis was employed to characterise the in vivo tumour heterogeneity of cell 
proliferation in breast tumours using 
18
F-FLT. The repeatability of the feature measurements 
was assessed in patients who had two 
18
F-FLT PET scans prior to therapy. Associations 
between features at baseline and clinical response measured after three cycles of 
chemotherapy were explored. Associations between feature changes after one week of 
chemotherapy and clinical response were also explored. Further, the influence of analysis 
parameters and imaging protocols were studied. A subset of textural features produced 
reliable measurements and these features, calculated prior to the commencement of 
chemotherapy, were associated with response to therapy. In addition, changes in certain 
image descriptors after one week of treatment were associated with treatment response.  
 
A technique based on fractal/multifractal analysis was also developed to characterise the 
space-filling properties of an object of interest in PET imaging. The derived spatial index was 
further combined with intensity metrics and the technique was shown to correct for partial 
volume effects. The method was illustrated on mathematical objects, validated on test-retest 
18
F-FLT PET clinical data and applied to realistic PET simulations.  
 
This work contributes to the demonstration that intensity and spatial-based image analysis 
methods can supplement existing methods in PET quantification studies. These techniques 
provide both improvements to existing methods to derive classical quantitative PET indices, 
and extraction of additional information to further characterise patient populations in the 
clinical setting and in relation to therapy. 
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Appendices 
  
 
Appendix A1   Literature review - search strategy 
 
The search was last run on 07/07/2013 (MEDLINE and Web Of Science) using the following 
search terms and combination: 
 
(variability OR heteroge* OR descriptor OR spatial OR feature)  
AND  
(characteri* OR quantificat*)  
AND  
(PET OR "Positron Emission Tomography") AND (cancer OR lesion OR oncolog* OR 
neoplas* OR tum*) 
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Appendix A2   Literature review – identification, screening and selection 
of publications for literature review 
 
 
 
  
Records identified through 
database searching  
N = 747 (MEDLINE)  
N = 1,032 (Web Of Science) 
N =  
 Records after duplicates 
removed 
N = 1,287 
Records selected (by title) 
N = 544 
 
Full-text article assessed for 
eligibility 
N = 35 
 
Records eligible for 
literature review 
N = 49 
 
Cited articles 
N = 14 
 
Records selected (by 
abstract) 
Image Descriptors  
N = 37 
 
Other sources  
N = 1 
 
Appendices  231 
   
Appendix B1   GLCM computation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 different offset directions Ө 
   
Offset – orientation Ө  
Direction 
x y z  
1 0 0  X 
0 1 0  Y 
0 0 1  Z 
1 0 1  
Z X 
1 0 -1  
0 1 1  
Y Z 
0 1 -1  
1 1 0  
X Y 
-1 1 0  
1 1 1  
X Y Z 
1 1 -1  
-1 1 1  
1 -1 1  
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Appendix B2   Example of GLSZM matrix computation  
 
 
 
 
 2 2 2   
3 2 2 3 1  
3 3 2 3 5 5 
 1 1 3 4 5 
 
1 4 4 4 
 
 
 
Principle of GLSZM calculation – example in 2 dimensions 
  
  Size of the zone 
1 2 3 4 5 6 
gl 
1 1 0 1 0 0 0 
2 0 0 0 0 0 1 
3 0 0 2 0 0 0 
4 0 0 0 1 0 0 
5 0 0 1 0 0 0 
Volume Of Interest GLSZM 
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Appendix B3   Normalisation of GLSZM features 
 
A normalisation factor, as described in Loh et al (1988), was applied to the GLSZM features 
incorporating a size area factor (SmallZone, LargeZone, Szonelogl, Szonehigl, Lzonelogl, 
Lzonehigl and Szvariance) so as to remove the influence of VOI size on the results.  
 
An example is given below for the same texture at different scales: 
 
2 2 2 
2 1 2 
2 2 2 
 
 
      Image 1     Image 2 
 
Size-zone percentage is the inverse of the average patch size in the VOI 
         
∑      
 
  
 
where ∑       is the number of different zones in the image,  is the number of voxels 
 
Szpcent1 = 2/9 
Szpcent2 = 2/36 = (1/4)*Szpcent1 
  
2 2 2 2 2 2 
2 2 2 2 2 2 
2 2 1 1 2 2 
2 2 1 1 2 2 
2 2 2 2 2 2 
2 2 2 2 2 2 
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Features value for the two images before normalisation: 
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Features value for the two images after normalisation: 
                
 
  
∑                                        
                     
                
 
  
∑     (
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where Nz is the number of zones in the image and gl is the grey level value of each zone  
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Appendix C   Influence of SUVBG estimate on TLA recovery 
 
 
Figure C.1 – Percent error in TLA recovery for BG_box at three different locations (left, 
middle, right columns) and as a function of FD computation box size. In each graph, results are 
given as mean TLA estimates recovered over FD computation boxes of identical size and for Q = 50. 
Results are compared for the FD_BGbox implementation in noiseless images (plain black line) and 
noisy images (plain dark-grey line). Results from the noiseless dataset but with a biased estimate of 
SUVBG (FD_BGbox implementation) are shown by the black dashed line. Results are compared to 
TLA estimates recovered using the FD_Delin method on both noiseless (light grey dotted line) and 
noisy (light grey continuous line) datasets. Results for case s.1.2 (A, B and C), case s.2.1 (D, E and F), 
case s.2.3 (G, H and I) and case s.3.2 (J, K and L) for BG_box_pos1, BG_box_pos2 and 
BG_box_pos3 (respectively).  
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Appendix D   Permission to republish textural work 
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